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ABSTRACT OF DISSERTATION

SYNTHESIS AND CHARACTERIZATION OF MAGNETIC HYDROGEL
NANOCOMPOSITES FOR CANCER THERAPY APPLICATIONS
Currently, cancer is the second leading cause of death in the United States.
Conventional cancer treatment includes chemotherapy, radiation, and surgical resection, but
unfortunately, all of these methods have significant drawbacks. Hyperthermia, the heating of
cancerous tissues to between 41 and 45°C, has been shown to improve the efficacy of cancer
therapy when used in conjunction with irradiation and/or chemotherapy. In this work, a
novel method for remotely administering heat is presented. This method involves heating of
tumor tissue using hydrogel nanocomposites containing magnetic nanoparticles which can be
remotely heated upon exposure to an external alternating magnetic field (AMF). The iron
oxide nanoparticles contained in the hydrogel nanocomposites are able to heat via an AMF
due to Brownian and Neel relaxation processes. The administration of hyperthermia via
hydrogel nanocomposites allows for local delivery of heat to tumor tissue while also
providing a drug depot to deliver chemotherapeutic agents. Both in vivo and in vitro studies
have demonstrated that numerous chemotherapeutic agents, when used in conjunction with
hyperthermia, show improved efficacy in treating cancer
Various magnetic hydrogel nanocomposites were synthesized and characterized for
this work including poly(ethylene glycol) (PEG)-based hydrogels, which were studied due to
their inherent biocompatibility and “stealth” properties, as well as, poly(β-amino ester)
(PBAE)-based hydrogels which have tailorable degradation properties. The PEG hydrogels
were investigated for their temperature-responsiveness swelling, mechanical strength, heating
capabilities, biocompatibility, ability to kill M059K glioblastoma cells via thermoablation,
and the ability to deliver paclitaxel, a chemotherapeutic agent. PBAE hydrogels were also
characterized for their degradation and swelling properties, ability to heat upon exposure to
an AMF, biocompatibility, mechanical strength, and ability to deliver paclitaxel in a
controlled fashion. Additionally, multiple cancer cell lines were exposed to a combination of
paclitaxel and heat (at 42.5 °C) in vitro and it was shown that A539 lung carcinoma cells
exhibit higher cytotoxicity when exposed to both heat and paclitaxel than either treatment
alone. Overall, magnetic hydrogel nanocomposites are promising materials that can be
utilized for the multi-modality treatment of cancer through the synergistic delivery of both
heat and chemotherapeutic agents.

KEYWORDS: Hydrogel, Nanocomposite, Iron Oxide, poly(ethylene glycol), poly(β-amino
ester)
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CHAPTER 1

1.1 Introduction
The development of cancer therapeutics is an important component of biomedical
research today because even though much has been done to overcome and treat the disease,
there are still many types of cancer, such as glioblastoma and pancreatic cancer (Sneed 1998),
that have extremely poor treatment success rates. Therefore, multiple-modality treatment has
become the preferred treatment approach. Hyperthermia, the heating of cancer tissues to
between 41 and 45°C, has been proven to have the potential to provide a straightforward and
effective way of treating cancer in combination with well-developed therapeutics such as
irradiation and chemotherapy (Falk and Issels 2001). Thermoablation, the thermal destruction
of cells at temperatures above 50°C, is another potential cancer therapy method involving heat
therapy (Jordan 1999). A novel class of biomaterials based on nanocomposite hydrogels,
specifically systems composed of poly(ethylene oxide) (PEG) or poly(β-amino ester) (PBAE)
and iron oxide, have the potential to be used in such hyperthermia applications. The exposure
of the gels to a high-frequency magnetic field leads to remote heating due to the magnetic
particles in the nanocomposite.
Hydrogels are three-dimensional, hydrophilic, polymeric networks that can absorb up
to thousands of times their dry weight in water or biological fluids (Corkhill 1989; Peppas
2000; Peppas 2006). They consist of polymeric chains with either physical or chemical
crosslinks preventing their dissolution while allowing swelling upon interaction with aqueous
solutions. They have been utilized in a wide variety of biomedical applications such as drug
delivery, contact lenses, and tissue engineering (Peppas 1987; Peppas 2006; Frimpong and
Hilt 2007). In particular, poly(ethylene glycol) (PEG)-based hydrogels have been widely
investigated and are considered “stealth” systems due to their high water content and the
presence of PEG chains which exhibit high biocompatibility. The biocompatibility of PEG
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stems from its ability to repel protein absorption, due to the hydrophilic nature of the polymer
(Nagaoka 1984; Jeon 1991).

PBAE polymers are of interest due to the simplicity in

synthesizing the macromers that make up the hydrogels, and the ability to tailor the properties
of the systems (such as degradation and mechanical strength) based on the chemistry of the
macromers used.
Despite the many advantages of using conventional hydrogels, their applications are
often limited due to their poor mechanical strength and somewhat limited response and
actuation properties (Xiang 2006). In recent years, hydrogel nanocomposites have received
increased attention as a result of their unique properties and expanded applications (Brazel
2009; Hawkins 2009; Satarkar 2009). Hydrogel nanocomposites involve the incorporation of
various nanoparticulate materials within a hydrogel matrix which provides an easy,
straightforward methods for enhancing the properties of hydrogels. The incorporation of
magnetic nanoparticles such as iron oxide nanoparticles into hydrogels can create tunable
nanocomposites that can be remotely controlled by a magnetic field (Frimpong and Hilt 2008;
Satarkar and Hilt 2008). In recent work by Satarkar and coworkers, remote-controlled heating
and drug release using hydrogel nanocomposites based on N-isopropylacrylamide (NIPAAm)
and Fe3O4 nanoparticles have been successfully demonstrated (Satarkar and Hilt 2008;
Satarkar and Hilt 2008). This controlled release was due to the thermally-responsive nature of
the NIPAAm, and the remote-controlled heating by applying an alternating magnetic field
(AMF) which heated the magnetic nanoparticles present in the hydrogel matrix causing them
to collapse and expel the drug.
In regards to the biocompatibility of hydrogel nanocomposites, a limited amount of
cytocompatibility or hemocompatibility studies have been reported. However, a wide variety
of literature is available regarding the biocompatibility of the hydrogels and nanoparticulate
components alone that make up a hydrogel nanocomposite (Meenach 2009). One of the
advantages of hydrogel nanocomposites is that hydrogels can provide increased
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biocompatibility over exposed, uncoated nanoparticulates because they encapsulate the
particulate matter in the composite matrix providing a barrier between the sensitive tissues and
the more harmful nanoparticulates.
The magnetic hydrogel nanocomposites used in this work were synthesized using
various PEG and PBAE macromer types and crosslinking amounts. This allowed for the
tailoring of various properties such as swelling, mechanical strength, heating via an AMF,
biocompatibility, and paclitaxel release profiles. Overall, these systems are promising for
applications in cancer therapy due to their ability to deliver both heat and chemotherapeutic
agents.

1.2 Objectives
The overall objective of this dissertation was to develop biocompatible magnetic
hydrogel nanocomposites with tailorable properties for the controlled delivery of heat and
therapeutic agents (e.g., paclitaxel) for synergistic cancer therapy applications. This involved
four projects and the specific objectives of these are outlined as follows:

1. “Poly(ethylene glycol)-Based Magnetic Hydrogel Nanocomposites for Hyperthermia
Cancer Therapy”:
a. Fabricate magnetic hydrogel nanocomposites based on PEG and iron oxide with
various crosslinking densities.
b. Analyze the swelling properties of the hydrogels.
c. Analyze the heating properties of the nanocomposites at a fixed AMF strength and
frequency.
d. Control the heating of the hydrogels by changing the AMF strength and frequency.
e. Characterize the toxicity potential of the hydrogels through the exposure of NIH
3T3 fibroblasts to the gels.
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f. Demonstrate the ability of the hydrogels to kill M059K glioblastoma in vitro upon
exposure to hydrogel nanocomposites heated in an AMF.

2. “Synthesis and Characterization of Thermoresponsive Poly(ethylene glycol)-Based
Hydrogels and Their Magnetic Nanocomposites”:
a. Fabricate magnetic hydrogel nanocomposites based on temperature-responsive
PEG methacrylates and iron oxide.
b. Analyze the swelling characteristics of the hydrogels at various temperatures.
c. Characterize the heating characteristics of hydrogel nanocomposites exposed to a
constant AMF.
d. Demonstrate the ability of the hydrogel nanocomposites to deswell rapidly upon
exposure to an AMF due to the heating of the gels.

3. “Combined Hyperthermia and Chemotherapeutic Delivery Via PEG-Based Hydrogel
Nanocomposites”:
a. Fabricate magnetic hydrogel nanocomposites based on PEG and iron oxide with
various crosslinking densities.
b. Analyze the swelling characteristics of the hydrogels at various temperatures.
c. Characterize the heating properties of the hydrogel nanocomposites upon exposure
to an AMF.
d. Determine the compressive moduli of the hydrogel nanocomposites.
e. Analyze and model paclitaxel release from the hydrogel nanocomposites.
f. Analyze the cytotoxicity of various cancer cell lines exposed to both paclitaxel and
heat versus either treatment alone.
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4. “Controlled Synergistic Delivery of Paclitaxel and Heat from Poly(β-amino ester)/Iron
Oxide-Based Hydrogel Nanocomposites”:
a. Synthesize and characterize poly(β-amino ester) (PBAE) macromers based on
poly(ethylene glycol) diacrylates and isobutylamine.
b. Fabricate magnetic hydrogel nanocomposites based on various PBAE macromers
and iron oxide.
c. Characterize degradation and swelling response of hydrogel nanocomposites.
d. Determine the compressive moduli of the hydrogel nanocomposites.
e. Characterize iron oxide loss via thermogravimetric analysis.
f. Characterize the heating properties of the hydrogel nanocomposites upon exposure
to an AMF throughout the degradation process.
g. Analyze and model paclitaxel release from the hydrogel nanocomposites.
h. Analyze the cytotoxicity of PBAE hydrogel nanocomposite degradation products.

This dissertation starts with Chapter 2 with background information on hydrogels in
cancer therapy applications including an introduction to hydrogels, a discussion of the
conventional cancer therapies and their limitations, and a review of previous work focusing on
hydrogel systems used in cancer therapy applications.

Chapter 3 includes the project,

“Poly(ethylene glycol)-Based Magnetic Hydrogel Nanocomposites for Hyperthermia Cancer
Therapy,” which looks at PEG-based hydrogels capable of both hyperthermia and
thermoablation.
Thermoresponsive

Chapter 4 focuses on the project, “Synthesis and Characterization of
Poly(ethylene

glycol)-Based

Hydrogels

and

Their

Magnetic

Nanocomposites,” which demonstrates

the temperature-responsiveness of PEG hydrogel

nanocomposites for the first time.

The project “Combined Hyperthermia and

Chemotherapeutic Delivery Via PEG-Based Hydrogel Nanocomposites” is presented in
Chapter 5 which examines PEG hydrogels for paclitaxel and heat delivery. Chapter 6 includes
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the final project, “Controlled Synergistic Delivery of Paclitaxel and Heat from Poly(β-amino
ester)/Iron Oxide-Based Hydrogel Nanocomposites,” which focuses on synthesizing and
characterizing degradable hydrogels capable of delivering paclitaxel and heat in a controlled
manner. The conclusions of this work are summarized in Chapter 7.

References
All references are located at the end of the dissertation.
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CHAPTER 2

Hydrogels for Cancer Applications

Hydrogels have been widely investigated for biomedical applications throughout the
past several decades. They offer many optimal characteristics for drug delivery including the
ability to tailor the release of drugs and their ability to be biocompatible due to their high
water content. One area of research that has received increased interest more recently is the
use of hydrogels to treat cancer. These materials have shown the ability to effectively deliver
chemotherapeutics, radionucleotides, and immunotherapeutics in both in vitro and in vivo
applications.

This delivery has been achievable via hydrogel systems that are non-

biodegradable, stimuli-responsive, natural, and/or biodegradable materials.

Particulate

hydrogels (nano- or micro-sized) have also been investigated for the delivery of cancer
therapeutics, and these materials have been able to be delivered specifically to cancer cells via
active ligand targeting and passive targeting via the enhanced permeation and retention effect.
In addition to cancer therapy, hydrogels have been investigated for other cancer-related
applications such as tumor embolization, three-dimensional cell culture to mimic the tumor
microenvironment, tumor imaging, and biosensors.

Overall, studies have shown that

hydrogels offer many advantages in cancer treatment and applications and should be
developed into more commercial and clinical applications.

This review will cover

conventional cancer therapies and their limitations, hydrogel systems that deliver
chemotherapeutics, radiation, and/or immunotherapeutic agents, and an overview of other
ways hydrogels are being used in cancer-related applications.
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2.1 Introduction

2.1.1 Types of Common Cancer Therapies and Their Limitations
Currently, cancer is the second leading cause of death in the United States. In 2009
alone, there were an estimated 1.5 million new cases diagnosed (ACS 2009). Cancer is a
disease that is characterized by aggressive growth of cells which divide without normal
limitations, invade and destroy adjacent tissues, and spread to distant sites throughout the
body through metastasis, which is a major cause of death (Ta 2008). Cancer may result from
a wide variety of external factors including exposure of healthy cells to physical carcinogens
such as ultraviolet and ionizing radiation, chemical carcinogens such as asbestos and tobacco
smoke, and biological carcinogens such as infections by viruses and contamination of food by
mycotoxins (Ta 2008). The most common types of cancer therapy include chemotherapy,
radiation, and/or resection. This often involves treating solid tumors via surgical removal
followed by irradiation and/or systemic chemotherapy to kill malignant cells which may have
survived the surgery and to treat any metastasis that may have occurred. Hormonal therapy
and immunotherapy are also being used, but their applications are currently limited to certain
types of cancer.
Unfortunately, intravenously delivered chemotherapy for certain types of tumors often
has limited effectiveness. Since only a small amount of systemic blood flow is directed to the
tumor, only a small fraction of the total dose reaches the tumor site and the remainder of the
dose is distributed to healthy organs and tissues (Weinburg 2008).

Additionally, most

chemotherapeutics are highly toxic and lack specificity in that they do not differentiate
between normal and cancer cells, leading to such severe side effects throughout the body (Ta
2008).

Initially, chemotherapy treatment is usually effective; however, this therapeutic

response is often only seen in the short term. Between treatments, there is often re-growth of
vascular endothelial cells that support the tumor which results in more aggressive cancers that
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are resistant to the cytotoxic drug being used for treatment. While continuous drug delivery
allowing for low levels of an anticancer agent over an extended period of time is ideal, patient
compliance and inconvenience limits this type of therapy. Also, drugs often have limited
bioavailability (the fraction of an administered dose of a drug that reaches the systemic
circulation). For example, 90 % of the chemotherapeutic agent cisplatin is bound to plasma
proteins in the blood causing decreased bioavailability. (Casolaro 2009). Therefore, drug
delivery systems are needed to achieve higher concentration of the drug locally in tumor
tissues and to control the release profile of these drugs. An alternative to conventional
treatment is an implantable device that can release the drug at a controlled rate for longer
periods of time. Implanting a biodegradable device loaded with a chemotherapeutic agent in
the cavity created by tumor removal can provide a high local concentration of the drug, killing
the surviving malignant cells while preventing systemic side effects. Additionally, clinicians
can use this type of system to pre-treat solid tumors prior to surgery in order to expose the
tumor to large concentrations of the drug (Shikanov 2008).

The advantages of such

implantable drug delivery devices may include more precise dose control, high release
efficiency, and lower systemic toxicity (Casolaro 2009).
Radiation is a type of cancer therapy that uses ionizing radiation to destroy cancer cells
at a specific site. Multiple types of cancer such as lung, breast, prostate, head and neck are
treated with radiation and nearly 60% of patients diagnosed with cancer undergo this type of
treatment (Azhdarinia 2005). Conventional external radiation can be limiting for certain types
of unresectable tumors as there is a certain tissue tolerance that must be taken into account.
Brachytherapy is a commonly used treatment option for prostate cancer as radioactive seeds
are directly deposited intratumorally which spares the surrounding healthy tissue from
damage. Unfortunately, these seeds are non-degradable and will remain at the tumor site after
injection (Azhdarinia 2005) and this treatment often requires relatively complicated placement
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and removal procedures (Azab 2007).

Fortunately, there are several radionucleotides

currently used for the treatment of cancer.
Beta-emitters are the most widely used in radiotherapy.

β-Electrons from

radionucleotides interact with atoms, mainly in water molecules, and lose their energy, which
leads to the generation of excited and ionized atoms and free radicals.

These are then

responsible for DNA damage in cells by inducing single strand breaks in DNA, preventing
cell division (Hamoudeh 2008). The ideal radiopharmaceutical should result in radioactive
energy that reaches the tumor tissue with no radiation reaching beyond to normal tissue.
Incorporating radiopharmaceuticals in nanoparticulate or microparticulate carriers can provide
a useful means for controlling the tissue and cellular distribution profiles of such agents
(Hamoudeh 2008). It is also possible to deliver radionucleotides more effectively and locally
through incorporation of such agents in hydrogel systems.
Although not yet a conventional method for treating cancer, hyperthermia is becoming
more prevalent as another tool for the multi-modality treatment of the disease. Hyperthermia
is the heating of tumor tissue to temperatures between 41 and 45°C (Jordan 1999). It is used
for up to a few hours in combination with other assisting toxic agents (mostly irradiation or
chemotherapy) for reliable damage of tumor cells (Hergt 2006). Cellular stress from heat
potentiates the effect of chemotherapy and ionizing radiation through increased intracellular
drug uptake and intratumoral drug concentrations, enhanced DNA damage, and improved
tissue oxygenation resulting from an increase in blood flow (van der Zee 2002; Janjetovic
2007).

One of the advantages of this therapy is that the tissue damage for normal tissue is

reversible while the tumor cells are irreversibly damaged (Neuberger 2005). When used with
radiation, hyperthermia has been shown to improve local tumor control and overall survival in
patients with advanced pelvic tumors, primary and recurrent breast cancer, head and neck
tumors, and glioblastoma (Roca 2003). Regarding chemotherapy applications, many reports
have discussed which anticancer drugs demonstrate a synergistic effect with hyperthermia and
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have described the mechanism of hyperthermic enhancements.

Some anti-cancer drugs

known to have a synergistic effect with hyperthermia include bleomycin, mitomycin C,
adriamycin, 5-fluorouracil, carboplatin, and cisplatin (Takahashi 2002).
Clinical hyperthermia can be divided into three separate categories: whole body
hyperthermia, regional hyperthermia, and local hyperthermia (including superficial local and
interstitial local hyperthermia).

The clinical application of heat can be induced by an

electromagnetic field technique, ultrasound, or perfusion methods (Falk and Issels 2001). One
of the challenges in using hyperthermia for cancer treatment is the restriction of heating
locally to the tumor site (Babincova 2001). Other limitations include the non-homogeneous
distribution of temperature over the cancer site, low specificity, patient discomfort, and
thermotolerance development (Guedes 2005).

Additionally, many of the methods are

moderately to severely invasive with negative side effects. Overall, hydrogels may potentially
be used for the local, synergistic delivery of therapeutic agents for the treatment of cancer.

2.1.2 Hydrogels: Definitions and Applications
Hydrogels are an important class of polymeric materials that have been utilized in a
wide variety of biomedical and pharmaceutical applications such as drug delivery, contact
lenses, and tissue engineering.

Hydrogels are three-dimensional, hydrophilic, polymeric

networks that can absorb up to thousands of times their dry weight in water or biological
fluids (Peppas 2000; Hoffman 2002). These systems consist of polymer chains with either
physical or chemical crosslinks preventing the dissolution of the systems while resulting in
swelling of the material upon interaction with aqueous solutions. Hydrogels are advantageous
for many biomedical applications due to their resemblance of natural living tissue and inherent
biocompatibility which can be partially attributed to their soft, flexible nature and high water
content (Hoffman 2002).

Hydrogel systems such as poly(hydroxyethyl methacrylate)

(PHEMA), poly(N-isopropylacrylamide) (PNIPAAm), poly(vinyl alcohol) (PVA), and
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poly(ethylene glycol) (PEG) have been widely investigated for a wide variety of biomedical
and pharmaceutical applications.
Despite the many advantages of using conventional crosslinked hydrogels, their
applications are often limited due to their poor mechanical and limited response properties
(Xiang 2006).

The random nature of the crosslinking reactions involved in hydrogel

fabrication and the resulting morphological nonhomogeneity can induce these limitations
(Haraguchi 2003).

Recently, work has been done to improve hydrogel properties (e.g.,

mechanical strength) and to add unique properties (e.g., response to novel stimuli) through the
fabrication of hydrogel nanocomposites (Frimpong 2006; Frimpong and Hilt 2008; Satarkar
and Hilt 2008; Satarkar and Hilt 2008; Hawkins 2009; Meenach 2009; Meenach 2009; Satarkar
2009).

Hydrogel nanocomposites involve the incorporation of various nanoparticulate

materials within a hydrogel matrix which can provide easy, straightforward methods for
enhancing the properties of hydrogels. Although a number of fabrication techniques have
been used to create such systems, in situ polymerization of particles within a monomer
solution is a common way to create hydrogel nanocomposites.
There are a handful of hydrogel-based systems that are currently commercially
available. One of the more widely studied systems is a once-yearly administered histrelin
acetate hydrogel implant that is used in the treatment of prostate cancer. The prolonged
release of histrelin suppresses testosterone production in the body reducing and often arresting
the growth of prostate tumors. This device has been used under the trade name Vantas
(Indevus Pharmaceuticals Inc.) in the U.S. for more than four years for patients with advanced
prostate cancer (Schlegel 2009). One study of this system shows the pharmacokinetics and
pharmacodynamics of the hydrogel implant for patients for 1 year indicating its effectiveness
for prolonged histrelin delivery for testosterone suppression (Dineen 2005).
ProGEL™ Pleural Air Leak Sealant, a hydrogel polymer sealant that forms when
mixing human serum albumin and a PEG-based crosslinker, has been developed by Neomend
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Inc. The resulting seal may be utilized to seal pleural air leaks during lung surgery (Neomend
2010). Amar Sawhney has turned several hydrogel-based inventions into FDA-approved
products (McBride 2008).

These include using hydrogels as surgical sealants, spacers

between tissues undergoing radiation to protect healthy surrounding tissue, and a product to
help treat adult incontinence.

Other products include extended wear contact lenses

(CooperVision 2008), NanoDOX™ Hydrogel, a topical doxycycline hydrogel for chronic
wounds (NanoDox 2008), and Avogel Scar Reduction Hydrogel Sheeting to reduce scars
(Avogel 2010).
Hydrogels are often used to delivery therapeutics for various applications, and have
recently been more widely investigated for the treatment of cancer. A partial list of hydrogel
systems currently being investigated and the cancer therapeutics they release can be seen in
Table 2.1. The National Cancer Institute has a goal of localizing cancer therapy by using
nanoparticles for localized chemotherapy, radiation, immunotherapy, hyperthermia delivery,
or a combination of these therapies (Brazel 2009), and it is the belief of many that hydrogel
systems may help achieve this goal. Hydrogels are often advantageous for drug delivery
because, depending on their formulation, hydrogels can exhibit a variety of drug release
profiles determined by their network structure. Thermosensitive and pH-sensitive hydrogels
are extensively studied gels because of their responsive-release characteristics. Hydrogels
have great swelling capacity and can therefore entrap high molecular weight drugs and often
release them in a controlled fashion (DiRamio 2005). Drug release can easily be tailored in
hydrogel systems by the type of polymer and crosslinking used, the density of crosslinking,
the amount of drug loaded, the method of drug loading, the pH of the release medium, and
external stimuli (Singh 2008). Additionally, many hydrogels are biodegradable and can be
easily cleared from the body once they lose their functionality.

Such degradation is

determined by chemical reactions in the hydrogel matrix including polymeric chain breakage
due to hydrolytic or enzymatic degradation within the hydrogel system. The degradation
13
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Table 2.1. Partial lists of types of polymers used in hydrogel systems for cancer therapy
applications and the types of therapeutics released from such systems.

Types of Polymers Used in Hydrogels
Synthetic Polymers
Natural Polymers
N-(2-hydroxypropyl)methacrylamide (HPMA)
Agarose
Poly(N-isopropylacrylamide (PNIPAAm)
Alginate
Poly(acrylamide) (PAAm)
Gelatin
Poly(β-amino ester) (PBAE)
Chitosan
Poly(ethylene glycol) (PEG)
Collagen
Poly(ethyleneimine) (PEI)
Dextran
Poly(lactic-co-glycolic acid) (PLGA)
Histrelin
Polaxamer
Human serum albumin (HSA)
Poly(organophosphazene)
Hyaluronan
Polyacrylamide (PA)
Psyllium
Polyether (PE)
Pullulan
Poly(vinyl alcohol) (PVA)
Silk
Poly(vinylpyrrolidone) (PVP)

Types of Therapeutics Released from Hydrogel Systems
Chemotherapeutics
Radionucleotides
Other Therapeutics
188
Cisplatin (CDDP)
Rhenium-188 ( Re)
Plasmid DNA
Adriamycin (ADM)
Holmium-166 (166Ho)
supercoiled DNA
131
Paclitaxel (PTX)
I-norcholesterol (131I) interleukin-12 (IL-12)
Doxorubicin (DOX)
histrelin
5-fluorouracil (5-FU)
GMCSF
Camptothecin (CPT)
vaccinia virus vaccine
Topotecan (TPT)
Daunomycin
Bleomycin A5 (BLM)
Methotrexate
Mitomycin C
Mitoxanthrone
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mechanisms possible for controlling release from biodegradable hydrogels can be surface or
bulk erosion (Hamidi 2008).

Ultimately, hydrogel implants may provide multi-modality

therapies to more effectively treat cancer, especially those that currently have poor survival
rates.

2.2 Implementation of Hydrogels for Cancer Therapy
Hydrogels can be implemented in a number of ways for the treatment of cancer. These
include solid hydrogels implanted near or within a tumor, solid hydrogels placed at a tumor
site post-resection, hydrogels that form in situ after being injected intratumorally, or hydrogel
nanoparticles that are delivered systemically or intratumorally. A schematic of these methods
may be seen in Figure 2.1. In most cases, hydrogels utilized in drug delivery are usually
formed outside of the body and imbibed with drugs before placement in the body. Many
crosslinking methods, such as UV, redox, or thermal polymerization, are available to form the
hydrogels (Hoare and Kohane 2008). Intratumoral implantation of these hydrogels provides
an optimal drug release profile that is characterized by the ability to deliver drug in a large
volume and to rapidly reach the therapeutic concentration for an extended time. Previous
studies have shown that limited drug penetration distance is one of the major restrictions on
the efficacy of intratumoral treatments (Weinburg 2008).
Hydrogel nanoparticles are advantageous in that they are able to load and carry drugs
yet they are small enough to travel systemically if desired (Hamidi, Azadi et al. 2008). Also,
such nanoparticles can be functionalized so that they travel to and deliver drugs to cancer cells
specifically. Targeted drug delivery systems increase the effective dose of the drug and
decrease systemic drug toxicity (Hidaka 2006). This molecular targeting therapy is becoming
more widely used as a therapeutic method for cancer treatment (Ferro-Flores and de Murphy
2008). Active targeting of cancerous tissue involves the conjugation of particles with a
targeting ligand that binds with receptors in the tumor cells. Also, passive targeting takes
15
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Figure 2.1. Schematic of the methods of implementation of hydrogels for cancer therapy
applications. These include: (a) a hydrogel implanted intratumorally, (b) a hydrogel
implanted near the tumor tissue, (c) a hydrogel implanted at a site where a tumor was
surgically resected, (d) a hydrogel that formed in situ when administered via injection, and (e)
hydrogel nanoparticles injected intratumorally.
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advantage of the enhanced vascular leakage and diminished lymphatic clearance at the tumor
site, which leads to the accumulation of the particles in tumor tissue (the so-called enhanced
permeability and retention effect). It has been demonstrated that the optimal particle size for
high cellular and tumor uptake is in the 100 to 200 nm range (Nair 2008). These methods of
implementation can be utilized for the various types of delivery systems such as those
delivering chemotherapeutics, radiotherapeutics, or immunotherapy agents.

2.3 Chemotherapeutic Delivery via Hydrogels
Using hydrogels for delivery of cancer therapeutics has been studied extensively.
There are many types of bulk hydrogel systems that have been investigated for
chemotherapeutic agent delivery comprised of a wide variety of materials which provide the
systems with tailorable properties. These include, but are not limited to, stimuli-responsive
materials, natural polymers, biodegradable materials, and sol-gel systems.

Furthermore,

hydrogel particles that have been investigated include both microgels and nanogels (hydrogel
nanoparticles). Microgels are hydrogels formed as microscale particles whereas nanogels are
particles formed at the nanoscale level. These systems are able to combine the advantages of
both nanoparticles and polymeric hydrogels.

Stimuli-responsive

hydrogels

are

particularly advantageous as the swelling of the systems can be controlled by external stimuli.
Temperature-responsive hydrogels are one of the most commonly studied classes of stimuliresponsive polymer systems in drug delivery research. A common characteristic of these
polymers is the presence of hydrophobic groups, such as methyl, ethyl or propyl groups (Qiu
and Park 2001).

Hydrogel swelling may also be changed through modification in

environmental pH or ionic strength, or by exposing the systems to electromagnetic radiation
(Peppas 2000; Peppas 2006).

In addition, biologically-responsive systems have been

developed which include glucose, enzyme, antigen, or redox/thiol-responsive polymers.
Field-responsive systems include electro-responsive, magneto-responsive, and ultrasound17

responsive polymers (Roy 2009). Natural polymers are also of great interest for hydrogel
cancer therapy. The most common natural polymer, chitosan, has been used in biomedical
applications as it is known to be metabolized by certain human enzymes and can be
considered biodegradable and biocompatible (Seo 2009). There are also numerous types of
biodegradable polymers which may be degraded via enzymatic of hydrolytic mechanisms.
Hydrogel particles are advantageous as they can retain the properties outlined above
while being delivered systemically. The particles are often able to retain a large amount of
drug and can be delivered to specific locations via ligand-mediated targeting or passive
targeting. These systems are also able to be tailored for specific release rates and can be
designed to degrade so there is little concern with their removal from the body. There are
numerous types of polymers used in these systems including poly(butyl acrylate),
poly(ethylene

oxide-poly(ethyleneimine),

poly(vinylpyrrolidone),

and

poly(N-

isopropylacrylamide). Examples of all of these types of systems will be covered in the next
section.

2.3.1 Hydrogel Systems
Hydrogels have been widely utilized in cancer therapy applications for the delivery of
an assortment of chemotherapeutic agents. One of the first examples using hydrogels for
delivery of chemotherapeutics was by Jeyanthi and coworkers (Jeyanthi and Rao 1990) who
used collagen-poly(hydroxyethyl methacrylate) (HEMA) hydrogels for this application. The
chemotherapeutics, 5-fluorouracil (5-FU), bleomycin A2 (BLM), and mitomycin C (MMC)
were entrapped in the hydrogel matrix and their in vitro release rates were found to follow
zero-order kinetics indicating controlled release. 98% of 5-FU was released in 10 days, 52%
of MMC was released in 12 days, and 74% of BLM was released over 11 days (Jeyanthi and
Rao 1990). Another group of investigators showed that N-(2-hydroxypropyl methacrylamide)
(HPMA) hydrogels successfully delivered doxorubicin (DOX) for the treatment of BLC1
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leukemia in mice. After the DOX-loaded hydrogels were implanted in the mice, the drug was
detectable in the bloodstream at therapeutic concentrations for more than 4 days. In addition,
animals treated with free DOX survived for 35 days versus 60 days for those treated with the
DOX-loaded hydrogel implant showing better efficacy with this type of therapy (St'astny
2002). Hydrogels containing L-phenylalanine and L-histidine complexed with cisplatin were
developed by Casolaro and coworkers (Casolaro 2009). The cisplatin release profile showed
an initial burst effect followed by a near zero-order release profile over the course of 7 days.
The poly(N-acryloyl-L-phenylalanine)-based hydrogel loaded with a water/DMSO mixture
released cisplatin three times greater than a gel loaded with water alone. However, the
cisplatin released from the hydrogels loaded with only water retained its cytotoxic activity
toward Me665/2/21 human melanoma cells, whereas there was no cytotoxic effect from the
drug released from the water/DMSO loaded hydrogels indicating more optimization may be
necessary for this system.
A more sophisticated system developed by Tauro and coworkers included hydrogel
matrices complexed with matrix metalloproteases (MMP) for the controlled delivery of active
cisplatin to tumor tissues (Tauro and Gemeinhart 2005; Tauro and Gemeinhart 2005).
Because MMPs are expressed and overactive in cancers such as malignant gliomas, such a
hydrogel system will allow for the active release of cisplatin only at the tumor site.
Poly(ethylene glycol) diacrylate (PEGDA) hydrogels were made with crosslinks containing
pendant MMP-sensitive peptides. Cisplatin was either entrapped in the hydrogels (without
peptide) or complexed to the MMP-sensitive peptides within the hydrogels. With this scheme,
cisplatin was released from the hydrogels as the free, native drug whereas when peptides were
incorporated in the hydrogel, it was released as both free cisplatin and cisplatin-peptide
complex. This system was the first reported for locally retaining a chemotherapeutic as a
hydrogel-prodrug that can be activated by naturally occurring extracellular proteases available
in cancer cells.
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Sol-gel hydrogels are systems that act as aqueous polymer solutions (usually at room
temperature) but form a more solid hydrogel once injected in the body and/or when they are
exposed to body temperature. Two such systems have been investigated for applications in
cancer therapy. Poly(organophosphazine)-paclitaxel conjugates were synthesized via covalent
ester

linkage

between

paclitaxel

(PTX)

and

a

carboxylic

acid-terminated

poly(organophosphazine) for their use in antitumor applications (Chun 2009).

Aqueous

solutions of these conjugates showed a sol-gel transition dependent on external temperature
and after local injection at the tumor site. Upon release from the hydrogel, the polymer-drug
complex was taken up by the cells where lysosomal enzymes cleave the PTX-polymer
complex releasing the active free PTX. These hydrogels were shown to inhibit tumor growth
more

effectively

than

paclitaxel

and

saline

alone.

Similarly,

aqueous

poly(organophosphazine) solutions containing DOX were transformed into hydrogels at body
temperature due to hydrophobic interactions. The release of DOX was sustained over 20 days
and in vitro studies with mouse lymphoblast cells showed the efficacy of DOX released from
the gels (Kang 2006). Overall, these systems are beneficial as they are able to increase the
solubility of hydrophobic anticancer drugs such as paclitaxel. The polymer surrounds the
drug in such a way as to prevent it from attaching with water molecules, while the hydrophilic
part of the polymer has positive interactions with surrounding water molecules increasing
solubility of the system (Kang 2006).
Stimuli-responsive hydrogels have also been used to deliver chemotherapeutics. For
example, Kang and co-workers synthesized thermosensitive [Np(IleOEt)1.20(AMPEG550)0.80]n]
hydrogels (Kang 2006) where AMPEG500 is α-amino-ω-methoxy-poly(ethylene glycol) and
IleOEt is L-isoleucine ethyl ester. The release of the DOX using the hydrogels was analyzed
over 20 days, showing control of the drug release. The delivery effect was further observed
using cancer cell line of mouse lymphoblast of P388D1, and it was observed that this drug
release remained constant over 30 days with no initial burst release. Similarly, a synthetic
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pH/temperature-sensitive block copolymer was used for the sustained delivery of PTX over 36
days with various drug loadings (Shim 2007).

The PTX-loaded polymer was injected

subcutaneously into tumor-bearing mice and the systems showed good anti-tumor effect for 2
weeks and induced strong apoptosis in tumor tissue.
pH-responsive, psyllium and polyacrylic acid-based hydrogel networks were prepared
by radiation-induced crosslinked polymerization and showed successful delivery of 5fluorouracil (Singh 2008). This system may be ideal to use for delivery of drug to the colon as
they could act as a double potential drug delivery device because psyllium itself has
therapeutic importance in reducing colon cancer risk. Additionally, the vasculature of tumors
is often insufficient to supply enough oxygen and nutritional needs for the expanding tumor.
The production of lactic acid under hypoxic conditions and the hydrolysis of ATP in an
energy-deficient environment contribute to an acidic micro-environment surrounding the
tumor cells. Because of this, it has been proposed that such pH-induced release of anti-cancer
drugs from pH-sensitive hydrogels could be a good mode of cancer treatment.
Hydrogel composites are systems that combine conventional hydrogels with
particulate materials improving on the characteristics of the hydrogel systems. An example of
this type of system is a two-phase hydrogel containing topotecan (TPT)-loaded liposomes
entrapped in a PEG-based hydrogel (Lalloo 2006). The physically entrapped TPT released
rapidly from the pure hydrogel system whereas controlled release was demonstrated for the
two-phase system. Rats inoculated with MAT B III breast cancer cells treated with this
system had longer tumor growth suppression and did not exhibit body mass loss in
comparison to other treatment modalities. Overall, bulk hydrogels may be easy to implement
and characterize, but they often lack the ability to degrade and therefore the necessity for posttreatment surgery may be necessary for their removal so other systems must be utilized.
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2.3.2 Hydrogels from Natural Polymers
Hydrogels from natural polymers are also of great interest for cancer therapy. Of
these, chitosan is the most commonly studied and Ta and coworkers recently provided an
excellent review of chitosan hydrogels for cancer therapy (Ta 2008).
biocompatible and biodegradable.

Chitosan is both

Obara and coworkers developed a photocrosslinkable

chitosan hydrogel that successfully delivers paclitaxel (Obara 2005).

The paclitaxel

remaining in the hydrogel retained its biological activity for at least 21 days and was released
in vivo upon degradation of the hydrogel. The paclitaxel incorporated gel inhibited the growth
of subcutaneously induced tumors with Lewis lung cancer (3LL) cells more effectively than
those treated with the chitosan hydrogel, free paclitaxel, and the non-treated control group.
Similarly,

fibroblast

growth

factor

(FGF)-2

and

paclitaxel

were

released

from

photocrosslinkable chitosan hydrogels for applications in wound repair, angiogenesis, and
tumor growth (Ishihara 2006). PTX was released from the hydrogel in a controlled fashion
via bulk degradation of the hydrogels and these systems were shown to effectively inhibit
tumor growth and angiogenesis in mice. On the other hand, the release of FGF-2 caused an
induction of angiogenesis showing the potential use in wound healing. An in situ gelling
chitosan hydrogel system was designed to deliver doxorubicin in a sustain time period for the
treatment of primary and secondary osteosarcoma in mice. The hydrogel system inhibited the
growth of osteosarcoma as well as lung metastasis and also reduced the side effects of DOX in
mice (Ta 2009).
Other natural polymers such as human serum albumin (HAS), alginate, and agarose
have also been studied. An in situ forming drug delivery system consisting of DOX in a
human serum albumin/tartaric acid derivative (HAS-TDA) tissue adhesive gel was developed
by Kakinoki and coworkers which showed an anti-tumor effect in mice (Kakinoki and
Taguchi 2007; Kakinoki 2007).

WiDr (human colon carcinoma) were implanted

subcutaneously into mice and the tumors grew up to approximately 1 cm in diameter.
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Aqueous solution of DOX and HSA-TDA was injected around the tumor via a syringe pump
and the gel was shown to reduce tumor volume in comparison to free DOX. Bouhadir and
coworkers developed sophisticated alginate-based hydrogels capable of delivering several
anti-cancer agents with different types of release (Bouhadir 2001).

Methotrexate was

incorporated within the pores of the gel, doxorubicin was covalently attached to the polymer
backbone of the gel, and mitoxantrone was ionically complexed to the polymer. This resulted
in diffusion-controlled release, release via chemical hydrolysis, and release after dissociation
from the hydrogels, respectively. A sodium dodecyl sulfate (SDS) micellar/agarose hydrogel
nanocomposite was developed for the delivery of the chemotherapeutic drug, camptothecin
(CPT) (Liu and Li 2005). CPT was first incorporated into the micelles from SDS and the
micellar drug solution was then used in the preparation of the agarose hydrogel. The CPT
diffusion from the hydrogels was shown to be Fickian and the SDS prolonged the drug release
by reducing the diffusion coefficient of CPT in the gel systems.

2.3.3 Biodegradable Hydrogels
The use of biodegradable hydrogels in the design of novel drug-delivery systems has
attracted interest and attention due to the many advantages associated with these systems.
These include controlled drug release via degradation as well as the ability to tailor the
balance of the hydrophilicity and hydrophobicity of the carriers allowing for the release of
different types of drugs (Guo and Chu 2007)). These materials are especially beneficial in
cancer therapy as they allows for the implementation of the hydrogel at the tumor site without
removal post-therapy.

Several of these systems are discussed below.

Shikanov and

coworkers investigated a poly(sebacic acid-co-ricinoleic acid ester anhydride) biodegradable
release implant for the delivery of paclitaxel to tumors in mice. The polymeric formulation
with paclitaxel was injected intratumorally (Shikanov 2008) and this was shown to inhibit the
growth of the tumors. Casadei and coworkers developed a pH-sensitive and biodegradable
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composite hydrogel of methacrylated and succinate derivative of dextran for use in colon
specific drug delivery (Casadei 2008). The hydrogel system showed pH-responsive swelling,
chemical resistance in simulated gastrointestinal fluids, and yet degradation was shown in
dextranase and esterase.

The gels were able to effectively release 2-methoxyestradiol.

Daunomycin was incorporated into a poly(aldehyde gluronate) hydrogel via labile covalent
bonds and showed release from the hydrogel system after the hydrolysis of the linkage
between the drug and polymer. These biodegradable devices were shown to successfully
release daunomycin in a range from 2 days to 6 weeks while maintaining the biological
activity of the drug (Bouhadir 2000). Additionally, fumerate-based unsaturated poly(ester
amide) and poly(ethylene glycol) diacrylate systems were used to deliver PTX (Gou 2008)
and biodegradable gelatin-based hydrogels were used to deliver cisplatin (CDDP) and
adriamycin (ADM).

2.3.4 Microgels and Hydrogel Nanoparticles (Nanogels)
As previously mentioned, hydrogel particles are advantageous in that they exhibit
features of both the hydrogels they are made up from and of particulate systems (Hamidi
2008). Microgels have been studied for oral delivery of chemotherapeutics. For example,
Bromberg and colleagues evaluated the possibility of using a pH- and temperature-sensitive
gel microparticles for this application (Bromberg and Alakhov 2003; Bromberg 2003). Gels
made using free-radical polymerization of poly(acrylic acid) (PAA), poly(ethylene oxide)
(PEO) and poly(propylene oxide) (PPO) were used. pH-sensitive microgels are useful in this
type of delivery due to their ability to stay collapsed in low pHs in the stomach and the ability
to swell in higher pHs in the small intestine, allowing for localized delivery.

Human

colorectal carcinoma (Caco-2) cells were used as the gastrointestinal model. P-glycoprotein
(P-gp) is a transmembrane protein known to be overexpressed in Caco-2 cells and other tumor
cell lines that pumps drugs out of the cell. The microgels were shown to inhibit P-gp24

mediated doxorubicin efflux from the cells, enhancing passive influx and the overall
absorption of the drug by the cells. This group also developed microgels comprised of loosely
crosslinked poly(acrylic acid) on which poly(ethylene oxide)-b-poly(propylene oxide)-bpoly(ethylene oxide) (PEO-PPO-PEO, Pluronic) copolymer segments were grafted. These
gels showed tailorable surfaces, structures, and ion-exchange capacity depending on the type
of Pluronic moiety grafted into the microgels. Studies were done to show the ability of these
microgels to uptake various anti-cancer drugs such as mitomycin, doxorubicin, and
camptothecin. These materials could potentially be used in oral delivery of anti-cancer drugs
due to the strong mucoadhesive properties of the system which allows them to adhere longer
onto mucosal tissues, thus providing the potential for sustained release of the loaded drugs by
diffusion.
Numerous other microgel systems may be used in cancer therapies via
chemotherapeutic delivery.

One such systems include ferrogels consisting of hydrogel

microspheres synthesized using irradiation of the emulsion of poly(N-vinylpyrrolidone)
PVP/ferromagnetic granule with cobalt γ-ray (Chen 2005). These self-assembled PVP/PVA
magnetic hydrogel microspheres were used to deliver bleomycin A5 to rabbit auricular VX2
tumors in New Zealand white rabbits in the presence of a 0.5 Te permanent magnet both
during and 24 hours after drug perfusion.

The microspheres, in conjunction with the

permanent magnet, successfully locally delivered the drug which shows the potential for their
use in magnetic drug targeting (Adriane 2006).

Poly(vinyl alcohol (PVA) hydrogel

microparticles were investigated and showed effective delivery of DOX to LoVo colon cancer
cells (Cavalieri 2008). Cisplatin was complexed with and released from poly(acrylic acid-comethyl methacrylate) microparticles where a burst release (40%) was shown in the first day
followed by zero-order kinetics.

The cisplatin had slightly lower activity and the

microparticles themselves exhibited low in vivo acute toxicity (Yan 2005).

Also,

biocompatible chitosan-based microgels were fabricated and loaded with methotrexate
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disodium (MTX) and then conjugated to the targeting molecule apo-transferrin.

Upon

intracellular delivery of the release vehicle, the microgel was exposed to low pH environments
that caused the pH-responsive chitosan to swell and release the drug (Zhang 2006).
There are many types of hydrogel nanoparticles that are able to deliver
chemotherapeutics. Paclitaxel was successfully delivered from the following systems: PEGPLA-PEG and PLA-PEG-PLA triblock nanoparticles which give a range of release profiles
from 90% total released after 12 days to only 20% released after 14 days (He 2007),
poly(ethylene oxide)-modified poly(β-amino ester) nanoparticles (100 - 150 nm) (Potineni
2003), and poly(ε-caprolactone)/Poloxamer 188 (PCL-PXA 188) nanoparticles which were
examined to determine their potential to overcome multidrug resistance (MDR) in a
paclitaxel-resistant human breast cancer cell line (Zhang 2009). Overall, the PCL-PXA 188
nanoparticles caused a significantly higher cytotoxicity than commercial PCL and free
paclitaxel. Doxorubicin has been delivered from multiple nanogel systems. These include
pH-responsive PEGylated nanogels comprised of 2-(N,N-diethylamino)ethyl methacrylate
used against breast and hepatoma cells (Oishi 2007), pH-sensitive hydrophobized pullulan
(PUL)-Nα-Boc-L-histidine (bHis) conjugates which increased in vitro cytotoxicity of MCF-7
breast cancer cells (Na 2007), dextran-doxorubicin (DEX-DOX) conjugates encapsulated in
chitosan hydrogel nanoparticles which resulted in biodegradable, biocompatible, long
circulating system (Mitra 2001), and cholesterol pullulan (CHP) hydrogel nanoparticles
conjugated with folic acid (FA) (Hidaka 2006). As the folate receptor (FR) is elevated in
many cancers, the FA-CHP nanoparticles exhibited greater cellular uptake in human
epidermal carcinoma (KB) cells that overexpress FR. In vivo studies indicated tumor volume
in nude mice was significantly suppressed by these nanoparticles (Hidaka 2006).
Other hydrogel nanoparticle systems used to deliver chemotherapeutics include
PVP/PVA-based hydrogel nanospheres to deliver bleomycin (Guowei 2007), core-shell
nanoparticles prepared from block copolymer of methoxy poly(ethylene glycol)26

polycaprolactone (mPEG-PCL) to enhance the circulation time of cisplatin and treat BGC823
(human gastric cancer) and H22 (murine hepatoma) cells (Li 2008), PNIPAAm nanogels for
the controlled release 5-FU, methotrexate, and mitomycin C (Blanco 2008), and carboxylic
acid-functionalized poly(β-amino ester)-graft-PEG nanogels which delivered cisplatin and
showed lower in vitro cytotoxicity to SKOV-3 ovarian cells versus free cisplatin (Jin 2007).
Additionally, 300 nm self-assembled hydrogel nanoparticles capable of specific targeting were
synthesized by Na and coworkers from carboxymethylated (CM)-curdlan, substituted with a
sulfonylurea (SU) as a hydrophobic moiety for self-assembly. All-trans retinoic acid (ATRA)
was used as their model anti-cancer drug and the nanoparticles were conjugated with
lactobionic acid (LBA) due to the ligand-receptor interactions between this moiety and HepG2
hepatic carcinoma cells. It was determined that these hydrogel nanoparticles are useful for the
treatment of liver cancer because of the ligand-receptor mediated specific interactions between
the particles and HepG2 cells and the controlled release of ATRA (Na 2000).
A very unique utilization of hydrogels for cancer therapy was completed by Lee and
coworkers who utilized nanogels in a novel manner to induce necrotic cell death in cancer
cells (Lee 2009). Nanogels were fabricated via light crosslinking of oligo(L-lactic acid)poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide)-oligo(L-lactic acid) and
poly(ethylene glycol) grafted poly(L-lysine). The nanoparticle exhibited a drastic volume
expansion from 150 nm diameter at 37 °C to 1.4 µm at 15 °C upon a brief cold-shock
treatment. The expansion of the nanogels severely damaged the cancer cells through the
disruption of the cytoskeleton and vesicular membranes as well as physically rupturing
cellular membrane structures which resulted in necrotic cell death.
Overall, there are numerous hydrogel systems that can be used for the delivery of
chemotherapeutic agents. These systems have the potential to overcome the limitations of
systemic chemotherapy delivery in that the drug may be released locally by a hydrogel depot
or the cancer cells may be specifically targeted via hydrogel nanoparticles. Additionally,
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these systems may provide advantages to free drug by increasing the delivery, solubility and
circulation of the drug while not requiring a continuous intravenous injection of the treatment
agent.

Fortunately, the use of hydrogel systems is not limited to just the delivery of

chemotherapeutic agents and this will be outlined in the remainder of this review.

2.4 Radiation Delivery via Hydrogels
Conventional external radiation therapy is another one of the major treatment
modalities used as a first-line treatment of cancer. It is often used in conjunction with
chemotherapy and/or surgical resection of a tumor. Despite the wide-spread use of radiation
to treat cancer it has several disadvantages including inconvenience (patients are often
required to undergo daily treatments for several weeks), local limitations (no systemic
delivery), and tissue tolerance, which limits the amount and location of radiation exposure.
Brachytherapy, the local delivery of radioactive seeds, is also commonly used, but it has its
own disadvantages including complicated implementation and the need to remove the seeds
after treatment. Hydrogels that deliver radionucleotides may have the ability to overcome
some of these limitations. The radiation would need to be delivered locally from the hydrogel
without effecting surrounding healthy tissue and if degradable, there would be no need for
removal post-treatment. There are several radionucleotides currently used for the treatment of
cancer, the most common being beta-emitters which induce DNA damage in cells (Hamoudeh
2008).
One such radionucleotide is Rhenium-188 (188Re), which decays by beta emission and
15% gamma emission which makes it suitable for both therapeutic and diagnostic purposes.
Also,

188

Re is suitable because of its deep tissue penetration (11 mm maximum, 3.8 mm

average) (Huang 2009). A biodegradable hydrogel comprised of sodium alginate and calcium
chloride was fabricated for the delivery of cisplatin (CDDP) and Rhenium-188 for combined
regional radiochemotherapy. This therapy was achieved in rats via in situ delivery of the
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hydrogel system into Fischer-344 rats to treat breast adenocarcinoma induced tumors. Tumor
volume measurements were lower after treatment with the CDDP/188Re-loaded hydrogels as
compared to various controls with limited changes in kidney function of the rats. Also, the
188

Re in the hydrogels allowed for the imaging of the hydrogel location and 188Re distribution

throughout the animals (Azhdarinia 2005).
Chitosan hydrogels have been investigated for the delivery of radionucleotides to
cancerous tissue. Huh and coworkers developed a Holmium-166 (166Ho)-chitosan hydrogel
complex which were injected into Wistar rats with cultured C6 glioma cells. A 97% reduction
in the tumor growth rate was shown in these animals and their survival rate was greater than
those in the control group (Huh 2005). These materials were then utilized in a phase IIB
clinical study with forty patients with hepatocellular carcinoma.

The complex was

administered percutaneously and after two months, 31 of the patients experienced complete
tumor necrosis with survival rates of 87.2, 71.8, and 65.3 % for 1, 2, and 3 years, respectively
(Cho 2005; Kim 2006). Crosslinked chitosan implants were also developed as a potential
biodegradable device to be used in brachytherapy (Azab 2006).

131

I-Norcholesterol was

incorporated into the chitosan/gluteraldehyde-based hydrogels, and 80% of the material was
released within a month after implantation. Histological examination of the implants without
131

I-norcholesterol indicated negligible tissue response to the implants in comparison to

degradable sutures (Azab 2006). Chitosan and β-glycerophosphate (β-GP) were used in the
preparation of thermosensitive hydrogel (C/GP) nanoparticles for a novel internal radiation
therapy (IRT) method for the controlled delivery of
the

188

188

Re-Tin colloids. Studies showed that

Re-Tin colloids within the hydrogel nanoparticles were approximately 12 nm in

diameter and these nanoparticles were localized around the injection site for up to 48 hours
after injection.

This type of IRT could be an effective treatment method for regional

radiotherapy (Huang 2009). Azab and coworkers used chitosan-norcholesterol hydrogels to
treat a mammary mouse tumor model which prevented 69% of tumor recurrence and
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metastatic spread of the disease (Azab 2007).

Overall these systems are a promising

alternative to current radiation therapy.

2.5 Immunotherapy, Gene Delivery, and Hormone Delivery via Hydrogels
Although these therapies are not yet widely used in conventional cancer treatment,
immunotherapy, gene therapy, and hormone therapy have been investigated for cancer therapy
applications via hydrogels. Immunotherapy aims to exploit the body’s natural anti-tumor
defenses by stimulating immunity above a threshold level necessary to overcome tolerance,
and thus leading to tumor regression (Havranek 2002). Using the protective mechanisms
naturally occurring in the body is attractive for numerous reasons, including low toxicity, a
high degree of specificity and the avoidance of cytotoxic drugs. Immunotherapy may provide
an additional treatment modality for malignancies that are resistant to conventional cancer
therapy. There are a variety of cytokines that have proven to be potentially effective in
inducing immune responses in the body to eliminate tumor cells. Interleukin-12 (IL-12) is one
of the most feasible cytokines to be utilized in immunotherapy. It induces the Th1 immune
response, promotes maturation of cytotoxic T lympohcytes, and promotes stimulation of
natural killer cells (Shimizu 2008).
For effective cytokine immunotherapy of cancer, a delivery system that ensures the
slow release of cytokines is necessary due to the short half-life of the molecules involved
(Shimizu 2008).

As such, Shimizu and coworkers have developed cholesterol-loaded

pullulan-based hydrogel nanoparticles that are able to encapsulate and stabilize various
biological molecules. These nanoparticles were used for the in vivo administration of IL-12
for the treatment of fibrosarcoma in mice.

The IL-12-loaded nanoparticles were

subcutaneously injected into the mice which resulted in the prolonged elevation of IL-12 in
the blood serum. Repetitive administration of the nanoparticles resulted in a drastic growth
retardation of subcutaneous fibrosarcoma in the mice without causing any serious toxic effects
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(Shimizu 2008). Similarly, two types of therapeutic devices were created and tested for the
delivery of IL-2 in a mouse tumor model. IL-2-containing macroscopic cylinder-shaped
hydrogels and injectable microspheres comprised of methacrylated dextran were investigated
and the therapeutic activity was tested in DBA/2 mice with SL2 lymphosarcoma. IL-2 was
slowly released from the hydrogel systems over a period of 5 to 10 days and the therapeutic
effects were very good or comparable to that of free IL-2.

This systems was more

advantageous than free IL-2, however, due to continuous delivery after one implantation of
the hydrogels versus 5 days of invasive treatments of free IL-2 (De Groot 2002).
GMCSF (granulocyte-macrophage colony-stimulating factor) is a potent cytokine that
has been demonstrated to improve the function of antigen presenting cells.

Cancer

immunotherapeutics involving this agent have resulted in long-lasting and specific anti-tumor
immune responses in animal models (Seo 2009). Seo and coworkers developed biodegradable
chitosan (CH)-based hydrogels loaded with GMCSF and various anticancer drugs
(doxorubicin, cisplatin, or cyclophosphamide) as a chemoimmunotherapeutic agent.

The

hydrogel system was tested on mice using TC-1 cervical tumor cells, which express the
tumor-specific antigen, HPV-16 E7. Delivering both the anticancer drug and GMCSF from
the CH hydrogel resulted in synergistic anti-tumor effects via the induction of a tumor
antigen-specific CD8+ T cell-mediated anti-tumor immunity. Also, a chitosan-based hydrogel
system which contained both doxorubicin and vaccinia virus vaccine expressing
Sig/E7/LAMP-1 inhibited tumor growth in mice when injected intratumorally. The result was
synergistic when the combined therapy was performed and the survival of the tumor-bearing
mice was dramatically improved (Han 2008). Additionally, injectable matrices capable of
delivering immunomodulatory factors were obtained by mixing alginate microspheres with
soluble alginate solutions. The soft macroporous gels that formed were able to be loaded
effectively with IL-2 which were delivered into bone marrow cells (Hori 2009).
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Gene therapy has emerged as a new method of cancer therapy targeted at the level of
cellular gene expression (Gomez-Navarro 1999). In this approach, the complex cancerous
physiological state is changed by delivering nucleic acids to tumor or normal cells where these
nucleic acids may be genes, portions of genes, oligonucleotides, or RNA. The delivery of
DNA for this application is difficult because once the vector-plasmid DNA is injected into the
body, gene expression cannot always been achieved due of the fast diffusion away from the
injection site. Therefore, the application of delivery depots such as hydrogels containing
plasmid DNA can be used to achieve controlled release over an extended period of time
(Fukunaka 2002). Megeed and co-workers investigated the influences of DNA molecular
weight, DNA conformation, and hydrogel shape on DNA release from silk-elastin like protein
polymer hydrogels (SELP). In vivo studies using mice showed that supercoiled DNA was the
main form released from the hydrogels (Megeed 2004). Fukunaka and coworkers developed a
biodegradable hydrogel through the cationization of gelatin for carriers of plasmid DNA.
125

Iodine-labeled plasmid DNA incorporated in cationized gelatin hydrogels were implanted

into the femoral muscle of mice and it was found that the intramuscular implantation of the
plasmid DNA-incorporated hydrogel enhanced the expression of the plasmid DNA around the
implantation site (Fukunaka 2002).
Hormone therapy is also effective in treating and preventing certain cancer, the most
prevalent of these being prostate cancer. An implant that delivers histrelin for testosterone
suppression has already been shown to decrease prostate cancer incidences (Schlegel 2009).
Histrelin-based hydrogels were investigated for the effectiveness of the implants in
suppressing testosterone production in men with prostate cancer. Gonadotropin-releasing
hormone agonist, histrelin, was reliably released from the gel systems and successfully
suppressed testosterone production in male patients with prostate cancer for 12 months after
hydrogel implantation. Prostate cancer is very hormone-sensitive and responds to androgen
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withdrawal leading to tumor regression and relief of symptoms from metastatic disease
(Schlegel 2001).

2.6 Hyperthermia Therapy via Hydrogels
As mentioned previously, hyperthermia is becoming more prevalent in the treatment of
cancer when used in conjunction with conventional therapies such as radiation and surgical
resection of tumor tissue. Mild hyperthermia is effective in increasing the radiation response
of tumors, as it oxygenates both diffusion-limited chronically hypoxic and perfusion-limited
acutely hypoxic cells (Song 2001). Additionally, although the role of hyperthermia alone as a
cancer treatment may be limited, there is extensive pre-clinical data showing that in
combination with radiation it is one of the most effective radiation sensitizers known
(Horsman and Overgaard 2007). Similarly, hyperthermia enhances the cytotoxicity of various
antineoplastic agents.

Applications of selected chemotherapeutic drugs at elevated

temperatures has been shown to enhance the inhibition of clonogenic cell growth in both in
vitro and in animal studies (Hildebrandt 2002). Some of the limitations of some of the current
methods of implementing hyperthermia were mentioned previously.
Magnetic fluid hyperthermia (MFH) involves the introduction of magnetic particles
into the tumor tissue and exposing the tissue to an external alternating magnetic field (AMF)
to increase the temperature in the tumor (Wang 2005). The heating occurs due to the presence
of magnetic nanoparticles which heat upon exposure to the AMF. The heating mechanism for
superparamagnetic particles is based on Brownian relaxation (rotation of the particle as a
whole according to external magnetic field) and Neel effect (reorientation of the
magnetization vector inside the magnetic core against an energy barrier) (Babincova 2001).
When superparamagnetic particles are used for localized hyperthermia therapy, only a weak
magnetic field is needed to generate heat compared to the strong field needed for
ferromagnetic particles.

The superparamagnetic particles are economical and have been
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shown to be biocompatible in many cases (Yang 2007). One of the biggest disadvantages of
MFH is the fact that the magnetic nanoparticles are often in an aqueous solution and even if
injected directly at the tumor site, there is no method to ensure the particles remain in that
location. Hydrogel nanocomposites that can physically entrap nanoparticles in the hydrogel
matrix may be used to deliver iron oxide nanoparticles directly to tumor sites so that
hyperthermia treatment is locally restricted. Along with delivering heat, these systems would
have the ability to deliver other therapeutic agents (chemotherapeutics, radionucleotides,
immunotherapeutics) outlined previously for a multi-modality treatment.

A handful of

systems have already shown potential for this.
For example, temperature-responsive magnetic PNIPAAm hydrogels were synthesized
by Ang and coworkers incorporating micron-sized iron and iron oxide nanoparticles. The gels
were shown to heat in an alternating magnetic field at a frequency of 375 kHz and field
strength range of 1.7 to 2.5 kA/m (Ang 2007). Le Rendard and coworkers developed a
magnetic particle-loaded, injectable, in situ gelling system for the local delivery of
hyperthermia.

The gels entrapped magnetic particles within human cancer tumors

xenografted in mice. Various systems were studied including a hydrogel, single-solvent
organogel, and cosolvent organogel formulation. A poly(ethylene-vinyl alcohol) system in
DMSO formed the most suitable system in terms of gel formation and heat delivery (Le
Renard 2010). These materials have also shown the ability to remotely delivery drugs through
the combination of temperature-responsive materials and the ability of these materials to
respond in an AMF because of the heat generated by entrapped iron oxide nanoparticles.
Such magnetically-responsive materials offer the benefit of controlling drug release in either a
single or multiple pulse formulation which benefits the patient by reducing the total amount of
drug required to reach the effective dose, reducing the frequency of administration (Brazel
2009). Satarkar has demonstrated this phenomenon with PNIPAAm gels loaded with iron
oxide nanoparticles to deliver a model drug (Satarkar and Hilt 2008). Pulsatile release of the
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drug was successful because upon exposure to the AMF, the PNIPAAm gels collapsed,
releasing the drug, whereas the amount released was less with the field turned off. Overall,
magnetic hydrogel nanocomposites are a promising avenue for multi-modality treatment of
cancer and should be investigated further to show their in vivo effectiveness.

2.7 Miscellaneous Uses of Hydrogels in Cancer-Related Applications
In addition to using hydrogels for the treatment of cancer, these systems have been
used in other cancer-related applications including tumor embolization, three-dimensional cell
culture to mimic the tumor microenvironment, tumor imaging, and biosensors.

A few

examples of these are outlined below.
Dextran hydrogel and Holmium-166 poly(L-lactic acid) microspheres were
investigated for their use in tumor embolization of Vx2 rabbit heat and neck cancers. Vx2
auricular tumors in rabbits were embolized via the caudal artery with these microspheres and
it was determined that the particles are potential candidates for the embolization of head and
neck cancer (van Es 2001).

Regarding biosensors, hybridization on a polyacrylamide

hydrogel microarray was developed by Fedorova and coworkers for the identification of point
mutations in BRCA1 (Fedorova 2006). BRCA1 mutations are associated with a higher risk of
breast and ovarian cancer in women (accounting for 56-80% of the total risk during the
lifetime) and testing for such mutations allows for better breast cancer prognosis, selection of
individual treatment strategy, and prevention of recurrence. The microarray was designed to
detect five-point mutations and was tested with 36 control specimens with known genotypes
and was then used to examine 65 breast cancer patients. The results demonstrated were that
the microarray detects about 90% of all BRCA1 mutations.
Unfortunately, solid tumors are often undetectable with most imaging techniques until
they grow to a substantial size. The difficulties in the fluorescent labeling of tumors may be
overcome through the use of quantum dots (QDs) which have higher molar extinction
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coefficients, increased light emission, better stability, and sustained luminescence in
comparison to conventional fluorophores. They also exhibit broad excitation but narrow
emission spectra, making them suitable for multi-modal detection. Cancer cells can be tagged
with QDs causing them to fluoresce when excited with light allowing for the determination of
the location of tumors (Nair 2008). As such, Nair and coworkers developed PNIPAAm
hydrogel nanoparticles with embedded quantum dots (QDs) for use as a functional device for
tumor imaging (Nair 2008). The hydrogel-encapsulated QDs and QD-PNIPAAm were taken
into JHU-31 (prostate) cancer cell lines and tumors in mice. Additionally, in a melanoma
model, they also preferentially accumulated in the tumor tissue compared to normal tissue and
also showed a 16-fold uptake in comparison to non-derivatized QDs.
The most common application of hydrogels in cancer applications is their use in 3-D
cell culture of cancer cells.

There are numerous limitations in using 2-D cell culture

experiments including the inability to reproduce physiological patterns of cell adherence,
cytoskeletal organization, migration, signal transduction, proliferation, differentiation, and
response to external stimuli (Hutmacher 2009). It has been demonstrated that 3-D models
demonstrate cell-extracellular matrix (ECM) interactions that enhance cell biological activities
making them more relevant to living organisms than simple 2-D in vitro adhesions (Dainiak
2008). The ECM environment should be mimicked by immobilizing cell adhesive proteins,
such as fibronectin, collagen, laminin, or other biomolecules, or by developing synthetic
polymers which have some key characteristics of ECM (Dainiak 2008). Hydrogels can allow
this to occur. Also, three-dimensional cultures have become more popular for evaluating the
therapeutic potential of anti-cancer agents. There are several examples of 3-D cell models
including multi-layer cell systems cultured on porous membranes, matrix-embedded cultures
of single cells or aggregates using various extracellular matrix compounds, or hollow fiber
bioreactors with cell cultured within networks of perfused capillaries (Friedrich, Ebner et al.
2007). Hydrogels have the potential to expand these types of systems.
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The establishment of cell-based assays to rapidly detect active drug candidates is an
important stage in the testing of anti-tumor therapeutics. For example, a 3-D model for the
evaluation of anti-cancer drug sensitivity was developed using hyaluronan hydrogels (David
2008). The crosslinked hydrogel provided a 3-D matrix in which three cell lines (SA87, NCIH460, and H460M) were able to grow resulting in clusters and colonies of cells within the
hydrogel system. When exposed to doxorubicin and 5-fluorouracil, the cancer cells were
more resistant in the 3-D model than monolayer cell systems. The 3-D culture allows the
cancer cells to adopt behavior similar to what is observed in the natural tissue matrix and
mimics in vivo behavior better than monolayer cultures.

Also, Dainiak and co-workers

synthesized macroporous hydrogels using NIPAAm, abRGDm, and abRDGm-NIPAAm
(Dainiak 2008). Cells were grown in 3-D cultures in these functionalized materials and
further developed by matching cell types with appropriate extracellular matrix components,
allowing for the potential of using these 3-D models for more realistic in vitro studies.
Similarly, an alginate-based hydrogel system was used to examine the role of the transition
from 2-D to 3-D cell culture on cancer cell angiogenic capability (Fischbach 2009). It was
found that the 3-D integrin engagement within the tumor microvasculature regulates cancer
cell angiogenic signaling, making them more valid for use in cancer therapy applications.

2.8 Future Work and Applications
The applications of hydrogels for cancer therapy can definitely be expanded upon in
the future. For the combination of radiotherapy and hyperthermia, the effect is greatest for
simultaneous application, but this is not necessarily feasible in clinical practice (Wust 2002).
Hydrogels could potentially overcome this through the combined delivery of heat and
radiotherapeutics. Other future directions include further development of in situ gelation, in
vivo biocompatibility studies on the effect of hydrogels, looking into the treatment of
metastasis, using hydrogels for the prevention of recurrence, delivery of other agents such as
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plasmids, short oligonucleotides, hormones, antibodies, and peptidic agents (Ta 2008).
Further studies also need to focus on hydrogel nanocomposites capable of delivering heat for
hyperthermia applications.

These materials

have been

widely investigated

for

chemotherapeutic delivery and the effectiveness of hyperthermia is well-established so this
should be a priority in those studying hydrogels for cancer therapy.

2.9 Conclusions
Hydrogels have been successfully implemented for the treatment of cancer in
numerous in vitro and in vivo applications. This includes using hydrogels and hydrogel
particle systems comprised of many types of polymeric materials as implantable or injectable
materials to deliver therapeutics.

These materials can deliver therapeutics such as

chemotherapeutic agents, immunotherapetics, radiotherapeutic agents, and heat. Hydrogels
offer great potential to improve upon current conventional cancer therapies which are often
limiting. They may also be utilized in non-therapy cancer applications such as biosensors, 3D cell culture, tumor imaging, and tumor embolization.
necessary for the future development of these applications.
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More in vivo studies will be

CHAPTER 3

Poly(ethylene glycol)-Based Magnetic Hydrogel Nanocomposites for Hyperthermia
Cancer Therapy

(Modified from article published in Acta Biomaterialia, 2009, 6, 1039-1046.)

Hyperthermia, the heating of cancerous tissues to between 41 and 45°C, has been
shown to improve the efficacy of cancer therapy when used in conjunction with irradiation
and/or chemotherapy. Here, a novel method for remotely administering heat is presented,
which involves the heating of tumor tissue using hydrogel nanocomposites containing
magnetic nanoparticles which can be remotely heated upon exposure to an external alternating
magnetic field (AMF).

Specifically, this research explores the use of hydrogel

nanocomposites based on poly(ethylene glycol) methyl ether methacrylate and dimethacrylate
(PEGMMA/PEGDMA) with iron oxide as implantable biomaterials for thermal cancer
therapy applications. Swelling analysis of the systems indicated a dependence of ethylene
glycol (EG) content and crosslinking density on swelling behavior where greater EG amount
and lower crosslinking resulted in higher volume swelling ratios. Both the entrapped iron
oxide nanoparticles and hydrogel nanocomposites exhibited high cell viability for murine
fibroblasts indicating potential biocompatibility. The hydrogels were heated in an AMF, and
the heating response was shown to be dependent on both iron oxide loading in the gels and the
strength of the magnetic field. For proof-of-concept of these systems as a thermal therapeutic,
the ability to selectively kill M059K glioblastoma cells in vitro with hydrogel nanocomposites
exposed to an AMF was demonstrated.
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Keywords
Hydrogel nanocomposite, poly(ethylene glycol), hyperthermia, thermoablation,
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3.1 Introduction
The development of cancer therapeutics is an important component of biomedical
research today because even though much has been done to overcome and treat the disease,
there are still many types of cancer, such as glioblastoma and pancreatic (Sneed, Stauffer et al.
1998) that have extremely poor treatment success rates.

Therefore, multiple-modality

treatment has become the preferred treatment approach. Hyperthermia, the heating of cancer
tissues to between 41 and 45°C, has been proven to have the potential to provide a
straightforward way of treating cancer in combination with well-developed therapeutics such
as irradiation and chemotherapy (Falk and Issels 2001). Extensive pre-clinical data has shown
that the combination of hyperthermia with radiation and/or chemotherapy improves the
efficacy of the prescribed treatment without affecting additional systemic toxicity (Horsman
and Overgaard 2007; Issels 2008). Aside from having a cytotoxic effect on cancerous tissue,
hyperthermia has been shown to increase tumor blood flow which induces hypoxia, acidosis,
and energy deprivation at the tumor site, thereby increasing therapy efficacy (Hildebrandt,
Wust et al. 2002).
Thermoablation, the thermal destruction of cells at temperatures above at least 50°C, is
another potential cancer therapy method involving heat therapy (Jordan, Scholz et al. 1999).
Currently, there are a number of obstacles hyperthermia treatment faces including restriction
of local heating into the tumor without damaging surrounding tissue (Moroz, Jones et al.
2002), and the inability to heat the cancer tissue locally without using invasive and
uncomfortable heating probes (Guedes, Sadeghiana et al. 2005). This can potentially be
overcome through the development of systems which can be delivered to and/or implanted at
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tumor sites and remotely heated from outside the body as seen in Figure 3.1. The hydrogel
nanocomposite composed here will be fixed in place due to compression by the surrounding
tissue, hence, providing local heating and overcoming less-specific whole-body and regional
heating.

A novel class of biomaterials based on nanocomposite hydrogels, specifically

systems composed of PEG and iron oxide, has the potential to be used in such hyperthermia
applications. The exposure of the gels to a high-frequency magnetic field will lead to remote
heating due to the magnetic particles in the nanocomposite.
Hydrogels are three-dimensional, hydrophilic, polymeric networks that can absorb up
to thousands of times their dry weight in water or biological fluids (Peppas 1987; Corkhill
1989; Peppas 2006). They consist of polymeric chains with either physical or chemical
crosslinks preventing their dissolution while allowing swelling upon interaction with aqueous
solutions.

Hydrogels are advantageous for many biomedical applications due to their

resemblance of natural living tissue and inherent biocompatibility, which can be partially
attributed to their soft, flexible nature and high water content (Peppas 2006). They have been
utilized in a wide variety of biomedical and pharmaceutical applications such as drug delivery,
contact lenses, and tissue engineering (Peppas 1987; Peppas 2000; Frimpong and Hilt 2007).
In particular, poly(ethylene glycol) (PEG)-based hydrogels have been widely investigated and
are considered “stealth” systems due to their high water content and the presence of PEG
chains which exhibit high biocompatibility. The biocompatibility of PEG stems from its
ability to repel protein absorption, due to the hydrophilic nature of the polymer (Nagaoka
1984; Jeon 1991). The PEG polymer component in this research shows the ability to shield
iron oxide nanoparticles incorporated in the polymer matrix.
Despite the many advantages of using conventional hydrogels, their applications are
often limited due to their poor mechanical strength and somewhat limited response and
actuation properties (Xiang 2006). In recent years, hydrogel nanocomposites have received
increased interest as a result of their unique properties and expanded applications
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Figure 3.1. Schematic of hydrogel nanocomposites placed near tumor and heated via an
external alternating magnetic field.
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(Brazel 2009; Hawkins 2009; Satarkar 2009; Schexnailder and Schmidt 2009). Hydrogel
nanocomposites involve the incorporation of various nanoparticulate materials within a
hydrogel matrix which provides easy, straightforward methods for enhancing the properties of
hydrogels. Thus far, a number of nanoparticulates have been utilized in nanocomposite
hydrogel systems including metallic nanoparticles, carbon nanotubes, clay, ceramics,
magnetic nanoparticles, hydroxyapatite, and semiconducting nanoparticles (Degirmenbasi
2006; Frimpong 2006; Okada and Usuki 2006; Zhang 2006; Meenach 2009; Meenach 2009).
The incorporation of magnetic nanoparticles such as iron oxide nanoparticles into hydrogels
can create tunable nanocomposites that can be remotely controlled by a magnetic field
(Frimpong 2006; Satarkar and Hilt 2008). In recent work by Satarkar and coworkers (Satarkar
and Hilt 2008; Satarkar and Hilt 2008), remote-controlled heating and drug release using
hydrogel

nanocomposites

based

on

N-isopropylacrylamide

(NIPAAm)

and

Fe3O4

nanoparticles have been successfully demonstrated. This controlled release was due to the
thermally-responsive nature of the NIPAAm, and the remote-controlled heating by applying
an alternating magnetic field (AMF) which heated the magnetic nanoparticles present in the
hydrogel matrix. Similarly, PEG methyl methacrylates demonstrate a thermal response with
tunable lower critical solution temperature (LCST) values depending on the PEG chain length
which may also allow them to be used in drug delivery applications (Lutz 2008).

At

temperatures below the LCST, hydrogel systems are swollen whereas above this temperature
the polymer matrix collapses. For these studies, iron oxide nanoparticles (20-30 nm diameter)
were incorporated into a PEG methyl ether methacrylate/dimethacrylate hydrogel matrix.
Upon exposure to an alternating magnetic field, superparamagnetic iron oxide nanoparticles
have the ability to heat primarily due to Brownian movement (frictional losses) and Neel
relaxation losses (Babincova 2001; Bahadur and Giri 2003) .
In regards to the biocompatibility of hydrogel nanocomposites, a limited amount of
cytocompatibility or hemocompatibility studies have been reported. However, a wide variety
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of literature is available regarding the biocompatibility of the hydrogels and nanoparticulate
components that make up a hydrogel nanocomposite (Meenach 2009). One of the advantages
of hydrogel nanocomposites is that hydrogels can provide increased biocompatibility over
exposed, uncoated nanoparticulates because they encapsulate the particulate matter in the
composite matrix and providing a barrier between the sensitive tissues and the more harmful
nanoparticulates.

In a recent publication, the encapsulation of uncoated iron oxide

nanoparticles within a poly(N-isopropylacrylamide) hydrogel (Meenach 2009) was shown to
exhibit a more favorable cell viability than the nanoparticles themselves. As more hydrogel
nanocomposites are fabricated and characterized for various applications, it is important that
biocompatibility issues and safety of these materials are examined.
The objective of this research was to develop biocompatible magnetic hydrogel
nanocomposites that exhibit favorable swelling and cytotoxicity properties, and these novel
biomaterials have the ability to be remotely-heated via an alternating magnetic field. Swelling
analysis showed the thermal-responsive nature of the hydrogels, which exhibited deswelling
behavior at higher temperatures.

In addition, murine fibroblasts exposed to the

nanocomposites showed viability similar to that of the control on polystyrene. Also, it was
shown that the thermal response of the nanocomposites can be controlled through the AMF
field strength so that they exhibit temperatures for either hyperthermia and thermoablative
treatment. For proof-of-concept of these systems as a thermal therapeutic, the ability to
selectively kill M059K glioblastoma cells in vitro with hydrogel nanocomposites exposed to
an AMF was demonstrated. Ultimately, these hydrogel systems have the potential to more
effectively treat localized tumor via both drug delivery and thermal therapy via hyperthermia.
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3.2 Materials and Methods

3.2.1 Materials
The

macromers

(PEG200MMA)

and

poly(ethylene
poly(ethylene

glycol)
glycol)

(N=200)

methyl

ether

methacrylate

(N=1000)

methyl

ether

methacrylate

(PEG1000MMA) and crosslinkers tetra(ethylene glycol) dimethacrylate (TEGDMA) and
poly(ethylene glycol) (N=400) dimethacrylate (PEG400DMA) were obtained from
Polysciences (Warrington, PA). The Fe3O4 nanoparticles (20-30 nm diameter, 0.2% PVPcoated) were obtained from Nanostructured and Amorphous Materials (Los Alamos, NM).
The initiator, ammonium persulfate (APS), accelerator, N,N,N',N'-tetramethylethane-1,2diamine (TEMED), and ethanol (95%) were obtained from Sigma Aldrich (St. Louis, MO) at
99 and 98% purity, respectively. All materials were used as received.

3.2.2 PEGMMA-PEGDMA hydrogel fabrication
Magnetic hydrogel nanocomposites were fabricated via free-radical polymerization
with various macromer (PEGMMA) and crosslinking (PEGDMA) amounts as seen in Table
3.1, resulting in various crosslinking densities. The structure of these compounds can be seen
in Figure 3.2. A schematic describing the fabrication can be seen in Figure 3.3. Ethanol was
added to the macromer solution in a 1:1 by weight basis based on the macromer and
crosslinker. For hydrogels with iron oxide nanoparticles, the particles were added at 5 weight
% based on the macromer and crosslinker and were exposed to an ultrasonic bath for 30
minutes to facilitate dispersion of the iron oxide nanoparticles throughout the solution. After
sonication, 2 weight % APS and 4 weight % TEMED were then added to the mixture to
initiate the free-radical polymerization. This solution was then sonicated further for 2 minutes
before being loaded into a template consisting of two 15 cm by 15 cm glass plates with a 1.5
mm

thick

Teflon

spacer.

The

gels
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were

kept

in

this

template

for

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxx

Table 3.1. Hydrogel nanocomposite systems fabricated. For the nanocomposite system
column, the numbers before the PEG constituents refers to the mole% added to the feed
solution. All gels were made with 5 weight% iron oxide nanoparticles based on the mass of
the macromer and crosslinker.

Nanocomposite
System
50PEG200MMA50PEG400DMA
80PEG200MMA20PEG400DMA
95PEG200MMA5PEG400DMA
50PEG200MMA50TEGDMA
50PEG1000MMA50PEG400DMA
50PEG1000MMA50TEGDMA

Abbrev

Macromer Feed

Crosslinker Feed

AM

50 mol%
PEG200MMA
80 mol%
PEG200MMA
95 mol%
PEG200MMA
50 mol%
PEG200MMA
50 mol%
PEG1000MMA
50 mol%
PEG1000MMA

50 mol%
PEG400DMA
20 mol%
PEG400DMA
5 mol%
PEG400DMA
50 mol%
TEGDMA
50 mol%
PEG400DMA
50 mol%
TEGDMA

BM
CM
DM
EM
FM
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Figure 3.2. Poly(ethylene glycol) methyl methacrylate and poly (ethylene glycol)
dimethacrylate structures. n refers to the number of ethylene glycol groups present in the
chain.
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Figure 3.3. Schematic of how magnetic hydrogel nanocomposites were fabricated via freeradical polymerization.
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at least 2 hours (usually overnight) to allow for completion of polymerization. To remove any
potentially unreacted and potentially toxic macromer, crosslinker, and initiator residues, the
hydrogels were washed with deionized water for at least one week.
Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) analysis was
performed to determine the conversion of available carbon-carbon double bonds present in the
PEG constituents of the hydrogel using a Varian Inc. 7000e step-scan spectrometer. Upon
addition of the initiator to the gel solution, a sample of the solution was placed on the diamond
ATR crystal and IR spectra were obtained for 90 minutes at 2 scans per minute at 8 cm-1
spectral resolution between 700 and 4000 cm-1.

The data was analyzed using Varian

Resolutions software.

3.2.3 Thermal gravimetric analysis (TGA) of hydrogel nanocomposites
TGA measurements were made to determine the actual iron oxide nanoparticle loading
in the hydrogel nanocomposites using a TA Instruments Q500 thermogravimetric analyzer. A
dry hydrogel sample of approximately 10 mg was exposed to heat at a rate of 20°C min-1 in
nitrogen flow conditions. At 120°C the sample was heated isothermally for 10 minutes to
vaporize residual water and other volatile compounds before being heated to a final
temperature of 700°C. Final TGA data was obtained after normalizing the results with respect
to the gel mass at 120°C.

3.2.4 Swelling characterization
Equilibrium swelling characteristics of the PEG-Fe3O4 hydrogel nanocomposites and
pure PEG hydrogels were measured using a gravimetric method based on a comparison of the
density measurements of both swollen and dry gels at equilibrium as described previously
(Frimpong 2006). Upon the completion of synthesis and washing, hydrogel discs 13.8 mm in
diameter were cut from the bulk hydrogel films. The discs were then placed in phosphate
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buffered saline solution (PBS, pH 7.4) for at least 3 days to reach equilibrium. The mass of
the discs were measured in air and then in n-heptane (non-solvent) in their swollen state at 22,
37, 43, and 63°C and in their dry state. Heptane was used for volumetric swelling studies as it
interacts little if any, with water in the hydrogel system. The masses of the hydrogels both dry
and swollen states in air and n-heptane then allowed for the calculation of the volume swelling
ratio (Q) at equilibrium:
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where V is the volume of the sample, ρheptane is the density of n-heptane, Mair is the mass of the
sample in air, and Mheptane is the mass of the sample in n-heptane. The subscripts s and d refer
to the swollen and dry forms of the samples, respectively.

3.2.5 Cytotoxicity analysis of iron oxide nanoparticles and hydrogel nanocomposites
The iron oxide nanoparticles and hydrogel nanocomposites were analyzed for tissue
cytotoxicity using NIH 3T3 murine fibroblasts (American Type Culture Collection, ATCC
Manassas, VA).

Fibroblasts were cultured in Dulbecco’s Modified Eagle’s Medium

supplemented with 10% v/v calf bovine serum, 100 I.U/ml penicillin, 100 µg/ml streptomycin
(ATCC), and 1 µg/ml antimycotic Fungizone® (Invitrogen, Carlsbad, CA) at 37°C and 5%
CO2 in a humidified incubator. The cells were used from passages 5 to 8.
For iron oxide nanoparticle analysis, fibroblasts were seeded at 2500 cells/cm2 in a
polystyrene 12 well plate. After 24 hours, the media was aspirated and 1 ml of nanoparticles
suspended in complete medium (at 100, 500, and 1000 µg/ml) was added to each well. The
well plates were then returned to the incubator for 24 and 48 hour exposure time periods after
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which the fibroblasts were assayed for cell viability. A two-color fluorescence Live/Dead
Viability Assay® (Molecular Probes, Carlsbad, CA) was used to assess the cell viability of
both attached and unattached fibroblasts. A schematic of this process can be seen in Figure
3.4.

Stained samples were observed using a NIKON Eclipse 80i microscope at 50x

magnification. The percent cell viability (live cells/total cells) was determined by manually
counting the live and dead cells imaged with NIS-Elements software. Both attached and
unattached fibroblasts were analyzed in three separate samples with ten images (5 live and 5
dead) taken for each.
For hydrogel analysis, the gels were cut into discs (12.5 mm diameter), placed in
complete fibroblast medium and incubated at 37°C for 48 hours as seen in Figure 3.5. NIH
3T3 murine fibroblasts were seeded at 2500 cells/cm2 for 24 hours in 12 well-plates. The
medium was then aspirated from the wells and discarded.

Next, the medium that the

hydrogels were soaked in was placed over the fibroblasts. The well plates were then returned
to the incubator for 24 and 48 hours. Afterward, both the attached and unattached cells were
assayed for cell viability using the method described above.

3.2.6 Remote-controlled heating of nanocomposite hydrogels
Prior to heating, hydrogel nanocomposites were cut into discs (8.2 mm in diameter)
and equilibrated in PBS at room temperature (22°C). Remote-controlled heating of the
hydrogel nanocomposites was completed using an alternating electromagnetic field induced
by a Taylor Winfield induction power supply (model MMF-3-135/400-2) equipped with a
solenoid with a 15 mm diameter and 5 turns. The hydrogel discs at their equilibrium swollen
state were covered with Saran wrap, placed on top of the solenoid coil and exposed to the
alternating magnetic field. Two types of thermal analyses were performed. First, all six
hydrogel nanocomposite systems were exposed to the same magnetic field power at 297 kHz
and 25 kA/m. Then, the hydrogel systems were heated to either hyperthermia temperature
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Figure 3.4. Schematic showing the cytotoxicity analysis of iron oxide nanoparticles. NIH 3T3
murine fibroblasts were exposed to the nanoparticles in solution then stained with a Molecular
Probes Live/Dead stained and imaged for viability.
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Figure 3.5. Schematic of the cytotoxicity analysis of magnetic hydrogel nanocomposites
soaked in complete medium for 24 hours. NIH 3T3 cells were exposed to the media wash
solution and stained with a Live/Dead stain prior to fluorescence imaging to determine cell
viability.
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range (41-44°C) or thermoablative temperature range (61-64°C) by controlling the magnetic
field strength. Thermal images and data were acquired using an infrared camera (AGEMA
Thermovision 470) which recorded the surface temperature of the hydrogels. The surface
temperature was recorded continuously for 5 minutes.

3.2.7 M059K glioblastoma cell thermoablation via hydrogel heating
PEG-based magnetic hydrogels were used to demonstrate that cancer cells can be
killed by heat generated by hydrogel nanocomposites upon exposure to an alternating
magnetic field (via thermoablation).

As seen in Figure 3.6, M059K glioblastoma cells

(ATCC) were cultured in DMEM/Ham’s F-12 medium supplemented with 0.05 mM nonessential amino acids and 10% fetal bovine serum at 37°C and 5% CO2 in a humidified
incubator.

The cells were then seeded in 35mm culture dishes at 20,000 cells/cm2 and

incubated for 24 hours.

50 mole% PEG400MMA/50 mole% TEGDMA hydrogel

nanocomposites were cut at 8.2 mm and equilibrated in PBS overnight at room temperature.
Prior to heating, the gels were placed in Saran wrap to prevent water loss, and then placed on
the AMF coil. M059K cells were removed from the incubator, medium was aspirated from
the culture dish, and the dish was placed directly on the hydrogel for heat treatment. The gel
and cells were then exposed to the AMF (297 kHz, 18 kA/m) for 5 minutes. An IR camera
was used to collect still IR images at the end of the heating experiment to show the actual
temperature of the cells after exposure. Controls were done with the cells only (with no
hydrogel) exposed to the AMF and with cells exposed to no field, both with medium removed
for 5 minutes. Upon heat and AMF exposure, the cells were returned to the incubator for 2
hours to allow time for cellular response to the heat treatment and then assayed using the
Molecular Probes Live/Dead Assay and fluorescence imaging.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxx
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Figure 3.6. Schematic of how M059K glioblastoma cells were exposed to heat from magnetic
hydrogel nanocomposites exposed to an AMF to induce cell death via thermoablation. The
cells were exposed for 5 minutes, returned to the incubator for 2 hours, then assayed via a
Live/Dead stain for fluorescence imaging.

55

3.2.8 Statistical analysis
All experiments were performed at least in triplicate. MYSTAT 12 for Windows
(12.02.00) was used for t-tests (paired t-test with unequal variances) to determine any
significance in observed data. A p-value of <0.05 was considered statistically significant.

3.3 Results

3.3.1 Polymerization analysis and TGA characterization of hydrogel nanocomposites
ATR-FTIR was used to determine the conversion of carbon-carbon double bonds
present in the hydrogels. Both PEGMMA and PEGDMA have C=C bonds which undergo
free radical polymerization to form the crosslinked hydrogel systems which decreases the
amount of C=C bonds available. The conversion of the double bonds of the PEG constituents
was determined using standard baseline techniques from the peak area of 1637 cm-1 for C=C
vibration and using the area of 1713 cm

-1

for C=O stretching as a reference. The C=C

conversion data can be found in Appendix A, Figure A.3.1. The percent conversion of the
double bonds was calculated from:

%  = ݊݅ݏݎ݁ݒ݊ܥቀ1 −

ோ
ோబ

ቁ  ݔ100%

(2)

where Rf is the ratio of the peak area of the C=C to the reference peak area of C=O at the final
time (90 minutes) and R0 is the ratio of the same peak at the initial time. The conversion for
all of the hydrogel nanocomposites after 90 minutes was at least 93% as seen in Table 3.2
indicating that the majority of the hydrogels were nearly completed reacted.
TGA was performed to determine the actual iron oxide nanoparticle loading in the
hydrogel nanocomposites. For all hydrogel nanocomposites, the iron oxide loading was found
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Table 3.2. Summary of characterization results for C=C conversion via ATR-FTIR, murine
fibroblast % cell viability for iron oxide nanoparticles and hydrogel nanocomposites at 24 and
48 hours, final temperature values for the gels exposed to AMF at constant field strength,
calculated iron oxide mass for the heated gels and AMF strengths needed for hyperthermia
and thermoablative temperatures.

System
50PEG1000MMA50TEGDMA
95PEG200MMA5PEG400DMA
50PEG1000MMA50PEG400DMA
80PEG200MMA20PEG400DMA
50PEG200MMA50PEG400DMA
50PEG200MMA50TEGDMA
100 µg/ml Fe3O4
500 µg/ml Fe3O4
1000 µg/ml Fe3O4
Control

C=C
% Conv.

Fibroblast %
Cell Viability
(24h)

Fibroblast %
Cell Viability
(48h)

96.3

95.7 ± 1.4%

97.2 ± 3.3%

94.2

97.3 ± 0.9%

97.4 ± 2.5%

99.4

97.9 ± 0.5%

96.8 ± 0.8%

97.3

96.0 ± 2.0%

97.8 ± 2.2%

93.3

97.0 ± 2.5%

97.8 ± 2.5%

95.0

96.9 ± 1.0%

98.0 ± 2.1%

---------

98.3 ± 0.5%
98.1 ± 0.4%
98.0 ± 0.2%
97.9 ± 0.6%

99.1 ± 0.1%
98.1 ± 0.6%
98.0 ± 0.5%
98.3 ± 1.3%
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Table 3.2 (con’t). Summary of characterization results for C=C conversion via ATR-FTIR,
murine fibroblast % cell viability for iron oxide nanoparticles and hydrogel nanocomposites at
24 and 48 hours, final temperature values for the gels exposed to AMF at constant field
strength, calculated iron oxide mass for the heated gels and AMF strengths needed for
hyperthermia and thermoablative temperatures.

System
50PEG1000MMA50TEGDMA
95PEG200MMA5PEG400DMA
50PEG1000MMA50PEG400DMA
80PEG200MMA20PEG400DMA
50PEG200MMA50PEG400DMA
50PEG200MMA50TEGDMA
100 µg/ml Fe3O4
500 µg/ml Fe3O4
1000 µg/ml Fe3O4
Control

Final T at
25 kA/m
(°C)

Fe3O4
Mass/Gel
Volume
(mg/cm3)

Hyper.
AMF
Strength
(kA/m)

Thermo.
AMF
Strength
(kA/m)

60.7 ± 0.7

1.58

17.3

25.3

59.5 ± 1.1

1.92

17.4

25.9

65.7 ± 1.7

2.74

16.5

24.2

66.1 ± 0.7

5.32

14.7

22.0

73.8 ± 0.8

7.24

14.3

23.0

79.6 ± 1.3

7.93

12.7

17.4

---------

---------
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to have a range of 5.48 ± 0.65 weight % (raw data shown in Appendix A, Figure A.3.2) which
is close to the initial loaded amount.

3.3.2 Characterization of hydrogel nanocomposite swelling behavior
The analysis of swelling behavior of hydrogels is necessary for determining the ability
of the gels to retain fluids for drug delivery applications. Hydrophobic drugs such as estradiol
and insulin (DiRamio, Kisaalita et al. 2005) and protein (bovine serum albumin) (Mellott,
Searcy et al. 2001) have already been successfully delivery from PEG-based hydrogels. The
swelling behavior of the nanocomposite gels was analyzed to determine the effects of iron
oxide nanoparticle loading, crosslinking ratio, crosslinking and macromer types, and
temperature.

Mesh size of the hydrogel systems was calculated using the Flory-Rehner

equation which incorporates the Peppas-Merrill modification (Flory 1953; Peppas and Merrill
1976). The mesh size was determined to be on the order of 10-20 angstrom, which is an order
of magnitude smaller than the iron oxide nanoparticles incorporated into the hydrogel matrix.
As such, it is hypothesized that the nanoparticles are physically entrapped in nanocomposite
and therefore particle loss from the systems is negligible (nor has it been observed).
The following descriptions apply for the hydrogels at 22°C.

For the

PEG200MMA/PEG400DMA systems, the amount of crosslinking varied from 5 to 50 mole%,
and as the amount of crosslinking increased, the swelling ratio decreased as seen in Figure 3.7.
As the amount of crosslinking is increased, the mesh structure of the hydrogel is tighter which
does not allow as much water into the system. For 50 mole % PEG200MMA crosslinked with
50 mole % PEG400DMA or TEGDMA, the volume swelling ratio was the same irrespective
of the crosslinker used. For 50 mole % PEG1000MMA systems with either crosslinker, the
volume swelling ratio was higher for the gel with TEGDMA versus the system with
PEG400DMA. This is contradictory to what was expected. TEGDMA has a much shorter
PEG chain length in comparison to PEG400DMA (approximately 4.5 versus 9 PEG groups,
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Figure 3.7. Swelling analysis results for all PEG hydrogel nanocomposites at 22, 37, 43, and
63°C showing the volume swelling ratio (Q) for each system.
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respectively), and it is expected that a system crosslinked with TEGDMA would exhibit a
tighter gel mesh and therefore have a smaller swelling ratio. It is hypothesized that in this
case, primary chain cyclization may have an effect on the structure of the hydrogel. This
occurs when a propagating radical reacts intramolecularly with a pendant double bond on the
same chain, (Elliott 2001). This results in a decrease in the crosslinking density and an
increase in the space between crosslinks.

For these systems, the solvent (ethanol)

concentration was relatively high (1:1 by weight of the macromer and crosslinker) which is
known to increase the probability of primary cyclization.
For the PEG200MMA and PEG1000MMA systems crosslinked with PEG400DMA,
the volume swelling ratio was smaller for the system containing the PEG200MMA macromer.
This is because the ethylene glycol (EG) content of PEG200MMA is much less than that of
PEG1000MMA (by a factor of 5) which makes the system less hydrophilic. For the same
macromers crosslinked with TEGDMA, the swelling ratio for PEG200MMA versus
PEG1000MMA was also lower resulting from the decreased EG content.

Iron oxide

nanoparticle loading had a slight effect on the swelling of the PEG-based hydrogel
nanocomposites. The gels with iron oxide nanoparticles exhibited slightly higher volume
swelling ratios than those without nanoparticles (data not shown). This may be attributed to
the particles interfering with the macromers and crosslinkers to cause less effective
crosslinking during the polymerization.
The PEG-based hydrogels were shown to be thermally-responsive as seen by the
change in their swelling properties when exposed to various temperatures. The swelling ratios
for all systems decreased as they reached their approximate LCST. For the PEG200MMA
hydrogels, the volume swelling ratio was approximately 2.2 at 63°C which is above the LCST
(Lutz 2008) of this compound explaining the partial collapse of the hydrogel structure. This
attribute of the hydrogels may allow them to be used in controlled drug delivery applications
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when switching the temperature of the system from below their LCST at room temperature to
above it in the body.

3.3.3 Cytotoxicity analysis of Fe3O4 nanoparticles and hydrogels
The effects of iron oxide nanoparticles on the cell viability of fibroblasts after 24 and
48 hours are shown in Table 3.2. For all nanoparticle concentrations, the cell viability was
statistically insignificant in comparison to the control sample regardless of the amount of
nanoparticle loading in the medium (p > 0.05). This indicates that the iron oxide nanoparticles
have the potential to be biocompatible (most likely due to their polymeric coating) and thus
should not be recognized by the body as foreign objects should they leach from the hydrogel
nanocomposites.
After the hydrogels were soaked in complete fibroblast medium for 48 hours, the
medium was transferred to fibroblasts for 24 and 48 hours. The results determined whether or
not any harmful substances leached from the hydrogels into the medium. As seen in Table
3.2, for all hydrogel systems, the cell viability was favorable and close to that of the control (p
> 0.05). This indicates minimal or no leaching of substances from the hydrogels, which was
as expected. Figure 3.8 shows the favorable response of the fibroblasts exposed to both the
nanoparticles and gel-exposed medium in comparison to a control on polystyrene. The cells
have good morphology and look similar to those of the control. Similar cell morphology was
seen for cells exposed to all nanoparticle concentrations and hydrogel systems (results not
shown). Overall, these results indicated that magnetic PEG-based hydrogel nanocomposites
have the potential to be biocompatible.

3.3.4 Characterization of the remote-controlled heating of nanocomposite hydrogels
Swollen hydrogels equilibrated at 22°C were exposed to an alternating magnetic field
for 5 minutes at 297 kHz and 25 kA/m to induce heating within the system. As seen in Figure
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Figure 3.8. Fluorescent microscopy images of NIH 3T3 after Molecular Probes Live/Dead
assay was performed to show live and dead cells. The images are fibroblasts exposed to: (a)
80 mole % PEG200MMA, 20 mole% PEG400DMA , 5 weight % Fe3O4 hydrogel
nanocomposite, (b) control on polystyrene, and (c) 1000 µg/ml Fe3O4 nanoparticles. The
scale bar represents 100 µm.
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Figure 3.9. Thermal response of hydrogel nanocomposites exposed to AMF at 297 kHz and
25 kA/m for 5 minutes. AM through FM gel abbreviations are defined in Table 1. The insert
represents hydrogel mesh structure and iron oxide particles for a gel with a higher volume
swelling ratio (left) and lower swelling ratio (right).
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3.9, the hydrogel nanocomposites reached their maximum temperature after 180 seconds.
Hydrogels without magnetic particles were also exposed to the alternating magnetic field (data
not shown) and exhibited minimal heating confirming that the heat generation was due to the
Fe3O4 nanoparticles. The amount of heating of the hydrogel systems was dependent on the
swelling ratio of the gel and subsequently the iron oxide nanoparticle loading per gel volume.
The estimated amount of Fe3O4 nanoparticles for a given swollen nanocomposite disc was
calculated from the following:

݁ܨଷ ܱସ ݉ܽ= ݏݏ

ெೞೌ


ெೞ

ݓ = ܯ௦௧ ൬ெೞ ൰ ݓ
ೞ

(3)

where Ms refers to the gels in the swollen state, Md in their dry state, and the superscripts heat
and subscript is refers to the gels prior to heating and data from the initial swelling data,
respectively. q is the mass swelling ratio calculated from the mass of swollen gels over dry
gels and wf refers to the initial weight % of the iron oxide loaded into the gels. The volume
for a swollen nanocomposite disc prior to heating was then determined from:
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where Mair and Mheptane are the mass of the gels prior to heating in air and in n-heptane,
respectively. The iron oxide mass per hydrogel volume was then calculated by taking the
ratio of the iron oxide mass and gel volume calculated above. As expected, as the amount of
iron oxide per volume in the gels increases, the final maximum temperature of the systems
increased as seen in Table 3.2. The variance in heating can be attributed to the fact that the
gels with a higher volume swelling ratio have a looser mesh and less particles present when
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cut at the same size as a gel with a lower Q value that has a tighter mesh and more particles.
A demonstration of this phenomenon can be seen in the insert of Figure 3.10.
For hyperthermia applications, the temperature of cancerous tissue needs to reach 42 45°C for effective therapy whereas temperatures above 50°C cause damage to cancer cells via
thermoablation. It was demonstrated that the temperature of the hydrogels can be controlled
by changing the alternating magnetic field strength so that the gels either reached
hyperthermia (42 to 45°C) or thermoablative (60 to 63°C) temperatures.

Figure 3.10

demonstrates that the final temperature the hydrogel nanocomposites reach can be tailored to
either one of these temperature ranges. The insert shows IR images of the gels heating at
hyperthermia temperatures (a-c) and thermoablative temperatures (d-e) for 15 seconds, 1
minute, and 5 minutes respectively.

The variance in the temperatures reached by the

hydrogels was directly controlled by the strength of the AMF as seen in Table 3.2. As
expected, for the hydrogel nanocomposites with less iron oxide per hydrogel volume, the
AMF strength needed to heat to the appropriate temperature range increased. This was true
for both the hyperthermia and thermoablative temperature ranges and the field strength needed
to heat gels for thermoablation was higher than that for hyperthermia.

3.3.5 Thermoablation demonstration with M059K glioblastoma cells exposed to hydrogels
heated in AMF
M059K glioblastoma cells were heated with hydrogel nanocomposites exposed to
AMF to both demonstrate the ability of the gels to kills cells via thermoablation and prove the
safety of exposure to the field. Figure 3.11 (top) shows the heating set up where the hydrogel
was placed in Saran wrap on the solenoid with the Petri dish containing cells on top of the
gel/wrap. Previous studies showed negligible heat loss through the Petri dish so that the cells
received direct heat through the polystyrene. An 8.2 mm hydrogel was placed under a 35 mm
dish so that only the center area of cells was affected by the heat. This resulted in an acute
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Figure 3.10. Thermal analysis of hydrogel nanocomposites exposed to varied AMF strengths
to control gel temperatures in the hyperthermia and thermoablative temperature ranges where
the Th and Hy after the gel abbreviations represents thermoablative and hyperthermia heating,
respectively. Transparent boxes represent the thermoablative (top) and hyperthermia (bottom)
temperature range goals for heating. The insert show IR images of gels for hyperthermia (a-c)
and thermoablation (d-f) at 15 seconds, 1 minute, and 5 minutes.
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Figure 3.11. (Top) schematics of M059K glioblastoma multiforme/hydrogel heating
apparatus (top) with hydrogel in Saran wrap on the solenoid then covered by the cancer cells
present in the Petri dish. (Bottom) schematic of cancer cells in Petri dish and their response
after exposure to gels heated in AMF. The gels cause acute cell death (red) at the center of the
dish with a distinct interface where outer cells are unaffected (green).
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cellular response as indicated in Figure 6 (bottom) where the center cells were killed by the
heat and outer cells were unaffected with a distinct interface between the live and dead cells.
A 50 mole% PEG200MMA, 50 mole% TEGDMA hydrogel was used as it showed the ability
to heat the highest with the lowest field strength. Figure 3.12 confirms the success of these
experiments where the left column of images are the M059K heated by the gel, the center is
the cells exposed to the field only, and the right is the control. The cells heated with the gel
showed distinct cell death at the center and interface whereas both of the controls showed
favorable cell morphology. The IR images show the final temperature the cells were exposed
to (63°C for thermoablation, j, and 24°C for AMF control, k). Overall, these results show the
ability of the gels to kill cancer cells without harming them with the magnetic field.

3.4 Conclusions
It was demonstrated that PEGMMA/PEGDMA magnetic hydrogel nanocomposites
can potentially be used in thermal cancer therapy through remote heating via application of an
alternating magnetic field. Swelling analysis of the hydrogels indicated a dependence of
swelling properties on both the EG content in the gels and crosslinking density of the system.
As either the amount of EG increased or crosslinking decreased, the volume swelling ratio of
the hydrogels increased.

The hydrogel systems were shown to be slightly temperature-

responsive. Increasing the temperature of the hydrogels decreased their volume swelling ratio
upon reaching the LCST. The exposure of murine fibroblasts to the hydrogel nanocomposites
and iron oxide nanoparticles was carried out and favorable cell viability was seen for both the
gels and particles indicating their safe use as in vivo systems. This is due to both the high EG
content and high water content of the hydrogels. Both hyperthermia and thermoablation are
therapies that increase the efficacy of both radiation and chemotherapy. Upon exposure to an
AMF, the hydrogels showed the ability to heat at both hyperthermia and thermoablative
temperatures which can be controlled by the content of the iron oxide in the hydrogel or
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Figure 3.12. M059K glioblastoma multiforme/hydrogel heating results. Images a through i
represent fluorescent microscopy images after live/dead assay of M059K cells where a-b are
at the center of the Petri dish, d-f at the interface between live and dead cells, and g-I at the
outer edge unaffected by heat. The first column of images are for the cells exposed to a DM
gel (50 mol% PEG200MMA, 50 mol% TEGDMA) at 297 kHz and 25 kA/m for 5 minutes,
the middle column are of cells exposed to AMF only at 297 kHz and 25 kA/m for five
minutes, and the right column is of cells not exposed to gels or AMF. Images j and k
represent IR images after the cells heated with the gel for 5 minutes (j) and exposed to AMF
for 5 minutes (k).
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changing the strength of the applied alternating magnetic field. For gels with higher iron
oxide content, lower field strength was needed to get the desired temperature and as the field
strength was increased for a particular system, the temperature was also increased.
A proof-of-point demonstration was done to show the ability of these hydrogel
nanocomposites to kill M059K glioblastoma in vitro by exposing the cells to hydrogels at
thermoablative temperatures. This concept can be further extended to systems for the delivery
of heat at hyperthermia temperatures with the delivery of chemotherapeutics as a dualdelivery system for cancer therapy. These systems could potentially be used to target cancer
in two primary applications including implantation after surgical resection of a tumor for
prevention of metastasis or recurrence and injection for in situ formation of the hydrogels in
difficult-to-reach locations. For this to occur, in vivo testing of these materials must be
completed including those demonstrating the biocompatibility of the nanocomposites (before
and after heating), potential iron oxide nanoparticle release during implantation, and overall
efficacy of the heating on surrounding tissues. The limitations of these systems that must be
overcome may include but are not limited to non-specific formation of the hydrogels during in
situ implementation, encapsulation of the hydrogel system, the need to surgically remove the
implant after its useful life, and the possible need for long-term drug delivery.
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CHAPTER 4

Synthesis and Characterization of Thermoresponsive Poly(ethylene glycol)-Based
Hydrogels and Their Magnetic Nanocomposites

Temperature-responsive hydrogels are one of the most widely-studied types of stimuliresponsive hydrogel systems. Their ability to transition between their swollen and collapsed
states makes them attractive for controlled drug delivery, microfluidic devices, and biosensor
applications. Recent work has shown that poly(ethylene glycol) methacrylate (PEGMA)
polymers are temperature-responsive and exhibit a wide range of lower critical solution
temperatures based on the length of EG units in the macromer chain. The addition of iron
oxide nanoparticles into the hydrogel matrix can provide the ability to remotely heat the gels
upon exposure to an alternating magnetic field (AMF). In this work, diethylene glycol methyl
ether methacrylate and poly(ethylene glycol) (n = 4.5) methyl ether methacrylate copolymers
were polymerized into hydrogels with 5 mole % poly(ethylene glycol) (n = 13.6)
dimethacrylate as the crosslinker along with 5 weight % iron oxide nanoparticles. Volumetric
swelling studies were done from 22 to 80 °C and confirmed the temperature-responsive nature
of the hydrogel systems. The ability of the gels to collapse in response to rapid temperature
changes when exposed to an alternating magnetic field was demonstrated showing their
potential use in biomedical applications such as controlled drug delivery and hyperthermia
therapy.

Keywords
PEG, hydrogels, nanocomposites, temperature-responsive, magnetic.
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4.1 Introduction
Stimuli-responsive hydrogels are one class of polymers that have been studied
extensively due to their ability to respond to external stimuli such as light, heat, pH, electric
fields and ionic strength (Peppas 2000). These stimuli allow for the control of the swelling
and deswelling behavior of the hydrogel matrices. These types of hydrogels have been
utilized in many biological applications such as drug delivery, artificial muscle, chemical
valves, immobilization of enzymes and cells, and in bioseparation applications (Qiu and Park
2001). Temperature-responsive hydrogels are among the most commonly studied types of
stimuli-responsive polymer systems. Negative temperature-responsive hydrogels exhibit a
lower critical solution temperature (LCST) at which they undergo a deswelling phenomenon
at this temperature due to thermodynamically-driven interactions between the polymer and its
surrounding media.

Typical LCST polymers that have been widely studied in hydrogel

applications include N-isopropylacrylamide (NIPAAm), as well as other types of acrylamides
and methacrylates (Fournier 2007). When such hydrogels are exposed to an aqueous solution
at a temperature that is below their LCST, solvent (water)-polymer interactions dominate and
the hydrogel swells, whereas above the LCST, hydrophobic interactions between the polymer
chains dominate and the hydrogel structure collapses, releasing water from the hydrogel
matrix. LCST hydrogels have been used successfully in drug delivery applications as they can
undergo triggered drug release by squeezing-controlled release as described by Brazel (Brazel
2009).
Poly(ethylene glycol) (PEG) is one of the most widely studied polymers for
biomedical applications. It is nontoxic, non-immunogenic, and approved by the US Food and
Drug Administration for various clinical uses (Peppas 1999; DiRamio 2005). Despite this,
PEG macromolecules and hydrogels have only recently been studied as temperatureresponsive polymeric systems. In particular, PEG methacrylate (PEGMA) macromolecules
have exhibited temperature-responsive behavior in physiological temperature ranges and are
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appealing to use because many PEGMA macromolecules are available commercially. Lutz
and coworkers have done extensive work synthesizing and characterizing the temperatureresponsive behavior of PEG methacrylate macromolecules (Lutz 2006; Lutz and Hoth 2006)
through the copolymerization of PEGMA oligomers with various EG unit lengths.

In

particular, random copolymers of diethylene glycol methacrylate (DEGMA, Mw = 188) and
PEG400 methacrylate (PEG400MA, Mw = 475) were shown to exhibit LCST values between
26 and 90 °C where this value can be precisely tuned by varying the comonomer composition
during the macromolecule synthesis. Similarly, LCST values of 32, 37, and 39 °C was
observed in pure water for these copolymers possessing an average 5, 8, or 10 % of DEGMA
units to PEG200MA (Mw = 300) units per chain(Lutz and Hoth 2006). This group has also
developed thermoresponsive P(DEGMA-co-PEG400MA) hydrogels (Lutz 2008), and they
exhibited LCST values comparable to those measured for their single-chain analogues (42-45
°C for a gel with 10 mole % DEGMA and 51-53 °C for a 20 % DEGMA). Preliminary
evaluation of the deswelling kinetics of these systems indicated that their thermally inducted
shrinkage is extremely fast which is important for drug delivery applications.
Hydrogel nanocomposites involve the incorporation of various nanoparticulate
materials within a hydrogel matrix which can provide easy, straightforward methods for
enhancing the properties of hydrogels. Thus far, a number of nanoparticulates have been
utilized in nanocomposite hydrogel systems including metallic nanoparticles, carbon
nanotubes, clay, ceramics, magnetic nanoparticles, hydroxyapatite, and semiconducting
nanoparticles (Meenach 2009). In particular, the incorporation of magnetic nanoparticles,
such as iron oxide nanoparticles, into hydrogels can create tunable hydrogel nanocomposites
that can be remotely heated by an electromagnetic field.

Potential applications of such

systems range from controlled drug release applications to hyperthermia treatments in cancer
patients.

By combining iron oxide nanoparticles with LCST polymers, an alternating

magnetic field (AMF) can be used to trigger localized heating of the nanoparticles within the
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hydrogel, which in turn causes the deswelling of the system (Brazel 2009). The heating
mechanism for paramagnetic iron oxide nanoparticles exposed to an AMF is based on
Brownian relaxation (rotation of the particle) and Néel effect (reorientation of the
magnetization vector inside the magnetic core) (Babincova 2001).

This type of AMF-

controlled, temperature-responsive behavior of hydrogel nanocomposites has been utilized
with poly(N-isopropylacrylamide) (PNIPAAm)-iron oxide hydrogels for remote-controlled
pulsatile drug delivery (Satarkar and Hilt 2008) and as remote-controlled microvalves
(Satarkar 2009).
This current work utilizes both magnetic iron oxide (Fe3O4) nanoparticles and LCST
PEG-based polymers to create a hydrogel that will heat upon exposure to an AMF causing a
rapid deswelling of the hydrogel matrix. This type of system could be applied for use as
magnetothermally-responsive nanomaterials to be used for drug delivery and hyperthermia
applications as described recently in a comprehensive review of these systems by Brazel
(Brazel 2009). The properties of the hydrogels can be controlled by the amount and type of
PEG macromer constituent as demonstrated by the heating, swelling, and mesh size analysis
of the systems. These particular hydrogels, comprised of PEGMA macromers, exhibited
broad swelling responses to a wide temperature range and exhibited tunability in their
swelling response depending on the amount of EG units present in the polymer matrix. This is
the first demonstration of PEG-based, easy-to-fabricate hydrogel nanocomposites that exhibit
such behavior.

4.2 Materials and Methods

4.2.1 Materials
The macromers diethylene glycol methyl ether methacrylate (DEGMA, Mw = 188) and
poly(ethylene glycol) (n = 4.5) methyl ether methacrylate (PEG200MA, Mw = 300) and the
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crosslinker poly(ethylene glycol) (n = 13.6) dimethacrylate (PEG600DMA, Mw = 754) were
obtained from Polysciences (Warrington, PA). Fe3O4 nanoparticles (25 nm diameter, 0.2%
polyvinylpyrrolidone-coated) were obtained from Nanostructured and Amorphous Materials
(Los Alamos, NM).

The free-radical initiator, ammonium persulfate (APS), accelerator,

N,N,N',N'-tetramethylethane-1,2-diamine (TEMED), and ethanol (95%) were obtained from
Sigma Aldrich (St. Louis, MO) at 99 and 98% purity, respectively. All materials were used as
received.

4.2.2 Fabrication of Poly(ethylene glycol)-Iron Oxide Hydrogel Nanocomposites
Magnetic hydrogel nanocomposites were fabricated via free-radical polymerization
with various macromer ratios (DEGMA to PEG200MA). The structures of these compounds
can be seen in Figure 4.1. Ethanol was added to the macromer solution in a 1:1 by weight
basis based on the macromer and crosslinker amounts.

For hydrogels with iron oxide

nanoparticles, the particles were added at 5 weight % based on the macromer and crosslinker
and were exposed to an ultrasonic bath for 30 minutes to facilitate dispersion of the iron oxide
nanoparticles throughout the solution. After sonication, 2 weight % APS and 4 weight %
TEMED were then added to the mixture to chemically initiate the free-radical polymerization.
This solution was then sonicated further for 2 minutes before being loaded into a template
consisting of two 15 cm by 15 cm glass plates with a 1.5 mm thick Teflon spacer. The gels
were kept in this template for at least 2 hours (usually overnight) to allow for completion of
polymerization.

To remove any potentially unreacted and potentially toxic macromer,

crosslinker, and initiator residues, the hydrogels were washed with deionized water for at least
one week.

The systems fabricated were comprised of 0, 25, 50, 75, and 100 mole %

PEG200MA to DEGMA based on the macromer amounts and were abbreviated 100DEGMA,
25PEG200MA, 50PEG200MA, 75PEG200MA, and 100PEG200MA, respectively.
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Figure 4.1. Schematic representations of (a) PEGMA and (b) PEGDMA structures.
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4.2.3 Swelling Analysis and Mesh Size Calculations
The equilibrium swelling characteristics of the PEG-Fe3O4 hydrogel nanocomposites
were measured using a gravimetric method based on a comparison of the density
measurements of both swollen and dry gels at equilibrium as described previously (Frimpong
2006). Upon the completion of synthesis and washing, hydrogel discs 13.8 mm in diameter
were cut from the bulk hydrogel films. The discs were then placed in phosphate buffered
saline solution (PBS, pH 7.4) and allowed to reach equilibrium for at least 72 hours. The
mass of the discs were measured in air and then in n-heptane (non-solvent) in their swollen
state at 22, 37, 43, and 60 and 80 °C and in their final dry state. The masses of the hydrogels
in both dry and swollen states in air and n-heptane were used to calculate of the volume
swelling ratio (Q) at equilibrium:
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where V is the volume of the sample, ρheptane is the density of n-heptane, Mair is the mass of the
sample in air, and Mheptane is the mass of the sample in n-heptane. The superscripts s and d
refer to the swollen and dry forms of the samples, respectively.
The bulk structure of hydrogels is important in determining their suitability for various
biomedical applications, especially drug delivery (Peppas 2006).

The most important

parameters used to characterize the network structure of hydrogels are the molecular weight of
 c) and the hydrogel mesh size
the polymer chain between two adjacent crosslinking points (
(ξ). The molecular weight between crosslinks and corresponding mesh size are measures of
the degree of crosslinking of the system. For poly(ethylene glycol) methyl ether methacrylate
(PEGMA) and poly(ethylene glycol) dimethacrylate (PEGDMA) hydrogels, the hydrogel
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mesh will be an amorphous mesh with PEGDMA acting as the “backbone” with PEGMA
incorporated into the hydrogel acting as a tether/brush throughout the system. The structural
characterization can be done by either equilibrium swelling theory or rubber-elasticity theory.
Traditionally, hydrogels that do not contain ionic moieties have been analyzed using FloryRehner theory (Flory 1953).

Elbert and coworkers have described another method of

c
hydrogel mesh analysis (Elbert 2001) and this was compared to the Flory-Rehner method. 
can be calculated from the Flory-Rehner equation which incorporates the Peppas-Merrill
modification (Peppas and Merrill 1976) for a neutral hydrogel prepared in the presence of a
swelling agent:
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 n is the number average molecular weight of the uncrosslinked chains, 5̅ is the
where 
specific volume of the polymer/crosslinker, V1 is the molar volume of water (18 cm3/mol), ν2,s
is the polymer volume fraction in the swollen state (1/Q), χ1 is the Flory polymer-solvent
interaction parameter (0.43, (Merrill 1993)), and ν2,r is the polymer fraction in the relaxed state
(amount of total polymer in initial feed versus total polymer plus solvent amount, based on the
 n was not
assumption of complete reaction with no volume change). For these studies 
determined experimentally and thus two values were used as a comparison. The first value
used was 100,000, a value that has been assumed for lightly crosslinked systems (Brazel and
 n was calculated from the molecular weight of the PEGMA chains
Peppas 1995). Then 
between each PEGDMA link (One PEGDMA plus 19 PEGMDA units). The number of C=C
bonds between two crosslinks can be calculated from the following:
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where Mr is the average molecular weight of the repeating (44 for ethylene glycol). The root
mean squared end-to-end distance of the polymer chain in the unperturbed state is then
calculated as:

89̅: ;/ = <8=& 7;/

(4)

where l is the carbon-carbon bond length (1.54 Å) and Cn is the Flory characteristic ratio of
the polymer (3.8, (Thomas 2007)). The mesh size (ξ) was then calculated as:
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 c and mesh size are derived for
It is important to note that the equations used to calculate 
polymer fractions up to 0.2 in solvent and therefore the values obtained for greater polymer
fractions are approximations (Brazel and Peppas 1995; Mellott 2001). In the analysis method
described by Elbert et al., the number of moles of elastically active chains in the hydrogel
network (ve) was calculated from:
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where Vp is the volume of the dry polymer calculated from the dry mass of the hydrogel and
the density of the polymer in the dry state (for PEG, 1.12 g/cm3) and f is the functionality of
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 c was then
the crosslinks (assumed to be 2 for the case of the dimethacrylated crosslinker). 
calculated from:

H =


I
J

(7)

where mp is the total mass of PEG in the hydrogel. ξ was then calculated using equations 3
through 5. Further explanation for mesh analysis can be found in Appendix B, Section B.4.1.

4.2.4 Thermal and Swelling Analysis of Hydrogels Exposed to an Alternating Magnetic Field
Prior to heating, hydrogel nanocomposites were cut into discs (8.2 mm in diameter)
and equilibrated in PBS at room temperature (22 °C). Remote-controlled heating of the
hydrogel nanocomposites was completed using an alternating electromagnetic field induced
by a Taylor Winfield induction power supply (model MMF-3-135/400-2) equipped with a
solenoid with a 15 mm diameter and 5 turns. Prior to heating, the gels were weighed in air
and n-heptane to determine their swelling characteristics.

The hydrogel discs at their

equilibrium swollen state were then covered with Saran wrap, placed on top of the solenoid
coil and exposed to the alternating magnetic field to induce heating.

The hydrogel

nanocomposite systems were each exposed to the same magnetic field power at 291 kHz and
24.8 kA/m for 5 minutes. Thermal data was acquired using an infrared camera (AGEMA
Thermovision 470) which recorded the surface temperature of the hydrogels. After heating,
the gels were re-weighed then placed immediately back in PBS at room temperature. The
swelling behavior of the hydrogel nanocomposites was characterized by evaluating the
volume swelling ratio of the hydrogels at various time points. The mass of the gels in their
swollen state were measured in air and n-heptane at the following times: before heating via the
AMF, immediately after heating, and 5 minutes, 20 minutes, 60 minutes, 3 hours, 24 hours,
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and 7 days after returning to PBS. The gels were then dried and re-weighed in air and nheptane and their volume swelling ratios were calculated as described previously.

4.2.5 Statistical Analysis
All experiments were performed at least in triplicate. MYSTAT 12 for Windows
(12.02.00) was used for t-tests (paired t-test with unequal variances) to determine any
significance in observed data. A p-value of <0.05 was considered statistically significant.

4.3 Results and Discussion

4.3.1 Swelling and Mesh Size Analysis
The swelling of the PEG-iron oxide hydrogel nanocomposites was initially determined
through a gravimetric analysis of the systems. The volume swelling ratio (Q) of the gels in
their swollen state was measured at 22, 37, 43, 60, and 80 °C to determine their swellingresponsive behavior with respect to a change in temperature. Previously, Lutz and coworkers
determined that DEGMA and PEG200MA have LCST values of 26 and 64 °C,
respectively(Lutz and Hoth 2006). The LCST of PEGMA macromolecules can be tuned by
varying the ratio of macromers with differing EG content.

Ratios of DEGMA and

PEG375MA (Mw = 475, LCST = 90 °C)-based macromolecules were synthesized by Lutz and
coworkers, and it was shown that they exhibit LCST values of 32, 37, and 39 °C for 5, 8, and
10% of DEGMA units, respectively (Lutz 2008). It was hypothesized that by fabricating
PEGMA-based hydrogels of DEGMA and PEG200MA that the swelling properties could be
tuned according to the amounts of each macromer type in the hydrogels. Figure 4.2 shows the
volume swelling data for all of the hydrogel systems from 22 to 80 °C. These results indicate
that as the temperature is increased, the volume swelling ratio of all hydrogel systems
decreases. These hydrogels, however, do not exhibit a sharp deswelling behavior around their
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Figure 4.2. Volume swelling ratio data for all hydrogel systems at 22, 37, 43, 65, and 80°C at
their swollen equilibrium state. N = 3 ± SE.
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LCST. This could be due to the PEG600DMA crosslinker which is the backbone of the
hydrogel matrix and could shift the LCST of the overall gel higher due to the increased EG
content it provides. The other trend shown in this data is that as the amount of PEG200MA
content of the gel increases, the volume swelling ratio also increases. This is because the
higher molecular weight EG chains in the hydrogel matrix results in a lower crosslink density
in the network.
 c) and mesh size (ξ) of the PEG
The average molecular weight between crosslinks (
hydrogels were determined via the modified Flory-Rehner and Elbert equations as described
in the Experimental section. Table 4.1 shows these values for all hydrogels systems at 22 °C.
For all methods of analysis, as the amount of PEG200MA in the hydrogel system increased,
both the average molecular weight between crosslinks and mesh size increased.

These

theoretical values (especially mesh size) can allow for the approximation of the size of drugs
or other molecules that could potentially be loaded and delivered from these hydrogel
nanocomposites. With the mesh size values ranging from 2.1 to 59.8 Å, a wide variety of
different size molecules may potentially be released from these hydrogel systems. Also, the
mesh size values indicate that the iron oxide nanoparticles are likely to be physically
entrapped in the hydrogel matrix as their aggregated size (100-200 nm) is much larger than the
reported mesh size values.

4.3.2 Remote-Controlled Heating of Hydrogels via AMF
Heating of the hydrogel nanocomposites is made possible by inducing heating of the
iron oxide nanoparticles within the hydrogel matrix via an AMF. Although the diameter of
the nanoparticles is small (approximately 25nm), they are known to form into 100-200 nm
aggregates as described by the company that provides them. As such, the nanoparticles are
believed to be physically entrapped within the hydrogel matrix as the theoretical mesh sizes of
the gels are much smaller than the size of these aggregates. The hydrogel systems were
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 c) and mesh size (ξ) of the PEG
Table 4.1. Average molecular weight between crosslinks (
hydrogels as determined via the Flory-Rehner equation. The values were tabulated using the
volume swelling ratio of the hydrogels at 22 °C.

System
100PEG200MA
25DEGMA
50DEGMA
75DEGMA
100DEGMA

Peppas-Merrill
Method
(Mn = 100,000)
c
Mesh
K
Size (Å)
(g/mol)
2324.2 ±
59.8 ±
58.7
1.0
453.7 ±
21.1 ±
6.2
0.2
345.2 ±
17.8 ±
4.1
0.1
210.0 ±
13.1 ±
2.3
0.1
91.6 ± 1.4 7.9 ± 0.1

Peppas-Merrill
Method
(Mn = calculated)
c
Mesh
K
Size (Å)
(g/mol)
1388.2 ±
46.2 ±
21.1
0.5
401.0 ±
19.8 ±
4.9
0.2
313.8 ±
17.0 ±
3.4
0.1
197.9 ±
12.7 ±
2.0
0.1
89.3 ± 1.3 7.8 ± 0.1
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Brandl Method
(No Mn, perfect gel)
c
K
(g/mol)
888.1 ±
26.7
128.0 ±
2.2
80.8 ±
1.1
34.8 ±
0.7
6.5 ± 0.2

Mesh
Size (Å)
35.4 ±
0.7
11.0 ±
0.1
8.4 ± 0.1
5.2 ± 0.1
2.1 ± 0.0

exposed to the alternating magnetic field at 291 kHz and 24.8 kA/m for 5 minutes, and the
resulting temperature profiles can be seen in Figure 4.3. For all systems, the equilibrium
temperature was reached after approximately 3 minutes. Also, the change in temperature
increased with increasing DEGMA content. This can be attributed to the swelling properties
of the hydrogels. Hydrogels with the highest DEGMA content swelled the least and therefore
had a tighter hydrogel mesh. Figure 4.4 is a representation of two hydrogel discs cut at the
same diameter. The gel on the left has a higher volume swelling ratio and looser mesh which
results in less iron oxide nanoparticles per swollen polymer, and therefore, these gels heat less
in the AMF. It is important to note that even for the hydrogel that heated the least (65°C), all
temperature values are well above what would be needed to induce a collapse in the hydrogel
matrices as seen by the temperature-responsiveness of the gels through their initial swelling
analysis.
One potential application of temperature-responsive biomaterials is their use as
magnetothermally-responsive materials where the hydrogels deswell as a result of the heating
of magnetic nanoparticles embedded in the polymer matrix. This could allow for remotecontrolled release of a drug via a “squeezing effect” as seen in Figure 4.5. Therefore, the
swelling properties of the PEG hydrogel nanocomposites were characterized for all systems
immediately before and after their heating in the AMF for 5 minutes. Figure 4.6 shows that
the volume swelling ratios of the gels change drastically before and after their heating in the
AMF.

All systems exhibited very fast deswelling (visually observed to occur almost

immediately after the gels neared their equilibrium temperature after approximate 2 minutes
of inducing heating), and their swelling decreased at least by half. As the gels are exposed to
the AMF, they heat because of the nanoparticles and deswell as the overall temperature
increases as seen in the schematic in Figure 4.7. This figure shows representative views of the
gel at the individual particle, microscopic, and macroscopic view of the hydrogel systems in
the field where localized heating of the nanoparticles affects the overall temperature of the
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Figure 4.3. Temperature profile of hydrogel nanocomposites upon exposure to AMF for 5
minutes. The initial temperature was 22 °C for all systems. N = 3 ± SE.
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Figure 4.4. Representations of magnetic hydrogel nanocomposites at various crosslinking
densities. The black lines represent the polymer chains present in the hydrogel matrix where
as the small brown circles represent iron oxide nanoparticles embedded in the system. (a)
represents a gel with a higher volume swelling ratio and loose hydrogel mesh, whereas (b)
represents a gel with a lower volume swelling ratio and tighter hydrogel mesh. The looser
mesh results in less polymer, less iron oxide, and more water which results in lower heating of
the gels when heated in an AMF.
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Figure 4.5. Hydrogel nanocomposite with iron oxide and loaded drug before and after AMF
exposure. Heat from the iron oxide nanoparticles causes the nanocomposite to collapse due to
the temperature-responsive nature of the polymer which causes drug to be expelled from the
gel via a squeezing effect.
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Figure 4.6. Volume swelling ratio of PEG hydrogel nanocomposites before and after heating
due to exposure to an AMF for 5 minutes. N = 3 ± SE.
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Figure 4.7. Schematic representation of magnetic hydrogel nanocomposites at their individual
particle, microscale, and microscale view. The left images show the gel now exposed to AMF
whereas those on the left are exposed to an AMF which results in localized heating of the
nanoparticle at the nanoscale level which results in the collapse of the hydrogel at the
macroscale level.
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hydrogel system. The final volume swelling ratio after heating decreased with increasing
DEGMA content.

This is due to the final heating properties of the gels.

For the

100PEG200MA system, the final temperature reached 65 °C whereas for the DEGMA system,
the final temperature was 104 °C. Therefore, the DEGMA system collapsed more due to this
increased temperature as would be expected due to the temperature-responsive effect seen in
the initial swelling profiles.
Although the deswelling behavior of the hydrogels is very important, their reswelling
behavior after heating is equally important for determining the usefulness of these gels in
various applications.

After being heated in the AMF, the volume swelling ratio of the

hydrogels was also measured 5 minutes, 20 minutes, 60 minutes, 3 hours, 24 hours, and 7 days
after the gels were allowed to reswell in PBS at 22 °C. Figure 4.8 shows the deswelling and
reswelling profile of the 100PEG200MA and 100DEGMA systems up to 3 hours after the gels
were heated in the AMF. The gels initially deswell due to their heating in the AMF where
they reach their lowest volume swelling ratio (time = 5 minutes).

After 5 minutes of

reswelling in PBS at 22° C the gels begin to reswell (time = 10 minutes), however, their final
equilibrium swelling ratio is not reached until after 3 hours (time = 185 minutes). The volume
swelling ratios at the 24 hour and 7 day time points were not included in this graph as they
were not statistically significant in comparison with the 3 hour time point. For both systems,
the final volume swelling ratio after reswelling was found to be the same as the initial volume
swelling ratio indicating that they can potentially maintain multiple cycles of deswelling and
swelling.

4.4 Conclusions
PEG/iron oxide-based hydrogel nanocomposites show the potential to be used as
magnetothermally-responsive materials in various biomedical applications.

PEGMA

hydrogels are temperature-responsive polymer systems that collapse due to their LCST
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Figure 4.8. a) Volume swelling ratio (Q) of 100PEG200MA and 100DEGMA hydrogel
nanocomposites with respect to time before, during, and up to 3 hours after their remote
heating in an AMF. Q was measure for the gels: initially, before heating (time = 0 minutes),
immediately after heating (time = 5 minutes), and after reswelling in PBS at 22°C for 5
minutes (time = 10 minutes), 20 minutes (time = 25 minutes), 60 minutes (time = 65 minutes),
and 3 hours (time = 185 minutes). b) denotes the on/off cycle of the AMF the hydrogel
nanocomposites were exposed to. N = 3 ± SE.
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behavior where polymer-polymer thermodynamic interactions become more favorable as their
surrounding temperature increases. PEG200MA and DEGMA-based hydrogels were made
with various ratios and the same crosslinking amount with PEG600DMA. The gels exhibited
temperature-responsive behavior as their volume swelling ratios decreased as the surrounding
temperature increased. Also, the systems behaved as magnetothermally-responsive materials
when they were exposed to an AMF. The iron oxide nanoparticles in the gels allowed for
heating in the AMF which caused rapid deswelling of the hydrogels due to the resulting rapid
localized heating. Overall, these systems have the potential to be used in various biomedical
applications such as drug delivery, hyperthermia, and as remote-controlled valves.

References
All references are located at the end of the dissertation.
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CHAPTER 5

Characterization of PEG-Iron Oxide Hydrogel Nanocomposites for Dual Hyperthermia
and Paclitaxel Delivery

Hyperthermia, the heating of tissue to 41 to 45°C, has been shown to improve the
efficacy of cancer therapy when used in conjunction with irradiation and/or chemotherapy. In
this work, hydrogel nanocomposites have been developed that can control the delivery of both
heat and a chemotherapeutic agent (e.g., paclitaxel). The nanocomposites studied involve a
stealth, poly(ethylene glycol) (PEG)-based system comprised of PEG (n = 1000) methyl
methacrylate and PEG (n = 400) dimethacrylate with iron oxide nanoparticles physically
entrapped within the hydrogel matrix. The capability of the hydrogels to be heated in an
alternating magnetic field was demonstrated.

The heating of the hydrogel systems was

dependent on the crosslinking of the hydrogel network where hydrogels with lower swelling
ratios were found to heat to a greater extent than those with higher ratios. In addition,
paclitaxel was shown to exhibit non-Fickian release from the hydrogel systems, with the rate
of release dependent on the hydrogel network structure.

Three cell lines: M059K

(glioblastoma), MDA MB 231 (breast carcinoma), and A549 (lung adenocarcinoma) were
exposed to paclitaxel only, hyperthermia heat only, and both paclitaxel and hyperthermia to
determine if a synergistic effect was possible for the cell lines. The efficacy of paclitaxel was
greater with hyperthermia for the A549 cells, however, the M059K and MDA MB 231 did not
show the same response.

Keywords
PEG, hydrogel nanocomposites, hyperthermia, paclitaxel.
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5.1 Introduction
Currently, cancer is the second leading cause of death in the United States. In 2009
alone, there were an estimated 1.5 million new cases diagnosed (ACS 2009). Conventional
treatment methods of cancer include surgery, radiation, and chemotherapy where
chemotherapy is often administered systemically or regionally.

During systemic

chemotherapy, drug delivery is dependent upon distribution through vasculature, transport
across microvessel walls, and diffusion into the tumor tissue. Regional chemotherapy relies
on injecting the drug directly into the tumor or peritumoral space, with diffusion through the
space between tumor cells as the primary mode of transport (Obara 2005). However, these
treatments are not always effective or possible due to the health of the patients, cancer types,
and severity of side effects. Therefore, it is necessary to develop novel, noninvasive, and
effective approaches to treat cancer. One such approach is the combination of treatment
modalities. Specifically, hyperthermia can be used in combination with chemotherapy and
radiation to more effectively treat cancer.
Hyperthermia is the controlled heating of cancerous tissues to between 41 and 45 °C
(Issels 2008). Depending on the type of cancer and implementation, current clinical treatment
options involving hyperthermia include devices for local, regional, and whole body
hyperthermia (Falk and Issels 2001). Local hyperthermia may be superficial, where heating
arrays are placed above shallow tumors in the skin, interstitial, or endocavitary, where a
heating probe is inserted into the skin, tissue or body cavity, respectively.

Regional

hyperthermia may involve external heating of a large area, or perfusion, where blood from the
region surrounding the tumor is removed, heated, and then pumped back into the area. Whole
body hyperthermia often utilizes equipment where tubes of heated water blanket the patient,
while simultaneously entrapping the heat and preventing sweating in order to quickly elevate
the patient’s body temperature (Babincova 2000). While some systemic toxicity has been
reported (Hergt 2006), generally, toxicity due to hyperthermia treatment is low and does not
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limit treatment, though treatment may result in burns or pain in the treated area. Tumors often
contain chaotic vasculature, which creates regions of low oxygenation and perfusion, and
higher acidity.

These environmental factors can make the cells less susceptible to

chemotherapy and radiation treatments. However, when hyperthermia is applied, perfusion
and oxygen levels in the tumor increase, thus increasing the effectiveness of chemotherapy or
radiation.

Additionally, direct tumor cytotoxicity from hyperthermia is possible and is

considered a result of denaturation of proteins in the nucleus, cytoplasm, or cell membrane
(Issels 2008). Additional mechanisms for improved efficacy of combined treatment include
an increased rate of drug alkylation, prevention of repair from drug-induced damage, and
increased uptake of drug.

Enhanced drug delivery is thought to be a result of improved

perfusion in the tumor and surrounding area, and increased vascular permeability (Wust
2002).
Paclitaxel (PTX, MW = 853.91) is a plant alkaloid, the structure of which is depicted
in Figure 5.1 (a). It effectively disrupts mitosis during the G2 phase of the cell cycle by
binding with the beta subunit of tubulin dimers, interfering with the dynamic instability of the
microtubules in the cytoskeleton and thus forming highly stable, rigid microtubules (Obara
2005; Michalakis 2007).

In addition to preventing proliferation, paclitaxel also inhibits

angiogenesis, cell migration, and collagenase production (Obara 2005). At micromolar doses,
paclitaxel has also been shown to initiate the release of cytokines and promote the expression
of certain genes, including those that encode tumor suppressors (Michalakis 2007). When
used in combination with hyperthermia, paclitaxel has been shown to have a complex effect
that is cell-line dependent, and effective in the range of 41.5 to 43°C.

PTX has been

commonly used to treat human carcinomas, with considerable antineoplastic activity
specifically against ovarian, head, and neck carcinoma (Issels 2008). As a chemotherapeutic,
paclitaxel has also been effective treating lung cancer, breast cancer, acute leukemia and other
solid tumors.

Currently, the most common formulation of paclitaxel used clinically is
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Figure 5.1. (a) Chemical structure of paclitaxel (Mw = 853.91) and (b) schematic showing the
use of hydrogel nanocomposites to treat cancer. The nanocomposite would be injected or
implanted within a tumor or at a tumor resection types. It would then release a
chemotherapeutic agent and upon exposure to an alternating field, release heat to increase the
efficacy of the drug treatment.
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Taxol®, which uses a solution of Cremophor® EL and ethanol to combat the drug’s high
hydrophobicity. Because of paclitaxel’s poor solubility in water, it is necessary to create
vehicles that can effectively deliver the chemotherapy treatment.
Hydrogels are three-dimensional, polymeric networks that are hydrophilic and able to
absorb large amounts of water, while remaining insoluble due to their crosslinked structure
(Lin and Cheng 2001; Hilt and Byrne 2004; DiRamio 2005). As such, hydrogels are able to
mimic human soft tissues and are thus suited for a variety of biomedical applications.
Hydrogels have been used as drug delivery devices, as scaffolds for tissue engineering, and in
biosensors

(Peppas 2000; Peppas 2006).

When nanoparticles are incorporated into the

hydrogel matrix, a nanocomposite is formed. The nanoparticles can strengthen the hydrogel
structure and/or enhance certain properties of the hydrogel (Meenach 2009). For instance,
hydrogel nanocomposites containing iron oxide (Fe3O4) have the ability to heat when placed
in an alternating magnetic field. This has lead to the use of magnetic nanocomposites in
remote-controlled heating (Meenach 2009; Meenach 2009), valves (Satarkar 2009), drug
release (Satarkar and Hilt 2008), and degradation applications (Hawkins 2009). The heating
mechanism of superparamagnetic magnetic materials via AMF is a combination of Brownian
and Néel relaxations.

Brownian relaxation results from the random motion of the

nanoparticles, which produce frictional energy losses. Néel relaxation can be attributed to the
reorientation of the magnetic dipole moments of the particles when exposed to the alternating
magnetic field (Babincova 2001). This release of heat from the hydrogel nanocomposite can
be used as a method for local or regional hyperthermia, and depending on the coating, iron
oxide particles can be well tolerated in the body (Bahadur and Giri 2003).
Because of their large swelling capabilities, hydrogels are able to release molecules
with a wide range of molecular weights, including chemotherapeutics. Obara and coworkers
were able to imbibe and release hydrophobic paclitaxel from chitosan-based hydrogels
successfully (Obara 2005). Additionally, DiRamio and coworkers used poly(ethylene glycol)
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methacrylate and poly(ethylene glycol) dimethacrylate polymers to create gels able to imbibe
and release hydrophobic estradiol and insulin (DiRamio 2005) indicating the potential use of
hydrogels to deliver various therapeutic agents.
Poly(ethylene glycol) (PEG) is known as a “stealth” material because of its limited
interaction with biological molecules, including proteins (Peppas 2006). During hydrogel
synthesis, Fe3O4 nanoparticles can be incorporated into the PEG matrix, resulting in a
hydrogel that can be remotely heated by an alternating magnetic field. When imbibed with
paclitaxel, the hydrogel nanocomposite has the capacity to release the chemotherapeutic
simultaneously with hyperthermia treatment.

For an improved therapy option, hydrogel

nanocomposites loaded with chemotherapeutic agents could be implanted or injected into a
tumor for treatment or implanted where a tumor has been resected to prevent recurrence. The
nanocomposite hydrogel would release drug into a localized area, thus reducing systemic side
effects and increasing regionally high concentrations of the drug.

When exposed to an

external alternating magnetic field, the hydrogel would be able to produce hyperthermia
conditions in the area surrounding the implant as seen in Figure 5.1 (b). The overall objective
of this work was to investigate magnetic PEG hydrogel nanocomposites that have the ability
to control the release of both PTX and heat for the treatment of cancer. Three cancer cell lines
were also evaluate in vitro for the effectiveness of their treatment with both PTX and
hyperthermia.

5.2 Materials and Methods

5.2.1 Materials
The macromer poly(ethylene glycol) (N = 1000) methyl ether methacrylate
(PEG1000MMA) and crosslinker poly(ethylene glycol) (N = 400) dimethacrylate
(PEG400DMA) were obtained from Polysciences (Warrington, PA). Fe3O4 nanoparticles (20100

30

nm,

99.5%

purity,

0.2%

polyvinylpyrrolidone-coated)

Nanostructured & Amorphous Materials (Los Alamos, NM).

were

purchased

from

The initiator, ammonium

persulfate (APS), accelerator N, N, N’, N’-tetramethylethane-1,2-diamine (TEMED),
Cremophor®

EL, and Tween® 20 were supplied by Sigma Aldrich (St. Louis, MO).

Methanol was purchased from Fisher Scientific (Pittsburgh, PA) and paclitaxel (PTX) was
obtained from LC Laboratories (Woburn, MA).

Cells, cell medium, and DMSO were

obtained from American Type Culture Collection (ATCC, Manassas, VA). The mammalian
cell live/dead assay was from Molecular Probes/Invitrogen (Carlsbad, CA). All materials
were used as received.

5.2.2 Magnetic Hydrogel Nanocomposite Fabrication
Three hydrogel systems were synthesized and characterized in these studies.
80PEG1000MA, 50PEG1000MA, and 20PEG1000MA gels were fabricated with 80, 50, and
20 mole % PEG1000MA macromer to PEG400DMA crosslinker, respectively. The structures
of these compounds are shown in Figure 5.2. After the crosslinker and macromer were added
to a glass vial, 25 weight % of methanol was added as a solvent.

5 weight % Fe3O4

nanoparticles were then added, and the mixture was placed in an ultrasonic bath for an hour to
promote dispersion of the nanoparticles. Following this, 2 weight % APS and 4 weight %
TEMED were added to the hydrogel solution to initiate free-radical polymerization of the
hydrogels. This mixture was then vortexed for approximately 10 seconds and pipetted into a
template of two 15 cm by 15 cm glass plates separated by 1.5 mm Teflon spacers. The
hydrogel remained in the template for at least two hours prior to removal in order to ensure
that the polymerization had gone to completion, and it was then washed for at least three days
in deionized water to remove any unreacted components.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Figure 5.2. Chemical structures of (a) the macromer poly(ethylene glycol) (n = 1000) methyl
methacrylate and (b) the crosslinker poly(ethylene glycol) (n = 400) dimethacrylate which
were used to fabricated the PEG-based magnetic hydrogel nanocomposites.

102

5.2.3 Swelling Analysis of PEG Hydrogel Nanocomposites
The volumetric swelling ratios of the hydrogel nanocomposite systems were
determined using a gravimetric density analysis method described previously (Frimpong
2006). Samples with 15 mm diameters were cut from each hydrogel system and were placed
in PBS (pH 7.4), and these were allowed to equilibrate at 22, 37, 43 and 65 °C. Hydrogels
were weighed in both air and n-heptane at each temperature. They were then completely dried
and weighed again in air and n-heptane. The volume swelling ratio of each system (Q) was
calculated using equation 1:
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where V is the volume of the sample, ρheptane is the density of n-heptane, Mair is the mass of the
sample in air, and Mheptane is the mass of the sample in n-heptane. The superscripts s and d
refer to the swollen and dry forms of the samples, respectively.

5.2.4 Remote-Controlled Heating of Nanocomposites by Exposure to Alternating Magnetic
Field
Samples with 15 mm diameters were cut from each hydrogel system using a cork borer
and placed in PBS and allowed to equilibrate at room temperature (22° C) overnight. Excess
moisture was removed from the hydrogels before placing them into Saran wrap which was
necessary to prevent evaporation of water during heating. The hydrogel and plastic wrap were
taped to a stage situated over the alternating magnetic field induction power supply (TaylorWinfield, MMF-3-135/400-2) equipped with a solenoid with a 15 mm diameter and 5 turns.
An infrared camera (AGEMA Thermovision 470) positioned over the hydrogel measured the
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surface temperature. The samples were exposed to the AMF for a period of 5 minutes at field
strength of 15.1 kA/m and frequency of 298 kHz. The change in temperature recorded was
the difference between the initial hydrogel surface temperature and the surface temperature
during the heating.

5.2.5 Mechanical Testing to Determine Compressive Modulus
Samples that were 8.5 mm diameter discs were cut from each hydrogel system, placed
in PBS, and allowed to equilibrate.

Using a BOSE ElectroForce 3300 mechanical test

instrument, a displacement method was performed to determine the compressive modulus of
the materials. A 1 mm displacement length, displacement rate of 0.05 mm/s, and 500 N load
were specified for each test. A stress versus strain curve was plotted for each system, and a
strain range of 0.05 to 0.10 was analyzed. From this information, the compressive modulus
was determined from the slope of the curve.

5.2.6 Paclitaxel Release from PEG Hydrogel Nanocomposites
Samples (8.5 mm diameter) from each hydrogel system were imbibed with drug by
placing them into a solution of Taxol®, the formulation of paclitaxel most commonly used for
cancer patient treatment. This consisted of 6 mg paclitaxel, 527 mg Cremophor® EL, and
49.7% (v/v) dehydrated ethanol, with each piece of hydrogel being placed in 1 ml of this
solution for two days at room temperature at 100 rpm in an incubator shaker. Release studies
were performed in a modified PBS medium comprised of PBS, 2.4 weight % Tween® 20, and
4 weight % Cremophor® EL where Tween and Cremophor® EL surfactants aided in the
release of the hydrophobic paclitaxel into the water-based medium. Hydrogels were placed in
6 mL of release medium at 37 °C and 100 rpm, allowed to release over a period of time, then
transferred to a fresh release medium to maintain infinite sink conditions.

The release

medium samples were prepared for high performance liquid chromatography (HPLC) by
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adding 4 mL acetonitrile to each sample. Reverse phase-HPLC was carried out on a Thermo
Finnigan Spectra System with ChromQuest 4.0 software. The mobile phase consisted of
acetonitrile and water (50:50 v/v), the injection volume was 20 µL, and the mobile phase flow
rate was 1.0 mL/min. The separation was achieved using a C18 Reverse Phase Column (4.6 ×
150 mm, pore size 5 µm, Waters, Milford, MA). The mobile phase was monitored at a
wavelength of 227 nm with a UV detector. A calibration curve of paclitaxel in acetonitrile
and PBS (50:50 v/v) was used to determine the concentration of paclitaxel released.

5.2.7 Mathematical Analysis of Paclitaxel Release
The modeling of drug release from hydrogels has been extensively studied in
literature. Higuchi (Higuchi 1961) developed a release model for a thin polymer slab of
thickness, ℓ, assuming perfect sink conditions, using Fick’s second law. For short times 0 <
Mt/M∞ < 0.6 (where Mt is the mass of drug released at time, t, and M∞ is the accumulated
mass of drug released at infinity), the solution of this model can be written as:

ெ

ெ∞
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(2)

where D is the diffusion coefficient for short times and t is time.

This model has its

limitations as it assumes Fickian diffusion, and therefore the more general power law seen
below is often used to better characterize drug release:

ெ
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where k is a constant that depends on the structural and geometrical characteristics and n is the
release exponent indicating the mechanism of drug release. An n value of 0.5 indicates Case I
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Fickian diffusion while values between 0.5 and 1 indicate anomalous diffusion, and a value of
1 indicates zero-order diffusion (Case II Fickian diffusion). A limitation of this model,
however, is the fact that it does not account for an initial burst release or lag time during the
initial phase of release. A more detailed description of Fickian drug release modeling is in
Appendix B.5.1.

5.2.8 In Vitro Paclitaxel/Hyperthermia Cancer Cell Studies
Three cancer cell lines were evaluated for their response to the chemotherapeutic
agent, paclitaxel, and hyperthermia temperatures induced in a humidified incubator. Three
cell lines were evaluated, including glioblastoma (M059K), breast adenocarcinoma (MDA
MB 231), and lung carcinoma (A549) cells which were all obtained from ATCC. The base
cell culture medium for each cell line was as follows: M059K used Dulbecco’s Modified
Eagle’s Medium and Ham’s F-12 medium (1:1), A549 used F-12K medium, and MDA MB
231 cells used Leibovitz's L-15 medium. The complete medium for all cell lines contained the
base medium supplemented with 10% v/v calf bovine serum, 100 I.U./ml penicillin, 100
µg/ml streptomycin, and 1 µg/ml antimycotic Fungizone® (Invitrogen).

The cells were

cultured at 37 °C and 5 % CO2 in a humidified incubator and were used from passages 4
through 8. Initially, M059K were seeded at 10000 cells/cm2, and A549, and MDA MB 231
cells were both seeded at 5000 cells/cm2 in 12 well plates and were placed in an incubator for
24 hours. The cells were then exposed for two hours to the following: 10 µM PTX, 50 µM
PTX, 10 µM PTX plus heat, 50 µM PTX plus heat, heat only, complete medium with 2%
(v/v) DMSO with and without heat, and medium only. The medium with PTX also contained
2% (v/v) DMSO to increase PTX solubility and the DMSO control was used as a comparison
to ensure no negative effects on the cells were due to the solvent. After 2 hours, the cells were
washed and exposed to fresh medium for 4 hours, 1 day, and 3 days before they were analyzed
for cytotoxicity. A two-color fluorescence Live/Dead Viability Assay® (Molecular Probes)
106

was used to assess the cell viability of the cells initially (corresponding to the PTX or heat
treatment for one sample set) or after exposed to fresh medium for the determined times.
Stained samples were observed using a NIKON Eclipse 80i microscope at 50x magnification.
The number of live cells was determined by manually counting the live and dead cells imaged
with NIS-Elements software. The cells were analyzed as three separate samples with ten
images (5 live and 5 dead) taken for each. Results were reported as the ratio of the number of
live cells for all samples exposed to treatment over the initial cell numbers counted prior to
treatment.

5.2.9 Statistical analysis
All experiments were performed at least in triplicate. MYSTAT 12 for Windows
(12.02.00) was used for t-tests (paired t-test with unequal variances) to determine any
significance in observed data. A p-value of <0.05 was considered statistically significant.

5.3 Results and Discussion

5.3.1 Swelling, Remote-Controlled Heating, and Mechanical Analysis
Swelling studies were performed on the hydrogels in order to determine their
capability for imbibing fluids. Figure 5.3 shows the volume swelling ratio (Q) for each
hydrogel system at various temperatures. From this, it can be seen that for all systems, Q
decreases from 22 to 37 °C (p-values < 0.05), Q is the same from 37 to 43 °C (p-value > 0.05),
and Q decreases again from 43 to 65 °C. Additionally, as the crosslinking density increases,
Q decreases. The volume swelling ratios for the 50PEG1000MA and the 20PEG1000MA
hydrogels were close despite the difference in crosslinking density but were still statistically
different (p-values were 0.016, 0.015, 0.011, and 0.020 for 22, 37, 43, and 65 °C,
respectively). The Q values for each hydrogel system did not vary between 37 °C and 43 °C,
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Figure 5.3. Volume swelling ratio (Q) for the hydrogel nanocomposites at various
temperatures with corresponding p-values. N = 3 ± SE.

108

which are body and hyperthermia temperatures, respectively.

This data may have

implications should the hydrogel be implemented as a treatment device, since the hydrogel
would not alter its swelling from being placed in the body or due to heating.
Remote-controlled heating data was analyzed by finding the change in temperature
from the initial room temperature to the surface temperature of the hydrogel after five minutes
of exposure to an AMF (∆T).

As seen in Figure 5.4, the higher crosslinked hydrogel

(20PEG1000MA) had a greater change in temperature after exposure to the AMF. This is due
to a higher iron oxide to hydrogel volume ratio (i.e., lower water content) in the gel. Because
the hydrogel is more densely crosslinked, a greater amount of iron oxide nanoparticles per unit
volume of the hydrogel are present in the swollen nanocomposite.

The ∆T for the

50PEG1000MA system is similar to the ∆T for the 20PEG1000MA hydrogel, and this is in
agreement with the swelling data which showed a significant difference between the lowest
crosslinked hydrogel and the highest, but less of a difference between the 50PEG1000MA and
the higher crosslinked 20PEG1000MA hydrogel. Importantly, each hydrogel was able to
reach temperatures well above hyperthermia range, thus demonstrating that the temperature
range for hyperthermia treatment can be reached using these hydrogel nanocomposite
systems.
Compression testing was done on three samples from each hydrogel system. Figure
5.5 shows the compressive modulus for each hydrogel. As expected, the hydrogel with the
lowest crosslinking density also had the lowest compressive modulus. As crosslinking density
was increased, the compressive moduli increased.
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Figure 5.4. Heating analysis of nanocomposites exposed to an alternating magnetic field (15.1
kA/m, 298 kHz) for 5 minutes. The change in temperature (∆Temperature) is relative to the
initial temperature of the hydrogel at room temperature. N = 3 ± SE.

110

Figure 5.5. Compressive modulus of hydrogel nanocomposites after mechanical analysis of
swollen hydrogels at room temperature using a displacement method. N = 3 ± SE.
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5.3.2 Mathematical Analysis of Paclitaxel Release
For purely Fickian diffusion, a model for drug release has been developed by Higuchi
which was described in equation 2. It is the power law, as seen in equation 3, however, which
can be used to determine the drug release mechanism of the system, whether the release is
Fickian or not. For this work, all three hydrogel systems were imbibed with PTX in a Taxol®
formulation, and its release was studied in a modified PBS solution at 37 °C. Figure 5.6 (a)
shows the fractional drug release with time, and PTX was released from all of the hydrogels
by 22 days. This data was analyzed using the power law from 0 < Mt/M∞ < 0.6 and the
corresponding n values can be found in Table 5.1. For all of the systems, the release exponent
(n) was less than 0.5 indicating the release mechanisms are non-Fickian. It was hypothesized
that this phenomenon was most likely due to the initial burst release from the hydrogels. In
addition, since the hydrogels were not dried prior to the release studies, the Taxol®
formulation loaded into the hydrogels increases the solubility of paclitaxel. The large initial
concentration gradient of Taxol® to PBS would act as a strong driving force to release the
paclitaxel quickly from the hydrogels.
The data indicates that the least crosslinked hydrogel system (80PEG1000MA)
released the paclitaxel the fastest, with the most crosslinked system (20PEG1000MA)
releasing the drug the slowest. This is due to the fact that hydrogel systems with less
crosslinking exhibit a looser mesh and larger mesh size, allowing for the drug to diffuse more
freely through the system.

Additionally, Figure 5.6b shows the cumulative release of

paclitaxel from the hydrogels.

80PEG1000MA was shown to imbibe and release more

paclitaxel with less drug being released in the more crosslinked systems. Overall, these
results indicate that paclitaxel can be release successfully from PEG hydrogel systems and this
release can be tailored by the crosslinking density of the hydrogel systems.
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Figure 5.6. Paclitaxel release data from PEG hydrogel nanocomposites versus time. (a) is the
fractional release of PTX whereas (b) is the total amount of paclitaxel released from the
hydrogel nanocomposites. N = 3 ± SE.
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Table 5.1. Drug release analysis values including the initial release exponent from the power
law prior (n) and the thickness of the gels (ℓ).

System

n

ℓ (cm)

20PEG1000MA

0.19

0.16

50PEG1000MA

0.24

0.17

80PEG1000MA

0.25

0.21
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5.3.3 Cancer Cell Response to Paclitaxel and/or Hyperthermia
In vitro studies were performed to determine the effect of paclitaxel and/or
hyperthermia on three cells lines: M059K (glioblastoma), MDA MB 231 (breast
adenocarcinoma), and A549 (lung carcinoma).

The cells were exposed to micromolar

concentrations of PTX and/or heat for 2 hours and then allowed to respond in fresh medium
for 3 hours, 1 day, and 3 days. The number of cells counted for each sample was ratioed
against the initial cell sample counted for each cell type. This then can show the effect the
different treatments have on the various cell lines.
As seen in Figure 5.7, for MDA MB 231 cells after 3 hours, there was no change in the
cells due to DMSO, heat, or PTX in comparison to the control (p-values > 0.05). 1 day after
exposure, there was no effect due to DMSO (p = 0.508), however, 10 and 50 µM PTX and
heat decreased the number of cells (p = 0.023, 0.001, 0.000, respectively). No synergistic
effect was for 10 and 50 µM plus heat in comparison to PTX alone (p = 0.362, 0.729).
Similar effects were seen 3 days with no DMSO effect (p = 0.134), a decrease in cells
compared to the control for 10 and 50 µM PXL or heat (p = 0.000, 0.001, 0.023). There was
no synergistic effect due to PXL and heat combines (p = 0.086 and 0.324 for 10 and 50 µM,
respectively). Figure 5.8 supports this data showing a decrease in the number of cells for
samples exposed to PTX or heat.
For the glioblastoma (M059K) cells 3 hours after exposure, there were no effects seen
due to any treatments (p > 0.05) as seen in Figure 5.9. 1 day after exposure, however, there
were no effects due to DMSO (p = 0.377) or heat (0.787), however, the cell number did
decrease for 10 and 50 µM PTX treatment (p = 0.015, 0.003). There was no synergistic effect
seen for 10 and 50 µM PTX plus heat (p = 0.053, 0.259). 3 days after treatment, M059K cells
showed a negative response to DMSO with a vast decrease in cell numbers in comparison to
the control (p = 000). Therefore, there was no was no way to determine what effect PTX or
heat had on this cell line. Figure 5.10 shows the cell morphology of the M059K cells 3 days
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Figure 5.7. In vitro analysis of MDA MB 231 (breast adenocarcinoma) cells exposed to PTX
and/or heat treatment for 2 hours and then analyzed (a) 3 hours, (b) 1 day, and (c) 3 days after
PTX or heat exposure, respectively. N = 3 ± SE.
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Figure 5.8. In vitro analysis of MDA MB 231 (breast adenocarcinoma) cells exposed to PTX
and/or heat treatment for 2 hours with fluorescent images of the cells 3 days after exposure for
the following conditions: (a) 10 µM PTX only, (b) 50 µM PTX only, (c) media only, (d)
DMSO in media, (e) 10 µM PTX plus heat, (f) 50 µM PTX plus heat, and (g) heating only and
(h) heat only with DMSO in media.
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Figure 5.9. In vitro analysis of M059K (glioblastoma) cells exposed to PTX and/or heat
treatment for 2 hours and then analyzed (a) 3 hours, (b) 1 day, and (c) 3 days after PTX or
heat exposure, respectively. N = 3 ± SE.
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Figure 5.10. In vitro analysis of M059K (glioblastoma) cells exposed to PTX and/or heat
treatment for 2 hours with fluorescent images of the cells 3 days after exposure for the
following conditions: (a) 10 µM PTX only, (b) 50 µM PTX only, (c) media only, (d) DMSO
in media, (e) 10 µM PTX plus heat, (f) 50 µM PTX plus heat, and (g) heating only and (h)
heat only with DMSO in media.
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after exposure and the effect of DMSO on the cells is evident with fewer cells which have
abnormal morphology.
There are no studies that show that either PTX or hyperthermia are effective in treating
M059K cell lines although PTX is effective in treating other types of glioblastoma cell lines
(Langer, Ruffer et al. 2001; Zhan, Gu et al. 2010). Similarly, there is no data that supports the
treatment of MDA MB 231 cells with PTX or heat. There are studies that illustrate the
effectiveness of paclitaxel in treating other breast cancer cells lines both in vitro (Ito, Kuga et
al. 2004) and in vivo (Cividalli, Cruciani et al. 1999). Overall, the data from the study in our
current project shows that other types of breast adenocarcinoma and glioblastoma cell lines
may need to be evaluated to show the efficacy of combined hyperthermia and paclitaxel
treatment so that this work can be effectively translated into in vivo studies.
Figure 5.11 shows the effect of the PXL and heat treatments on A549 (lung
adenocarcinoma) cells 3 hours, 1 day, and 3 hours after exposure. For the 3 hour samples,
there was no effect on the cells in comparison to the control due to DMSO or 10 or 50 µM
PXL (p = 0.519, 0.598, 0.998, respectively). The number of cells did decrease in comparison
to the control (p = 0.048), however, there was no synergistic effect due to PXL plus heat
compared to PXL alone (p > 0.05). 1 day after exposure, there was no effect on the cells due
to DMSO, 10 or 50 µM PXL, or heat only in comparison to the control (p = 0.223, 0.888,
0.553, 0.691, respectively). There was, however, a synergistic effect when combining the
PXL treatment with heat (p = 0.014 and 0.000 for 10 and 50 µM PXL plus heat, respectively).
Similar effects were seen 3 days after exposure with no effect due to PXL, 10 or 50 µM PTX,
or heat (p = 0.123, 0.148, 0.103, 0.380). For 10 and 50 µM PTX plus heat, however, the
number of cells decreased significantly compared to the PTX only treatment (p = 0.000 for
both PTX concentrations). Figure 5.12 shows the A549 cells 3 days after PTX and/or heat
exposure and it can be seen that the cell morphology is the same for all of the cells except for
the samples exposed to both PTX and heat. For these two samples, the cell morphology is
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Figure 5.11. In vitro analysis of A549 (lung adenocarcinoma) cells exposed to PTX and/or
heat treatment for 2 hours and then analyzed (a) 3 hours, (b) 1 day, and (c) 3 days after PTX
or heat exposure, respectively. N = 3 ± SE.
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Figure 5.12. In vitro analysis of A549 (lung adenocarcinoma) cells exposed to PTX and/or
heat treatment for 2 hours with fluorescent images of the cells 3 days after exposure for the
following conditions: (a) 10 µM PTX only, (b) 50 µM PTX only, (c) media only, (d) DMSO
in media, (e) 10 µM PTX plus heat, (f) 50 µM PTX plus heat, and (g) heating only and (h)
heat only with DMSO in media.

122

abnormal with fewer cells which may be due to dying cells detaching from the surface of the
well plates. Overall, this shows the potential to use both PTX and hyperthermia to treat lung
adenocarcinoma cells more effectively than PTX alone. Although previous in vivo studies
support the effectiveness of both PTX alone in treating this cancer cell line (Shen, Hu et al.
2008), this is the first time the synergistic effect of paclitaxel at micromolar levels and
hyperthermia has been demonstrated.

5.4 Conclusions
Magnetic PEG-based hydrogel nanocomposites have been demonstrated to have the
ability to deliver both paclitaxel and heat for the potential treatment of cancer. The swelling,
heating, and mechanical characteristics of the hydrogel nanocomposites were able to be
tailored by the crosslinking density of the hydrogel systems. All of the hydrogels were shown
to heat well above the temperature needed for hyperthermia upon exposure to an alternating
magnetic field. The drug release mechanism of the hydrogels was not found to be purely
Fickian and it was shown the lower crosslinked hydrogels released PTX more quickly, which
would be expected.

In vitro cell studies showed that combined PTX and hyperthermia

treatment increases the efficacy of PTX for A549 lung carcinoma cells.

Overall, these

hydrogel nanocomposites may have the ability to treat this type of cancer along with
numerous other cancer types.

References
All references are located at the end of the dissertation.
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CHAPTER 6

“Controlled Synergistic Delivery of Paclitaxel and Heat from Poly(β-amino ester)/Iron
Oxide-Based Hydrogel Nanocomposites”

This research investigates the use of poly(β-amino ester) (PBAE) biodegradable
hydrogels and iron oxide for combined chemotherapeutic and heat delivery in hyperthermiabased treatment of cancer. Hyperthermia, the heating of cancerous tissue from 41 to 45°C,
has been shown to increase the efficacy of conventional cancer therapies such as irradiation
and chemotherapy.

The hydrogel nanocomposites in this work provide a drug delivery

vehicle (via the biodegradable PBAE polymer network) and the ability to be heated remotely
upon exposure to an alternating magnetic field (via iron oxide nanoparticles).

PBAE

macromers comprised of poly(ethylene glycol) (N=400) diacrylate (PEG400DA) or diethylene
glycol diacrylate (DEGDA) with isobutylamine (IBA) have been synthesized via a simple
condensation reaction. The macromers were analyzed via gel permeation chromatography to
determine their molecular weight and polydispersity index values. Hydrogel nanocomposites
were fabricated via free-radical polymerization of two types of PBAE macromers with iron
oxide nanoparticles, the chemotherapeutic agent paclitaxel, and ammonium persulfate as the
free radical initiator. The degradation of the hydrogel nanocomposites was carried out in
phosphate buffered saline solution at 37°C. A pure 2EG-IBA (1:1.2 molar ratio of IBA to
DEGDA)-based hydrogel exhibited complete degradation after approximately 7 weeks
whereas the pure 9EG-IBA (1:1.2 molar ratio of IBA to PEG400DA)-based hydrogel
degraded in 11 hours. The hydrogels all heated upon exposure to an alternating magnetic field
throughout the degradation process. Additionally, the degradation products exhibited cell
viabilities ranging from 53% for a pure 2EG-IBA gel at 4.5 mg/ml and 92% for a pure 9EGIBA gel at 0.15 mg/ml. The paclitaxel release was controlled via bulk degradation of the
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hydrogels with time. Overall, the tailorability and biodegradable nature of the PBAE hydrogel
nanocomposites makes them solid candidates for combined hyperthermia and chemotherapybased treatment of cancer.

Keywords: Hydrogel, nanocomposites, poly(β-amino ester), hyperthermia, paclitaxel, cancer.

6.1 Introduction
Currently, cancer is the second leading cause of death in the United States. In 2009
alone, there were an estimated 1.5 million new cases diagnosed (ACS 2009). Despite the
amount of research being done to overcome this disease, there are still many types, such as
glioblastoma and pancreatic cancer (Sneed 1998), which have extremely poor treatment
success rates. Therefore, multiple-modality treatment has become the preferred treatment
approach. Hyperthermia, the heating of cancer tissues to between 41 and 45°C, has been
proven to provide a straightforward and more effective way of treating some types of cancer
in combination with well-developed therapeutics such as radiation and chemotherapy (Falk
and Issels 2001). Aside from having a cytotoxic effect on cancerous tissue, hyperthermia has
been shown to increase tumor blood flow which can decrease hypoxia, acidosis, and energy
deprivation at the tumor site, thereby increasing therapy efficacy as these conditions often
make the treatment of cancer more difficult (Hildebrandt 2002). Hyperthermia therapy faces a
number of obstacles including being able to restrict local heating of the tumor without
damaging surrounding tissue (Moroz 2002) and the inability to heat the cancer tissue locally
without using invasive and uncomfortable heating probes (Guedes 2005). This can potentially
be overcome through the development of systems which can be delivered to and/or implanted
at tumor sites and remotely heated from outside the body. This work presents a hydrogel
nanocomposite capable of delivering both heat and a chemotherapeutic for local synergistic
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treatment of cancer through the implantation or in situ injection of the hydrogel within or near
malignant tumors.
Hydrogel nanocomposites involve the incorporation of nanoparticulate materials
within a hydrogel matrix which often provide easy, straightforward methods for enhancing the
properties of conventional hydrogel systems. Thus far, a number of nanoparticulates have
been utilized in nanocomposite hydrogel systems including metallic nanoparticles, carbon
nanotubes, clay, ceramics, magnetic nanoparticles, hydroxyapatite, and semiconducting
nanoparticles (Meenach 2009). Hydrogels themselves are advantageous for many biomedical
applications due to their resemblance of natural living tissue and inherent biocompatibility,
which can be partially attributed to their soft, flexible nature and high water content (Peppas
2006).

Magnetic hydrogel nanocomposites containing nanoscale superparamagnetic iron

oxide nanoparticles have the potential to be used in hyperthermia therapy due to their ability
to heat upon exposure to an alternating magnetic field (AMF). The heating mechanisms for
these paramagnetic particles are based primarily on Brownian relaxation (rotation of the
particle as a whole according to external magnetic field), the Neel effect (reorientation of the
magnetization vector inside the magnetic core against an energy barrier), and often some
minimal hysteresis losses (Babincova 2001). Hydrogel nanocomposites containing iron oxide
nanoparticles have already been utilized in applications such as remote-controlled drug
delivery (Satarkar and Hilt 2008), microfluidic valves (Satarkar 2009), hydrogel degradation
(Hawkins 2009) and thermoablation (Meenach 2009; Meenach 2009).
In addition to delivering heat, these materials also have the potential to deliver
therapeutic agents for cancer therapy and other diseases. There are many disadvantages to
using systemic chemotherapy delivery for cancer treatment including systemic toxicity, low
drug bioavailability, and difficulty in delivering the drug(s) effectively within tumors (Ta
2008). Hydrogel nanocomposites have the ability to overcome these obstacles through the
local delivery of chemotherapeutic agents at therapeutic doses. In recent years, poly(β-amino
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ester) (PBAE) hydrogels have been widely investigated for various biomedical applications
such as drug delivery and tissue engineering. Anderson and coworkers have developed the
first combinatorial library of biodegradable crosslinkable biomaterials characterizing a wide
variety of PBAE macromers. This library consists of acrylate-terminated poly(β-amino ester)s
synthesized via a condensation reaction that combines primary or secondary amines with
diacrylates (Anderson 2006). There are many benefits to using these diacrylate-terminated
biodegradable hydrogel systems including: 1) monomer reagents that are inexpensive and
commercially available, 2) macromer polymerization that can be completed without additional
protection/deprotection schemes because the amine participate directly in the bond-forming
processes in the reactions, and 3) no byproducts generated during the synthesis so that no
purification steps are necessary (Anderson 2006). Utilizing PBAE macromers in a hydrogel
matrix can allow for hydrogel systems whose degradation, mechanical strength, and toxicity
can be controlled based on the monomer reagents used for macromer synthesis.
Paclitaxel (PTX) is a plant alkaloid which effectively disrupts mitosis during the G2
phase of the cell cycle by binding with the beta subunit of tubulin dimers. This interferes with
the dynamic instability of the microtubules in the cytoskeleton where the cells form highly
stable, rigid microtubules preventing proliferation (Obara 2005; Michalakis 2007).

In

addition, PTX also inhibits angiogenesis, cell migration, and collagenase production. PTX
and hyperthermia have a complex relationship in the treatment of cancer in that their
combined effect is both cell-line dependent and there is variable effectiveness in the
hyperthermia temperatures utilized (Issels 2008). PTX has been commonly used to treat
human carcinomas, with considerable antineoplastic activity specifically against ovarian,
head, and neck carcinoma. As a chemotherapeutic, paclitaxel has also been effective in
treating lung cancer, breast cancer, acute leukemia and other solid tumors (Issels 2008).
Currently, the most common formulation of paclitaxel used clinically is Taxol™, which uses a
carrier of Cremophor® EL and ethanol to increase the solubility of the highly hydrophobic
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drug. The objective of this work was to fabricate and characterize biodegradable PBAE-based
hydrogel nanocomposites for the combined delivery of heat and paclitaxel for potential cancer
therapy applications. The degradation of the hydrogels allows for the controlled release of the
chemotherapeutic, paclitaxel, whereas the iron oxide nanoparticles in the hydrogel matrix
allows for the remote heating of the systems via an AMF. In addition to the characterization
of the degradation, mechanical, heating, and release properties of these systems, the
cytotoxicity of the degradation products was analyzed to show the inherent safety of these
materials to be used in biomedical applications.

6.2 Materials and Methods

6.2.1 Materials
Diethylene glycol diacrylate was obtained from Polysciences (Warrington, PA). The
Fe3O4 nanoparticles (20-30 nm diameter, 0.2% polyvinylpyrrolidone-coated) were obtained
from Nanostructured and Amorphous Materials (Los Alamos, NM). Paclitaxel (99.5%) was
from LC Laboratories (Woburn, MA). Ammonium persulfate (APS), isobutylamine (IBA),
Cremophor EL®, Tween® 20, tetrahydrofuran, and poly(ethylene glycol) (N=400) diacrylate
(PEG400DA) were obtained from Sigma Aldrich (St. Louis, MO). Cells and cell medium
were obtained from American Type Culture Collection (Manassas, VA). The mammalian cell
live/dead assay was from Molecular Probes/Invitrogen (Carlsbad, CA). All materials were
used as received.

6.2.2 Synthesis and Characterization of Poly(β-amino ester) Macromers
Two biodegradable poly(β-amino ester) macromers were synthesized via condensation
reactions of isobutylamine (IBA) with excess poly(ethylene glycol) (PEG) diacrylates. For
one macromer, a 1:1.2 molar ratio of IBA to diethylene glycol diacrylate (with 2 ethylene
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glycol units, n = 2) was reacted for 48 hours at 85°C with mixing (thereby denoted as 2EGIBA). The second macromer was comprised of a 1:1.2 molar ratio of IBA to poly(ethylene
glycol) (N=400) diacrylate (9 EG units, n = 9) reacted for 15 hours at 85°C (denoted 9EGIBA). These compounds and the resulting macromer structure can be seen in Figure 6.1. The
macromers were then analyzed via a Shimadzu gel permeation chromatography (GPC) system
to determine the average molecular weight and polydispersity index (PDI) of the macromers.
The analysis was completed at 0, 24, and 48 hours for the 9EG-IBA macromer and 0 and 15
hours for the 2EG-IBA macromer. For the systems studied, the macromer solution was mixed
with tetrahydrofuran (THF) to a concentration of 5 mg/mL prior to GPC analysis. Attenuated
Total Reflectance Fourier Transform Infrared (ATR-FTIR) analysis was performed to
determine the conversion of available carbon-carbon double bonds present in the PEG
diacrylate constituents of the macromers using a Varian Inc. 7000e step-scan spectrometer. A
sample of the macromer solution was placed on the diamond ATR crystal and IR spectra were
obtained at 8 cm-1 spectral resolution between 700 and 4000 cm-1.

6.2.3 Fabrication of Poly(β-amino ester)/Iron Oxide Hydrogel Nanocomposites
Magnetic hydrogel nanocomposites were fabricated via chemically-initiated freeradical polymerization with various ratios of the two crosslinkable macromers, resulting in
hydrogels with differing degradation profiles. The resulting systems had 0, 25, 50, 75, and
100 weight % 2EG-IBA macromer (100 9EG-IBA, 25 2EG-IBA, 50 2EG-IBA, 75 2EG-IBA,
and 100 2EG-IBA, respectively). 5 weight % iron oxide nanoparticles and 5 mg of paclitaxel
per g of macromer were added to the macromer solution which was exposed to ultrasonication
to facilitate dispersion of the nanoparticles and drug. After sonication, 1.5 weight % of APS
dispersed in water (2 ml water per gram of APS) was then added to the mixture to initiate the
free-radical polymerization. This solution was then mixed well before being loaded into a
template consisting of two glass plates with a 1.5 mm thick Teflon spacer. Gels without
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Figure 6.1. Schematic for synthesis reaction of poly(β-amino ester) macromers comprised of
excess poly(ethylene glycol) (n) diacrylate with isobutylamine resulting in diacrylateterminate structure. This structure has C=C bond end groups allow them to be reacted into
hydrogel nanocomposites via free-radical initiation. Also, the macromers are biodegradable
due to hydrolysis of the available ester bonds present.
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paclitaxel used for cytotoxicity analysis were made the same as described only without
paclitaxel. The gels were kept in this template at least overnight to allow for completion of
polymerization after which they were removed from the templates and placed in a desiccator
to prevent degradation.

6.2.4 Characterization of Hydrogel Nanocomposite Degradation and Swelling Response
The degradation and swelling response of the hydrogel nanocomposites were
determined with respect to time. After polymerization, the hydrogels were cut into 8.2 mm
diameter discs. The initial mass of each gel (mi) was recorded and they were placed in
individual tissue cassettes in PBS (pH 7.4) in an incubator shaker at 37°C and 100 rpm. The
gels were removed at given times, their mass was recorded again in their swollen state (ms),
and they were freeze-dried to remove any residual water. Their mass was then taken again in
their dry state (md). The mass loss of the hydrogels was characterized by calculating the mass
fraction remaining:

mass fraction remaining =



(1)



The swelling of the gels was then characterized by the mass swelling ratio (q):

q=

ೞ

(2)



6.2.5 Mechanical Testing: Determination of Compressive Modulus
Compressive modulus of the hydrogel nanocomposites was determined with
compressive mechanical testing. Gels were cut and placed in PBS at 37°C and 100 rpm. The
gels were tested using the displacement method on a BOSE ElectroForce 3300 with 1 mm
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displacement at a displacement rate of 0.05 mm/s with a 500 N load. Stress versus strain data
was plotted and a strain range of 0.05 to 0.10 was analyzed for each gel.

From this

information, the compressive modulus of the gel could be determined from the slope of the
stress versus strain plot.

6.2.6 Iron Oxide Loss Studies via Thermogravimetric Analysis
Thermal gravimetric analysis was completed to determine the actual iron oxide
nanoparticle loading in the hydrogel nanocomposites as they degraded. The 100 9EG-IBA
hydrogel system was analyzed as a representative sample as it has the fastest degradation
profile. A Netzsch STA 449A system (NETZSCH Instruments, Inc., Burlington, MA) was
used to perform this analysis. From an initial temperature of 20°C, the gel samples were
heated up to 120°C at 5°C per minute, kept at 120°C for 20 minutes to allow for water
evaporation, and then heated up to 590°C at 3°C per minute. The remaining mass was
recorded with time.

6.2.7 Remote-Controlled Heating of PBAE Hydrogel Nanocomposites via an AMF
The magnetic hydrogel nanocomposites were heated using an alternating magnetic
field (AMF) at different times throughout degradation to show their potential to heat and the
effect of degradation on their heating properties. Prior to heating, hydrogel nanocomposites
were cut into discs (8.2 mm in diameter). The hydrogels were initially heated in their dry state
prior to starting degradation. The gels were then placed in PBS at 37°C and 100 rpm.
Remote-controlled heating of the hydrogel nanocomposites was completed using an AMF
induced by a Taylor Winfield induction power supply (model MMF-3-135/400-2) equipped
with a solenoid with a 15 mm diameter and 5 turns. After a specified time, the hydrogel discs
in their wet state were covered with Saran wrap, placed on top of the solenoid coil and
exposed to the alternating magnetic field at 294 kHz and 17.4 kA/m. Thermal images and
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data were acquired using an infrared camera (AGEMA Thermovision 470) which recorded the
surface temperature of the hydrogels. The surface temperature was recorded continuously for
5 minutes.

6.2.8 Characterization of Paclitaxel Release
The release of paclitaxel from the hydrogel nanocomposites was measured via reversephase high performance liquid chromatography (HPLC). 8.2 mm samples were cut and
placed in 3mL of a modified PBS-based release medium comprised of PBS, 2.4 wt% Tween®
20, and 4 wt% Cremophor® EL which aid in the release of the hydrophobic paclitaxel into the
water-based medium.

The release took place at 37°C and 100 rpm, and the gels were

periodically placed in fresh medium to maintain infinite sink conditions. Prior to HPLC
analysis, 2 mL of acetonitrile were added to each tube to ensure complete solubility of PTX in
the solution.

HPLC was performed using a Thermo Finnigan Spectra System with

ChromQuest 4.0 software for data analysis. The mobile phase consisted of acetonitrile and
water (50:50) with a 20 µL injection volume and 1.0 ml/min mobile phase flow rate. The
separation was achieved using a reverse-phase C-18 Symmetry column (4.6 x 150 mm, 5 µm
pore size) from Waters Corporation. The column eluate was evaluated at 227 nm for the
detection of paclitaxel in the samples.

6.2.9 Cytotoxicity Analysis of PBAE Hydrogel Nanocomposite Degradation Products
The degradation products of the hydrogel nanocomposites were analyzed for their
cytotoxic effects.

NIH 3T3 murine fibroblasts obtained from American Type Culture

Collection (ATCC) were used for the cytotoxicity tests.

The complete culture medium

included Dulbecco’s Modified Eagle’s Medium supplemented with 10% v/v calf bovine
serum, 100 I.U./ml penicillin, 100 µg/ml streptomycin, and 1 µg/ml antimycotic Fungizone®
(Invitrogen). The fibroblasts were cultured at 37°C and 5 % CO2 in a humidified incubator
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and were used from passages 4 through 8. 8.2 mm diameter hydrogel nanocomposites with no
paclitaxel were allowed to completely degrade in 5 ml of PBS at 37°C and 100 rpm. The
degradation products were then diluted to samples of 0.15, 1.5 and 4.5 mg/ml in solutions
comprised of 25% (v/v) PBS to complete cell medium. 25% (v/v) PBS to medium sample
acted as the control. The fibroblasts were seeded at 17,500 cells/ml in 35mm Petri dishes and
were placed in an incubator for 24 hours. After this, the medium was removed from the Petri
dishes and replaced with the hydrogel degradation product media samples for 48 hours.
The viability of the fibroblasts was determined by counting the live and dead cells
after 48 hours using a Cellometer® Automated Cell Counter from Nexcelom Biosciences
(Lawrence, MA). Initially, the medium from each Petri dish was removed and collected in
individual centrifuge tubes.

The fibroblasts were then trypsinized and transferred the

corresponding centrifuge tubes and centrifuged for 3 minutes. After the supernatant was
removed, 0.5 ml of Molecular Probes Live/Dead assay solution was added to the tube, the
cells were resuspended in the solution, and placed in an incubator at 37°C for at least 20
minutes before counting with the Cellometer®. The Live/Dead assay solution was comprised
of calcein AM which fluorescently stains live cells green and ethidium homodimer-1, which
stains dead cells red. The cell viability was then calculated as the number of live cells over the
total number of live and dead cells.

6.2.10 Statistical analysis
All experiments were performed at least in triplicate. MYSTAT 12 for Windows
(12.02.00) was used for t-tests (paired t-test with unequal variances) to determine any
significance in observed data. A p-value of <0.05 was considered statistically significant.
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6.3 Results and Discussion

6.3.1 Synthesis and Characterization of Poly(β-amino ester) Macromers
PBAE macromers composed of excess PEGDA and isobutylamine were synthesized
via a simple condensation reaction resulting in macromer chains with diacrylate endchain
groups (as seen in Figure 6.1) allowing for their crosslinking into hydrogel matrices. GPC
was used to analyze the molecular weight and polydispersity index (PDI) of the macromers.
These values can be seen in Table 6.1.
For the 2EG-IBA macromer, the average molecular weight after 15 hours (completion
of reaction) was 2206 g/mole whereas for the 9EG-IBA macromer, the molecular weight
increased with reaction time going from 2103 g/mole at 24 hours to 3663 g/mole after 48
hours (completion of reaction). The PDI values were 1.87 for the 2EG-IBA macromer and
2.57 and 3.03 for the 9EG-IBA macromer after 24 and 48 hour reaction times. These values
increased with reaction time resulting in a broader range of macromer chain lengths in the
solutions for these samples. ATR-FTIR was used to determine the conversion of carboncarbon double bonds present in the PBAE macromers. As the macromer reaction occurs, the
C=C bonds react with IBA, decreasing the C=C peak at 1637 cm-1 which is confirmed in the
IR spectra. This peak does not completely disappear, however, as the final macromer product
has available C=C bonds from the PEGDA due to it being present in excess during the
macromer synthesis. Both the GPC and IR spectra can be seen in Figure 6.2 and Figure 6.3,
respectively.

6.3.2 Hydrogel Nanocomposite Degradation and Swelling Response
Magnetic hydrogel nanocomposites were fabricated via free-radical polymerization
resulting in a biodegradable material. Degradation studies were completed for hydrogels
based on 0, 25, 50, 75, and 100 weight % 2EG-IBA macromer. Figure 6.4 shows both the
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Table 6.1. Molecular weight (MW) and polydispersity index (PDI) of macromers from gel
permeation chromatography. 15 and 48 hours denote the final reaction time for the 2EG-IBA
and 9EG-IBA systems, respectively.
System
2EG-IBA
9EG-IBA
9EG-IBA

Time (hours)
15
24
48

MW
2206
2103
3663

PDI
1.87
2.57
3.03

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Figure 6.2. Gel permeation chromatograms for PBAE macromers where a) is for 1:1.2
diethylene glycol diacrylate to isobutylamine (2EG-IBA) for 0 and 15 hours and b) is for 1:1.2
poly(ethylene glycol) (n = 9) diacrylate to isobutylamine (9EG-IBA) at 24 and 48 hours.
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Figure 6.3. ATR-FTIR spectra of (a) 2EG-IBA macromer (1:1.2 diethylene glycol diacrylate:
isobutylamine) spectra before and after synthesis (0 and 15 hours) and (b) 9EG-IBA
macromer (1:1.2 PEG400DA:isobutylamine) spectra before (0 hour), 24 hour, and 48 hours
after synthesis.
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Figure 6.4. Mass fraction remaining and mass swelling ratio (q) data for: a) 100 9EG-IBA b)
25 2EG-IBA, c) 50 2EG-IBA, d) 75 2EG-IBA, and e) 100 2EG-IBA magnetic hydrogel
nanocomposites with time. f) is a table detailing the final q value for all systems the
corresponding fraction remaining. For all graphs, the blue diamonds correspond to the
fraction remaining (md/mi) on the left x-axes and the red squares correspond to the volume
swelling ratios (q) on the right x-axes. N = 3 ± SE.
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fractional mass remaining and mass swelling ratio of the hydrogel nanocomposites with times.
The 100 9EG-IBA hydrogel completely degraded in approximately 11 hours whereas the 100
2EG-IBA hydrogel completed degraded over the course of approximately 75 days.
Additionally, 25, 50, and 75 2EG-IBA hydrogels completely degraded in approximately 5, 15,
and 68 days. The final data was not collected due to the difficulty in handling the hydrogels
near the end time points and the end of the degradation time for all systems was determined
via visual observations. The faster degradation of the 100 9EG-IBA hydrogel is a result of the
presence of more ethylene glycol (EG) groups in the macromer backbone in comparison to the
100 2EG-IBA hydrogel resulting in a more hydrophilic macromer and hydrogel. The mass
fraction curve was slightly sigmoidal-shaped for all hydrogels. This profile is likely due to the
broad PDI of both macromers resulting in both shorter and longer chains present in the
macromer where shorter chains in the gel will degrade faster and longer chains will have a
slower degradation which affects the initial and final degradation response of the systems.
Figure 6.5 shows a comparison of the fractional mass remaining of all of the hydrogel
systems. These hydrogels exhibited degradation times in between that of the 100 2EG-IBA
and 100 9EG-IBA hydrogels due to the mixture of the two macromers present in the
hydrogels. The 75 and 100 2EG-IBA hydrogel exhibited similar final degradation time which
is likely a result of the 9EG-IBA macromer degrading quickly out of the 75 2EG-IBA
hydrogel causing it to behave similarly to the 100 2EG-IBA gel.

The mass swelling ratio of

all of the hydrogels increased with time as seen in Figure 6.4. This is due to the continued
degradation of the gels with time which results in breakage of the crosslinking in the hydrogel
matrix allowing for increased water content. These curves were also all slightly sigmoidal in
shape. As seen in Figure 6.4f, the 100 9EG-IBA hydrogel had the highest mass swelling ratio
with time (12.4), and the final mass swelling ratios for the other hydrogels decreased with
increasing 2EG-IBA content (3.3) despite the degradation being further along for the more
hydrophobic samples. This is due to the increase in hydrophobicity due to 2EG-IBA as well
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Figure 6.5. Mass fraction remaining data for all magnetic hydrogel nanocomposites over time.
N = 3 ± SE.
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as the fact that the average molecular weight of the 2EG-IBA macromer is lower than that of
9EG-IBA resulting in a tighter hydrogel mesh. The hydrogels exhibited bulk degradation as
evidenced by their increased swelling with continued degradation. Overall, this data shows
the ability to tailor the degradation and swelling profiles of these hydrogels by adjusting the
macromer content.

6.3.3 Mechanical Testing: Determination of Compressive Modulus
Compressive testing was performed on all PBAE hydrogel systems at two time points
(i.e., an initial time point after 30 minutes in PBS for all gels and a second time point after the
hydrogels were partially degraded). This second time point was 3 hours, 1 day, 9 days, 28
days, and 42 days for 0, 25, 50, 75, and 100 9EG-IBA hydrogels, respectively.

This

corresponds to fractional mass values of 0.78, 0.43, 0.41, 0.46, and 0.28 for these hydrogel
systems, respectively. Representative stress versus strain plots can be seen in Appendix A,
Figure A.6.1 and Figure A.6.2. The final data can be seen in Figure 6.6 and contrary to what
was expected, the gels with higher 9EG-IBA content exhibited a greater compressive
modulus.
The lower molecular weight macromer (2EG-IBA) was expected to result in hydrogels
with higher compressive modulus due to the tighter hydrogel mesh. This was not observed,
however, and it is believed that this is due to two potential factors. First, there are unreacted
PEGDA monomers present in the macromer solution. Also, shorter PEGDA chains are
present in the macromer as indicated by the large PDI for the 9EG-IBA macromer. In turn,
hydrogels fabricated with this macromer have a greater compressive modulus. The lower
modulus for the 100 9EG-IBA system for the initial time point is a result of it already
degrading slightly more than the other gels after 30 minutes. The modulus of all hydrogel
systems decreased during degradation due to decreasing crosslinking density which results in
a weakening of the hydrogel matrices.
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Figure 6.6. Compressive modulus data for magnetic hydrogel nanocomposites after initial
exposure to PBS at 37°C (Initial Time) and for a second time point for each system after the
hydrogels are partially degraded (2nd Time). The second time for the systems are: 3 hours for
100 9EG-IBA, 1 day for 25 2EG-IBA, 9 days for 50 2EG-IBA, 28 days for 75 2EG-IBA, and
42 days for 100 2EG-IBA. N = 3.
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6.3.4 Iron Oxide Loss Studies via Thermogravimetric Analysis
TGA was performed to determine the actual amount of iron oxide nanoparticles
present in the hydrogel nanocomposites as they degrade. Samples were analyzed at 0, 0.5, 3,
and 8 hours for the 100 9EG-IBA hydrogel systems as a representation of what occurs in the
remaining hydrogel nanocomposites as seen in Appendix A, Figure A.6.3. Interestingly, as
time and degradation increased, the mass % of the iron oxide in the nanocomposites (iron
oxide to polymer amount) increased. The polymer degradation byproducts were able to
diffuse more readily out of the hydrogels than the iron oxide nanoparticles themselves. The
effect of this phenomenon will be discussed further in the next section concerning the remotecontrolled heated of the hydrogel nanocomposites.

6.3.5 Remote-Controlled Heating of PBAE Hydrogel Nanocomposites Via an AMF
PBAE hydrogel nanocomposites can potentially be used in hyperthermia applications
where heating of the magnetic hydrogel matrix can be achieved by exposure to an alternating
magnetic field. This phenomenon is due to the Fe3O4 nanoparticles present in the hydrogel
matrix. In these studies, the swollen hydrogels were exposed to an electromagnetic field for 5
minutes at 294 kHz and 17.4 kA/m to induce heating within the systems for the following
conditions: dry hydrogels and hydrogels after degradation at various time points.

As seen in

Figure 6.7 for the 100 9EG-IBA hydrogel system, the hydrogels were able to heat for all
conditions, and the maximum temperature reached decreased as the gels degraded. This
response was similar for the other four hydrogel systems as seen in Appendix A, Figure A.6.3.
The amount of heating of the hydrogel systems is dependent on multiple factors including the
amount of iron oxide present in the gel volume and the amount of water present in the gels,
which can dissipate the heat generated by the iron oxide nanoparticles. Table 6.2 shows the
relationships between the ∆T values, mass swelling ratio, fractional mass remaining, TGA
iron oxide mass %, and actual average iron oxide mass remaining in each gel. As time
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Figure 6.7. Thermal analysis of 100 9EG-IBA magnetic hydrogel nanocomposite with time
upon exposure to an alternating magnetic field at 17.4 kA/m and 294 kHz for 5 minutes. N =
3 ± SE.
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Table 6.2. Comparison of mass swelling ratio (q value), fraction of mass remaining, final
temperature of hydrogel surface temperature after 5 minute exposure to an AMF, iron oxide
loading amount from TGA data, and the calculated mass of iron oxide remaining for the 100
9EG-IBA hydrogel system with time.
Time

q value

Initial
30 min
3 hour
8 hour

1.00
1.6 ± 0.0
2.6 ± 0.1
12.4 ± 0.1

Fraction Mass
Remaining
1.00
0.97 ± 0.01
0.78 ± 0.01
0.29 ± 0.01

Final ∆T (°C)

% Iron Oxide

55.0 ± 1.9
41.8 ± 1.6
36.9 ± 0.5
30.6 ± 0.4

4.9 ± 0.1
4.7 ± 0.0
5.3 ± 0.1
12.4 ± 0.2

146

Fe3O4 Mass
Remaining (mg)
4.4 ± 0.0
4.1 ± 0.0
3.7 ± 0.1
3.2 ± 0.1

increases, the mass swelling ratio increased with degradation allowing for more water into the
hydrogels. Additionally, as the hydrogels degraded the actual iron oxide mass decreased.
These two factors together resulted in a decrease in the heating of the hydrogels with time.

6.3.6 Characterization of Paclitaxel Release
In order to evaluate the ability of PBAE hydrogels to effectively deliver paclitaxel, in
vitro release studies were performed in a PBS solution containing 2.4 weight % Tween® 20
and 4 weight % Cremophor® EL at 37°C and 100 rpm. The PTX concentrations were
determined using a standard curve from the PTX concentration and HPLC data in a 60:40
(v/v) release medium to acetonitrile solution as seen in Appendix A, Figure A.6.4. Figure 6.8
shows the release profile of PTX from the PBAE hydrogels. The PTX was continuously
released from the hydrogels, and a near zero-order release was initially evident for all
hydrogel systems. After approximately 60-70% release, the PTX release slowed for most
systems. Similar to the degradation data, the 100 9EG-IBA released paclitaxel the fastest due
to its higher hydrophilicity in comparison with the gels containing 2EG-IBA macromer. This
data suggests that these hydrogels have the potential to be used as good controlled drug
delivery carriers, and the drug release time can be controlled by the degradation rate of the
hydrogel system.

6.3.7 Cytotoxicity Analysis of PBAE Hydrogel Nanocomposite Degradation Products
Cytotoxicity analysis of the PBAE hydrogel nanocomposite degradation products was
analyzed as these gels can potentially be used as implantable or injectable in vivo drug
delivery depots. Hydrogels without paclitaxel were completely degraded in PBS resulting in
18 mg/ml hydrogel to PBS solutions. These solutions were then diluted to 0.15, 1.5, and 4.5
mg/ml in 25% (v/v) PBS to complete fibroblasts medium. NIH 3T3 fibroblasts were then
exposed to these solutions for 48 hours, and their cytotoxicity was analyzed using a
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Figure 6.8. Analysis of paclitaxel release from hydrogel nanocomposites over time via HPLC.
N = 3 ± SE.
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Cellometer® Automated Cell Counter. Figure 6.9 shows the % cell viability (number of live
cells versus total number cells) for 100 2EG-IBA, 50 2EG-IBA, 100 9EG-IBA, and a PBS
control. For all hydrogels, the cell viability decreased with increasing degradation product
concentration.

Additionally, the viability was greater with increasing 9EG-IBA content.

Overall, these results show differences in cell viability for different conditions, and in vivo
evaluation will be necessary to show the overall safety of these systems. However, this does
show the potential for safety with the correct degradation product clearance from the
implantation site.

6.4 Conclusions
Magnetic PBAE-based hydrogel nanocomposites have the ability to successfully
deliver both heat and the chemotherapeutic agent, paclitaxel, in a controlled fashion. Both the
degradation and PTX release profiles can be tailored based on the type of macromer used with
the more hydrophilic hydrogel system (100 9EG-IBA) degrading in 11 hours versus over
nearly 7 weeks for the more hydrophobic system (100 2EG-IBA). The paclitaxel release
profiles were controlled by the degradation of the hydrogels as they underwent bulk
degradation. The heating capability of the hydrogels when exposed to an AMF decreased as
the hydrogels degraded. This is due to an increase in their swelling (and therefore increase in
water content) and decrease in the amount of iron oxide present in the hydrogels with time.
The degradation products exhibited cell viabilities ranging from 53 to 92% depending on the
type of hydrogel and concentration of degradation products. Overall, these systems have the
potential to be used as implanted or injected drug (and heat) delivery depots for the synergistic
treatment of cancer.

References
All references are located at the end of the dissertation.
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Figure 6.9. Cytotoxicity analysis of NIH 3T3 murine fibroblasts exposed to completely
degraded PBAE hydrogel nanocomposites at various concentrations for 48 hours. N = 3 ± SE.
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CHAPTER 7

Conclusions and Future Work

7.1 Conclusions
Due to the limitations and side effects often association with conventional cancer
therapies such as chemotherapy and radiation, significant emphasis is being placed on the
development of novel cancer therapeutics that explore a multi-modality approach to
overcoming this problem.

Although chemotherapy and radiation are often used

synergistically with success, there are still many types of cancers and patients that do not
respond well to this line of treatment. A significant amount of literature has supported the idea
that hyperthermia, the heating of tumor tissue to 41 to 45 °C, can help overcome the
limitations of either chemotherapy or radiation. Hyperthermia has its own limitations, the
most significant being a method of delivering heat to a localized area via non-invasive
methods. This work presents a class of biomaterials, magnetic hydrogel nanocomposites,
which may be able to overcome this constraint. The hydrogel matrix can provide a drug depot
for the delivery of chemotherapeutic agents, and iron oxide nanoparticles embedded in the
system can provide heat upon exposure to an alternating magnetic field (AMF).

These

materials can be implanted or injected in or around tumor sites for synergistic treatment of the
cancerous tissue. Although numerous types of hydrogels could be used for this type of
therapy, poly(ethylene glycol) (PEG) and poly(β-amino ester) (PBAE) hydrogel systems were
the focus of this research.
Initially, PEG-based magnetic hydrogel nanocomposites were investigated for their
swelling, heating, and biocompatibility properties. It was shown that the swelling of the
hydrogels could be controlled by both the crosslinking density and that these systems
exhibited a swelling response with changes in the temperature of the surrounding medium.
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This was the first time this phenomenon was demonstrated for PEG-based nanocomposite
hydrogels. The cytotoxicity of iron oxide nanoparticles in the hydrogels as well as potential
unreacted components from the hydrogel were evaluated for 24 and 48 hours using murine
fibroblasts, and the results were the same as fibroblasts exposed to media only. The heating
profiles for all the hydrogel systems heated in the AMF were dependent on the swelling of the
hydrogel systems, where higher crosslinked gels heated more than lower crosslinked gels due
to less water (i.e., a greater fraction of polymer and iron oxide) present in the system. The
heating of the hydrogels was able to be controlled by the strength of the AMF so that the
systems could reach either hyperthermia or thermoablation temperature ranges. It was also
demonstrated that these hydrogel systems heated to thermoablation temperatures in the AMF
and have the ability to kill M059K glioblastoma cells in vitro. Unexpected temperatureresponsive properties resulted from the initial investigation of the PEG-iron oxide
nanocomposites.

Similar PEG-based hydrogels comprised of diethylene glycol methyl

methacrylate and PEG200 methyl methacrylate were investigated to better characterize these
properties.

The gels were shown to be temperature-responsive at various temperatures.

Additionally, they demonstrated a sharp decrease in swelling upon heating in the AMF due to
the local heat generated from the iron oxide nanoparticles.

This is the first time this

phenomenon has been demonstrated with PEG-based nanocomposite hydrogels.
PEG magnetic hydrogel nanocomposites were then studied for their ability to deliver
heat and a chemotherapeutic agent, paclitaxel. Similar to before, the swelling of these systems
was tailorable and was dependent on the crosslinking density of the system. Mechanical
analysis showed expected values for compressive moduli, and these values were dependent on
crosslinking (the more crosslinked system had a higher modulus). Heating results in the AMF
were once again dependent on the crosslinking of the hydrogels with the lower crosslinked
system heating less than the others. The hydrogel nanocomposites were able to release
paclitaxel in a modified release medium that aided in the solubility of the highly hydrophobic
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drug. A modified power law was used to model the drug release. Finally, it was shown that
A549 lung carcinoma cells exhibit higher cytotoxicity when exposed to both heat (at 42.5 °C)
and paclitaxel (at micromolar amounts) in comparison to either treatment demonstrating that
this type of therapy could be beneficial for treating lung carcinoma whereas M059K
(glioblastoma) and MDA MB 231 (breast adenocarcinoma cells) did not show an increase in
paclitaxel efficacy when combined with hyperthermia therapy.
Although PEG hydrogels are advantageous in that they exhibit “stealth” properties,
they do not readily degrade once exposed to the body. For applications where biodegradable
systems would be desired, PBAE hydrogels, which degrade via ester linkages, were studied
for the delivery of both heat and paclitaxel. Both swelling and degradation of the systems
were dependent on the type of macromer used in the hydrogel with the more hydrophilic
systems degrading more quickly.

As expected, the mechanical strength (compressive

modulus) of the hydrogels decreased as they degraded.

Cytotoxicity of the degradation

products of the hydrogels was studied and the viability ranged from 55 to 95% depending on
the gel type and concentration of the materials in PBS solution. Finally, it was demonstrated
that paclitaxel can be released in a controlled manner via bulk degradation of the hydrogels.
This system may be especially advantageous for the synergistic delivery of heat and
chemotherapeutics as it has the potential to be injected in situ at a tumor site due to the
chemically-initiated polymerization it undergoes to form a solid hydrogel. Overall, these
systems are promising for use in hyperthermia and chemotherapy applications upon further
evaluation of their properties and applications.

7.2 Future Work
The work described in this dissertation is hopefully just the beginning regarding the
investigation of magnetic hydrogel nanocomposites for hyperthermia applications. Future
work to build upon this project may include, but is not limited to:
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•

Optimization of a PBAE-based system with less iron oxide nanoparticles that can deliver
heat at hyperthermia temperatures while degrading and delivering the appropriate amount
of chemotherapeutic agent.

•

Investigation of the temperature-responsiveness of PBAE systems containing PEG based
macromers, which have the potential to be temperature-responsive.

•

Optimization of the release method of hydrophobic drugs from PEG-based hydrogel
systems. The current method involves imbibitions in methanol in which the gels cannot be
dried. Ideally, the drug would be incorporated during the fabrication of the hydrogels.

•

Incorporation of iron oxide nanoparticles that have a Curie temperature (maximum
temperature that they can heat in an AMF) in the hyperthermia range so that the heating of
the hydrogels can be better controlled.

•

Investigation of the release of other types of cancer therapeutics which could include:
radionucleotides, chemotherapeutics, immunotherapy agents.

•

In vitro cytotoxicity analysis of other cancerous cell lines via multiple methods:
o Exposing cells to chemotherapeutic agent and heat via incubator then analyzing via
staining with a Live/Dead stain with fluorescence imaging to determine cell
viability or counting cells via Cellometer® to determine cell viability
o Exposing cells to chemotherapeutic agents and hyperthermia heat from hydrogels
heated in AMF then analyzing via methods described above.

•

In vivo analysis of optimized magnetic hydrogel nanocomposites implanted or injected
intratumorally which can deliver both a chemotherapeutic agent and hyperthermia.
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APPENDIX A

Supplemental Figures and Tables
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Figure A.3.1. FTIR conversion data of PEG magnetic hydrogel nanocomposites. Completion
of reaction was determined by the amount of C=C bonds broken during the hydrogel
fabrication when undergoing free-radical polymerization.
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Figure A.3.2. Thermal gravimetric analysis of PEG magnetic hydrogel nanocomposites.
Weight remaining was measured with time to determine the actual iron oxide nanoparticle
content within the hydrogels. (a) is all data from 200 to 600 °C whereas (b) is a close up of
the data from 400 to 600 °C.
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Figure A.6.1. Representative stress versus strain curves obtained during mechanical testing
(compression analysis) of PBAE magnetic hydrogel nanocomposites 30 minutes after
degradation has been underway for the following samples: (a) 100 9EG-IBA, (b) 25 2EGIBA, (c) 50 2EG-IBA, (d) 75 2EG-IBA, and (d) 100 2EG-IBA.
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Figure A.6.2. Representative stress versus strain curves obtained during mechanical testing
(compression analysis) of PBAE magnetic hydrogel nanocomposites for the 2nd time point for
the following samples and times: (a) 100 9EG-IBA (3 hours), (b) 25 2EG-IBA (1 day), (c) 50
2EG-IBA (9 days), (d) 75 2EG-IBA (28 days), and (d) 100 2EG-IBA (42 days).
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Figure A.6.3. Heating analysis of PBAE magnetic hydrogel nanocomposites in their dry and
swollen states (after degradation) for (a) 25 2EG-IBA, (b) 50 2EG-IBA, (c) 75 2EG-IBA, and
(d) 100 2EG-IBA systems.
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Figure A.6.3 (con’t). Heating analysis of PBAE magnetic hydrogel nanocomposites in their
dry and swollen states (after degradation) for (a) 25 2EG-IBA, (b) 50 2EG-IBA, (c) 75 2EGIBA, and (d) 100 2EG-IBA systems.
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Figure A.6.4. Calibration curve of paclitaxel in 50:50 (v/v) solution of water:acetonitrile
created via HPLC data.
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APPENDIX B

Supplemental Information

B.4.1 Mesh Size Calculations and Analysis
Characterizing the molecular structure of hydrogels is important in determining their
suitability for various biomedical applications, especially drug delivery. The most important
parameters used to characterize the network structure of hydrogels are the polymer volume
fraction in the swollen state (νs,2), the molecular weight of the polymer chain between two
 c), and the hydrogel mesh size (ξ). The polymer fraction in the
adjacent crosslinking points (
swollen state describes the amount of polymer present in a swollen hydrogel (which
corresponds to the inverse of the volume swelling ratio) whereas the molecular weight
between crosslinks is the measure of the degree of crosslinking of the system. The mesh size
is the space availability between the macromolecular chains which is important for
determining whether or how therapeutic agents are released out of a hydrogel for drug
delivery applications.
For poly(ethylene glycol) methyl ether methacrylate (PEGMA) and poly(ethylene
glycol) dimethacrylate (PEGDMA) hydrogels, the hydrogel mesh will have PEGMA acting as
the “backbone” and providing a brush-like structure and with PEGDMA crosslinking these
chains as seen in Figure B.1. There are several methods available for evaluating the mesh
characteristics of hydrogel systems.

The most commonly utilized mathematical

characterization for this involves a model developed by Flory and Rehner (Flory and Rehner
1943; Flory 1953) for hydrogels formed via a vulcanization process (i.e. random crosslinking
along the backbone of a polymer). This equation is:
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Figure B.4.1. Schematic of PEGMA/PEGDMA-based hydrogels with an amorphous mesh
with PEGDMA acting as the “backbone” with PEGMA incorporated into the hydrogel or
acting as a tether/brush. The green lines represent the PEGMA moieties whereas the
PEGDMA crosslinker is represented in blue.
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 c is the average molecular weight of the polymer chain between two adjacent
where 

 n is the number average molecular weight of the polymer backbone if
crosslinking points, 

prepared under the identical conditions but without the crosslinker present, "̅ is the specific
volume of bulk PEG in the amorphous state (0.893 cm3/g, (Cruise 1998)), ν2,s is the polymer

volume fraction in the swollen state (1/Q), Q is the volume swelling ratio, and χ1 is the Flory
polymer-solvent interaction parameter (0.43, (Merrill 1993)).

For neutral (non-ionic)

hydrogels prepared in the presence of a swelling agent such as water, the Peppas-Merrill
modification (Peppas and Merrill 1976) of the Flory-Rehner equation may be used:
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where V1 is the molar volume of the solvent (water, 18 cm3/mol) and ν2,r is the polymer
fraction in the relaxed state (as synthesized) which is equal to the amount of total polymer
(monomer plus crosslinker) in initial feed versus total polymer plus solvent amount, based on
 c the number
the assumption of complete reaction with no volume change. After calculating 
of C-C bonds between two crosslinks (n) can then be calculated:

)=
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$

where Mr is the average molecular weight of the repeating unit, which is 44 for ethylene
glycol. The root mean squared end-to-end distance of the polymer chain in the unperturbed
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state (*+̅, -/ ) can then be calculated as:

*+̅, -/ = . */ )-/

(4)

where l is the carbon-carbon bond length (1.54 Å) and Cn is the Flory characteristic ratio of
the polymer (3.8 for PEG) (Thomas 2007). The mesh size is then calculated from:
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where α is the elongation ratio of the polymer chains in any direction. An important limitation
of this analysis is that these equations were derived for polymer fractions up to 0.2 and
therefore the values obtained for greater polymer fractions are approximations (Brazel and
Peppas 1995; Mellott 2001). Another assumption is that the χ1 for PEG is similar to that for
PEG in water, neglecting the influence of the methyl and methacrylate end groups and
comonomer in the system.
 n, is the
The number average molecular weight of the uncrosslinked chains, 
parameter that often requires assumptions when not determined experimentally and can
provide the greatest source of error for the Flory-Rehner analysis. This value has been
assumed (i.e. 100,000 for poly(N-isopropylacrylamide), (Brazel and Peppas 1995)),
determined experimentally by synthesizing the polymer system without crosslinker and
determining the value, or assumed to be the average molecular weight of the monomer before
crosslinking (Mellott 2001). In Chapter 4, the mesh analysis was calculated using two ways to
 n was assumed to be 100,000, the largest value often
show the effect of this value. First, 
seen for these calculations. Then, it was assumed to be the molecular weight of the PEGMA
tethered chain between the PEGDMA crosslinks as seen in Figure B.4.2. This would be the
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average of the longest chain possibly present in the hydrogel matrix for a perfect,
homogeneous hydrogel. For the systems studied in Chapter 4, with 5 mole % PEGDMA to
PEGMA, this would result in approximately 19 PEGMA molecules to PEGDMA molecules.
Although both of these methods have their own drawbacks, the range of values calculated
should give an idea to the actual characteristics of the hydrogel mesh.
Elbert and coworkers have presented another method for characterizing the mesh of
hydrogels (Elbert 2001) in which they present a model for condensation or “perfect”
hydrogels. Vulcanized hydrogels (which includes most types of hydrogels) have a terminal
mer on the polymer which almost never participates in a crosslink which means that almost
every chain in the hydrogel network will have dangling ends which do not contribute to the
structural or mechanical integrity of the gel. Furthermore, the value of the molecular weight
between crosslinks follows a Gaussian distribution as the spacing between the crosslinks is
irregular (Elbert, Pratt et al. 2001). A perfect gel would have no dangling ends with a more
uniform distribution in the distance between crosslinks. An example of this was recently
described by Brandl and coworkers for a 4-arm PEG system (Brandl 2010). As the FloryRehner model assumes uniform molecular weight between crosslinks, it is well suited to also
describe perfect hydrogels. First, the number of moles of elastically active chains in the
network is calculated:
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which is very similar to the modified Flory-Rehner equation although without the dependence
 n which is advantageous in the uncertainty in this value. In this equation, Vp is the
on 
volume of the dry gel as determined from the mass of the dry gel and the density of
amorphous PEG (1.12 g/cm3) and f is the functionality of the crosslinks (which is 2 for a
167

Figure B.4.2. Representation of a PEGMA/PEGDMA chain. The average molecular weight
 n) was assumed to be the average molecular weight of the
of the uncrosslinked polymer (
PEGMA tethers in between crosslinks as shown by the red arrow. n represents the number of
EG units in PEGMA, m is the number of EG units in PEGDMA, and x is the total number of
PEGMA chains in the structure.
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difunctional crosslinker as used in these experiments). Assuming a perfect network free of
defects, the average molecular weight between crosslinks is calculated from:

> =


?@

(7)

:A

where mp is the total mass of PEG in the hydrogel. From this parameter, the hydrogel mesh
size (ξ) can then be calculated using equation (5). The Elbert/Brandl method for perfect
hydrogels was also used to characterize the PEG gels for this research as a comparison. The
calculated values were smaller than those calculated via the Flory-Rehner equation which was
as expected as it takes into account for imperfections.
Overall, each hydrogel system whose mesh is characterized via these models should
take into account the type of mesh. Having an exact value for the molecular weight of the
 n) will help in calculating the mesh values to a more accurate
uncrosslinked polymer (
degree.

B.5.1 Fickian and Non-Fickian Drug Release from Hydrogels
Modeling the controlled release of drugs from polymeric devices has been of great
interest for many decades resulting in the development of various models to describe this
phenomenon from many types of systems. Many of these models were originally published in
the classic book by Crank (Crank 1975) although many other equations have been described
more recently. Ritger and Peppas originally described equations for Fickian and non-Fickian
solute release from both swellable and non-swellable devices of various geometries (Ritger
and Peppas 1987; Ritger and Peppas 1987). One-dimensional Fickian release from a thin
polymer film is often utilized to describe release from thin hydrogel systems with aspect ratios
(diameter versus thickness) greater than 10, where edge effects can be ignored. This release
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involves a thin polymer slab of thickness, ℓ, where the system is initially maintained at a
constant uniform drug concentration, C1, and the concentration of the surface of the hydrogel
and surrounding release media immediately surrounding the hydrogel are kept at a constant
drug concentration, C0 (see Figure B.5.1). This condition is typical for release experiments
and is often termed a ‘perfect sink condition’ allowing that there is no concentration gradient
in the release medium preventing free diffusion from the hydrogel. For one-dimensional
diffusion in the x-direction with a constant drug diffusion coefficient, D, Fick’s second law of
diffusion can be written as the following with the corresponding initial and boundary
conditions for hydrogel thin polymer slabs:

B5
BC

B 5

= D BE 

(1)

with the initial and boundary conditions being the following:

t=0

-ℓ/2 < x < ℓ/2
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t>0
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The resulting solution is in the form of a trigonometric series:
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(5)

Figure B.5.1. Schematic of polymeric slab releasing a drug with thickness, ℓ, constant
concentration, C1, and in a constant release medium at concentration C0.

W
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here Mt is the mass of the drug released at time, t, and M∞ is the mass of the drug released as
time approaches infinity. For short times (0 < Mt/M∞ < 0.6), equation 5 can be written in a
simplified form:

G
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=4

PC /

Kℓ



(6)

Fickian release from a hydrogel thereby has a t1/2 time dependence of the drug released, and
this type of release is often described as Case I Fickian release. Another limiting case of
release (Case II) is one where the drug release is independent of time resulting in zero-order
kinetics:

G

H

= U′W

(7)

Many release processes involve a combination of these two cases resulting in anomalous
release and this can be represented by an expression combining equations 6 and 7:

G

H

= U W/ + U W

(8)

This expression can be written in the generalized power law expression:

G

H

= UW 

(9)

where k is a constant that depends on the structural and geometrical characteristics and n is the
release exponent indicating the mechanism of drug release. An n value of 0.5 indicates Case I
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Fickian diffusion while values between 0.5 and 1 indicate anomalous diffusion, and a value of
1 indicates zero-order diffusion (Case II transport). A limitation of this model, however, is the
fact that it does not account for an initial burst release or lag time that can occur during the
initial phase of release.
Huang and Brazel (Huang and Brazel 2001) introduced a modified power law
incorporating a burst release parameter, α, as seen in the following expression:

G

H

= UW  + 1

(10)

The constant α is added to fit the experimental data and it accounts for a rapid jump in drug
concentration at t = 0. This value can be determined through extrapolation of the drug release
data at the start of the release. For this model α is assumed to be unrelated to time and the
entire release curve is shifted up by added the burst release term which is a limiting factor for
this model.
Viitala (Viitala 2007) described a model that accounts for both burst release for both
the amount and time of this phenomenon resulting in a modified power law model:

G  
∞

= U? *W − W -Y

(11)

where M2 is the amount of drug released within the initial release phase that differs from the
main release phase, t2 is the end time point of the initial release phase, and km is the
corresponding k constant. The variable, nm is the modified release exponent that can be
treated the same as the n value in the original power law.
Overall, these models represent a handful of methods to account for the type of drug
release from hydrogel systems. Oftentimes, release phenomenon is non-Fickian and therefore
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other models accounting for this, as presented above, are necessary to be able to fit the release
data.
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